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ABSTRACT 
The purpose of this dissertation was 1) to develop noninvasive strategies to assess skeletal 
muscle size, architecture, and composition in young and old adults (study #1) and 2) evaluate the 
impact of chemotherapeutic treatment on skeletal muscle satellite cells and capillaries (study #2). 
For study #1 ultrasound images were obtained from the quadriceps muscles of young (8 m, 8 f) 
and older (7 m, 5 f) participants on two occasions, separated by 5-15 days. Images were collected 
while the participants were both standing and supine, and were analyzed for muscle thickness, 
pennation angle, and echogenicity. In addition, test-retest reliability and ICCs were evaluated for 
each posture and when imaging sites remained marked or were re-measured from visit #1 to visit 
#2.  Generally, in both younger and older adults muscle thickness was greater and echogenicity 
was lower in the anterior quadriceps when images were collected standing versus supine. 
Maintaining the imaging site between visits did not influence test re-test reliability for either age 
group. Older adults exhibited smaller muscle thickness, lower pennation angle and increased 
echogenicity. Further, variability for the use of ultrasound to determine muscle thickness and 
pennation angle was greater in older versus younger adults. Findings from study #1 highlight 
several methodological considerations for US-based assessment of skeletal muscle characteristics 
that should be considered for improving reproducibility and generalizability of US to assess skeletal 
muscle characteristics and function across the aging spectrum. This is particularly relevant given 
the emerging use of ultrasound to assess skeletal muscle characteristics in healthy and clinical 
populations. In the second study, ovariectomized female Sprague-Dawley rats were randomized to 
receive three bi-weekly intraperitoneal injections of the chemotherapeutic drug, Doxorubicin (DOX) 
(4mg/kg; cumulative dose 12mg/kg) or vehicle (VEH; saline). Animals were euthanized 5d following 
the last injection, and the soleus (SOL) and extensor digitorum longus (EDL) muscles were 
dissected and prepared for immunohistochemical and RT-qPCR analyses. Relative to VEH, cross-
sectional area (CSA) of the SOL and EDL muscle fibers were 26% and 33% smaller, respectively, 
in DOX animals (P<0.05). In the SOL satellite cell and capillary densities were 39% and 35% lower, 
respectively, in DOX animals (P<0.05), whereas in the EDL satellite cell and capillary densities 
were unaffected by DOX administration (P>0.05). In the SOL MYF5 mRNA expression was 
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increased in DOX animals (P<0.05), while in the EDL MGF mRNA expression was reduced in DOX 
animals (P<0.05). Chronic DOX administration is associated with reduced fiber size in multiple 
skeletal muscles, however DOX appears to impact the satellite cell and capillary densities in a 
muscle-specific manner. These findings from study #2 highlight that therapeutic targets to protect 
skeletal muscle from DOX may vary across muscles. Collectively, these findings 1) improve the 
ability to examine muscle size and function in younger and older adults, and 2) identify promising 
therapeutic targets to protect skeletal muscle from the harmful effects of chemotherapy treatment.  
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CHAPTER ONE 
INTRODUCTION 
 
Skeletal muscle is a highly plastic tissue, demonstrating remarkable adaptation and 
remodeling in response to a variety of stimuli, particularly exercise (46) and nutrition (255). For 
example, it is well understood that exercise training can alter the size and metabolic profile of 
skeletal muscle (43), producing a muscle phenotype that is better able to perform an exercise or 
movement. While the plasticity of skeletal muscle is relatively well preserved throughout the aging 
process, a gradual deterioration of cellular structure and function can occur in skeletal muscle, 
particularly in response to aging and disease (43, 118). In particular, aging is associated with a 
progressive decline in skeletal muscle size and function (60, 141), termed sarcopenia, that has 
detrimental effects on the quality of life in elderly populations. Further, medications that are often 
used in elderly populations can also impact skeletal muscle function. For instance, common over-
the-counter analgesics have been shown to interfere with adaptations of skeletal muscle to exercise 
(246), while chemotherapeutic agents can have toxic effects on skeletal muscle (94). In particular, 
these unfavorable adaptations occurring in skeletal muscle not only impair movement, but also 
affect overall metabolic health as skeletal muscle serves as an amino acid reservoir, provides 
substrate for other tissues, and delivers substrate during malnutrition, starvation, and injury (153). 
Skeletal muscle adaptation is regulated through an intricate array of molecular events that 
ultimately lead to the accumulation of specific proteins in the muscle fibers (72). For example, 
changes in transcriptional activity and the rate of translation dictate which specific proteins are 
produced, and consequently, which unique functional changes will manifest in skeletal muscle. In 
addition, skeletal muscle satellite cells have also been identified to serve an essential role in 
skeletal muscle growth and regeneration. Consequently, identifying the specific molecular 
mechanisms regulating the unique adaptation of skeletal muscle to various stimuli, and how these 
mechanisms impact the size and function of skeletal muscle, provides a platform to 1) establish 
important therapeutic targets for intervention during unfavorable muscle adaptations, and 2) identify 
overlap between these targets and those stimulated by various therapeutic strategies. This 
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dissertation is comprised of two independent projects aimed at addressing challenges to skeletal 
muscle in advancing age. 
The purpose of the first project is to directly assess the reliability of two predominate 
methodologies for ultrasound-based examination of quadriceps muscle size, architecture, and 
composition in young and old individuals. The emergence of ultrasonography has allowed clinicians 
and researchers to detect changes in whole muscle characteristics, include fiber pennation angle 
and muscle composition (67, 139). Along with muscle size, these variables largely dictate the 
functional capacity of a muscle (140, 173). Ultrasound has been valuable in demonstrating age-
related impairments in pennation angle (167, 236) and muscle composition (17, 236, 247). 
However, the current body of literature lacks consensus on a standardized method to assess 
skeletal muscle characteristics, with two primary methodologies being practiced (4, 25). The 
underlying difference in each protocol involves the posture of the subject during image acquisition, 
where the subject is either standing (4) or lying supine (25). Each postural approach has its own 
unique advantages, especially when the patient population may be limited in their ability to assume 
one posture over the other. For example, patients with congestive heart failure are reluctant to lay 
supine due to the increased incidences of dyspnea and pulmonary edema (178), while individuals 
who are bed-ridden may be unable to stand. To our knowledge, differences in the measures of 
skeletal muscle characteristics and the test-retest reliability of each distinct postural approach to 
ultrasound have not been investigated. The goal of this study is to better understand the reliability 
and variability of different ultrasound protocols and techniques to examine whole skeletal muscle 
characteristics and how they relate to muscle function. This information is necessary to improve 
the ability of ultrasound to identify individuals at risk for skeletal muscle decline and evaluate the 
progress of therapies aimed at improving skeletal muscle. 
The purpose of the second project is to determine the impact of a common 
chemotherapeutic drug on the satellite cell and capillary content in multiple skeletal muscles. In 
addition to aging, disease and associated treatments can accelerate reductions in muscle quality. 
For instance, cancer survivors comprise a growing portion of the elderly population (55). However, 
while cancer treatments have become more effective, some are accompanied with negative side 
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effects leading to skeletal atrophy (27, 32) and dysfunction (33, 91, 111). The common 
chemotherapeutic drug Doxorubicin (DOX) is associated with many negative side effects in skeletal 
muscle including muscle atrophy (27, 32) and dysfunction (33, 91, 111, 122), however the cellular 
mechanisms responsible are still unclear. Unfortunately, this knowledge gap impedes our ability to 
develop effective therapies to protect skeletal muscle from DOX.  In this regard, satellite cells are 
a population of resident stem cells that govern the regenerative program in skeletal muscle (230). 
In addition, these cells engage in unique crosstalk with neighboring capillaries to facilitate myogenic 
and angiogenic processes (6, 45), both of which are critical to skeletal muscle health. The impact 
of DOX on skeletal muscle satellite cells and capillaries is still unclear, thus, there remains a need 
to explore the impact of DOX administration on satellite cells and capillary contents in skeletal 
muscle. The goal of this study is to more precisely characterize the impact of DOX on the 
populations of vital cells within skeletal muscle. This information is critical to identify therapeutic 
targets for the development of strategies aimed at mitigating the deleterious off-target effects of 
DOX in skeletal muscle. 
 
I.  AIMS AND HYPOTHESES 
 Through the studies described here, this dissertation will address distinct aspects of the 
age-related challenges (i.e. sarcopenia, drug side-effects) to skeletal muscle while traversing the 
translational spectrum. 
 
Study 1 Aim: Directly assess the influence of posture on ultrasound based 
measures of skeletal muscle and determine the test-retest reliability 
of each distinct postural approach to skeletal muscle ultrasound in 
a cohort of young and older males and females.  
Study 1 Hypothesis: We hypothesize that measures of whole skeletal muscle 
characteristics will differ between each postural approach to 
ultrasound and that aging will be associated with lower test-retest 
reliability for ultrasound measured of skeletal muscle characteristics. 
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Study 2 Aim: Determine the impact of chronic DOX administration on satellite cell 
and capillary populations in multiple skeletal muscles. 
Study 2 Hypothesis: We hypothesize that DOX administration will be associated with 
lower satellite cell and capillary content in multiple skeletal muscles. 
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CHAPTER TWO 
REVIEW OF LITERATURE 
 
I.  INTRODUCTION 
The contents of this literature review are focused on skeletal muscle physiology/biology 
during advancing age. Attention is given to discuss relevant topics ranging from the specific 
molecular processes occurring within skeletal muscle cells to whole muscle characteristics. Further, 
this Dissertation includes research that spans the clinical translational spectrum from basic animal 
research to applied human studies. Consequently, this literature review includes relevant literature 
from both animal and human-subject studies. Specific topics related to the subsequent chapters 
are also highlighted within this literature review, in particular: the impacts of drug treatment, 
exercise, and aging on various processes in skeletal muscle vital to healthy aging; methodological 
approaches to assess in-vivo characteristics of whole muscle, with a focus on ultrasonographic 
imaging; and cellular processes within skeletal muscle, examined through whole-transcriptome 
RNA sequencing. 
 
II.  SKELETAL MUSCLE STRUCTURE, FUNCTION, AND ADAPTATION 
Skeletal muscle is a highly organized and complex tissue that comprises approximately 
40% of total body weight and contains 50-75% of all body proteins. While skeletal muscle 
significantly contributes to multiple bodily functions, arguably a primary function of skeletal muscle 
is the conversion of chemical energy into mechanical work to generate force and power, maintain 
posture, and produce movement (76). 
 
A.  Whole Skeletal Muscle 
1.  General Skeletal Muscle Structure  
Each whole skeletal muscle is enclosed by connective tissue called the epimysium. Within 
each whole skeletal muscle are multiple fasciculi, which contain bundles of muscle fibers (the cell 
of muscle tissue), blood vessels, and nerves that are enclosed by connective tissue called the 
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perimysium. Each individual muscle fiber within the fasciculi is enclosed by connective tissue called 
endomysium. Thus, the endomysium is what separates each muscle fiber. Together, the 
epimysium, perimysium, and endomysium extend beyond the belly of the muscle to form the tendon 
or aponeurosis which anchors to the periosteum of bone or connective tissue of another muscle, 
respectively. The connective tissue networks within skeletal muscle plays an important role in 
structure maintenance and the transmission of force from the muscle to the bone during contraction 
(133). 
 
2.  Whole Skeletal Muscle Function 
Muscle architecture is a major determinant of whole muscle contractile function (39). 
Pioneered by the studies of Gans and Bock (83) and Gans and De Vries (84), measurements of 
muscle architecture commonly include pennation angle, fiber (or fascicle) length, and physiological 
cross-sectional area as these characteristics impact whole muscle function (see below). Pennation 
angle is defined as the angle to which the fiber (or fascicle) runs relative to the force-generating 
axis of the muscle, and typically ranges from 0° to 30° (140). The degree and direction of pennation 
varies between and sometimes within skeletal muscles, where muscles with greater pennation 
angle tend to contract slower but produce more force (143). Pennation allows for “fiber packing” or 
the inclusion of more fibers in parallel within a muscle, contributing to the overall force producing 
capacity (142). 
Muscles with larger pennation angles also tend to have shorter fascicle (or fiber) lengths. 
Even the most longitudinally oriented muscles (or muscles with lowest pennation angles) have 
fibers that extend only about 60% of the muscle length (140). Fascicle length is directly related to 
contractile velocity, which is vital for the production of muscle power (rate of force generation over 
time) (140). Together, fascicle length and pennation angle, along with muscle mass and density, 
allow for the calculation of a muscle’s physiological cross-sectional area (pCSA). The pCSA 
represents the theoretical sum of the cross-sectional area of all muscle fibers within a muscle (143), 
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and is the only architectural parameter that is directly proportional to the maximal tetanic force 
produced by a muscle (194).  
 
B.  Skeletal Muscle Fiber 
1.  Skeletal Muscle Fiber Structure 
In addition to whole muscle architecture, the function of a muscle also depends on function 
of the cells (muscle fibers) that comprise it. A skeletal muscle is composed of anywhere from 
several hundred to over a million individual muscle fibers (69). On average, the cross-sectional 
area of muscle fibers in adult humans ranges from 2000-7500 µm2 (35). Each muscle fiber is 
encased in two separate membranes, the basement membrane and plasma membrane, or 
sarcolemma which constitutes the endomysium. The basement membrane is a composed of 
glycogen proteins and collagen networks and is freely permeable to proteins and metabolites (35). 
The plasma membrane is selective in what ions and substrates cross it, and it plays an active role 
in transmitting action potentials that facilitate a muscle contraction.  
Within the skeletal muscle fiber are approximately 2000 myofibrils, each approximately 1-
2 µm2 in area (150). Within each myofibril, the contractile units of skeletal muscle, known as 
sarcomeres, are arranged in series. The striated appearance of myofibrils stems from the regional 
density of thick and thin filaments with the sarcomeres. The thin filaments are anchored to a z-disc, 
which borders the ends of each sarcomere, called the I band. Thin filaments are comprised of the 
proteins actin, troponin and tropomyosin. Thick filaments are largely comprised of myosin heavy 
chain (MHC) and myosin light chain proteins. The interaction between the thick and thin filaments 
within sarcomeres are the mechanical bases of all muscle contractions. 
 
2.  Skeletal Muscle Fiber Function 
The theory that explains the contractile function of a muscle fiber, termed the sliding 
filament theory, was first proposed in 1954 by two independent labs (120, 121). Upon the excitation 
of a motor unit by an alpha motor neuron, an action potential along the sarcolemma of the muscle 
fiber, triggering the Dihydropyridine receptors to open ryanodine receptors, which engages the 
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release of calcium into the cytosol of the fiber. Calcium binds to troponin within the thin filament, 
which shifts the position of tropomyosin, exposing a myosin binding site on actin. A cross-bridge 
forms when the MHC protein binds to actin and performs a power stroke, sliding the thick and thin 
filaments relative to one another. This action ultimately pulls the z-discs towards the midline of the 
sarcomere, resulting in sarcomere shortening. Adenosine triphosphate (ATP) then binds to the 
myosin head, where it is hydrolyzed, resulting in the detachment of the existing cross-bridge and 
recurrence of this cycle. The number of actin-myosin cross-bridges largely dictates the magnitude 
of force produced by a sarcomere (76). Joint movement is realized once the generated force is 
transmitted from the z-discs of the sarcomeres in series to the myotendinous junction and tendon, 
eventually reaching bone (76). 
 
3.  Skeletal Muscle Fiber Types 
Skeletal muscle is comprised of different types of muscle fibers. These muscle fiber types 
are differentiated by the MHC isoform expressed within the myosin head, which largely dictates 
each fiber’s contractile characteristics (202). In human adult skeletal muscle, three distinct MHC 
isoforms exist, MHC I, MHC IIa, MHC IIx (225). Comparatively, in other mammals such as rodents, 
four distinct MHC isoforms exist, MHC I, MHC IIa, MHC IIb, MHC IIx (26). “Hybrid” fibers are skeletal 
muscle fibers that contain two or more MHC isoforms (262, 263), whereas a fiber that contains only 
one MHC isoform is referred to as a “pure” fiber.  
Pure MHC IIa and MHC IIx fibers are able to produce slightly more isometric force 
compared to pure MHC I fibers (29, 30, 259, 260). On the other hand, fiber excursion (contractile 
velocity) of MHC IIa and IIx fibers is much greater compared to MHC I fibers (29, 245), which is 
directly related to the rate at which the specific MHC isoform hydrolyzes ATP (16). MHC IIa and 
MHC IIx fibers are capable of generating five to six times more power than MHC I fibers (30, 245, 
260), which is largely the result of their greater contractile velocity (as compared to their slight 
differences in force generating abilities). 
 
 
 9 
C. Skeletal Muscle Adaptation 
1. General Overview 
Skeletal muscle possesses significant plasticity. It is capable of modifying its functional and 
metabolic properties in response to repeated and chronic disruptions in homeostasis. The ability 
for muscle to adapt is the consequence of a series of molecular events that ultimately lead to the 
accumulation of specific proteins. For instance, during exercise, contractions trigger transient 
surges in the quantity of messenger RNA (mRNA) that occur 3 to 24 hours following the exercise 
bout, depending on the specific mRNA and exercise modality (23, 264). This increase in mRNA is 
coupled with an increase in the rate of protein synthesis (translation), which can remain elevated 
for 48-72 hours following acute exercise (160, 190). Thus, in general the directional changes in the 
quantity of specific mRNA are in synchrony with the directional change of a particular protein (28). 
Therefore, repeated exercise stimuli repeatedly increase mRNA quantity eventually resulting in 
measureable alterations in protein content and function. Collectively, long-term changes in skeletal 
muscle morphology and function are the product of the cumulative effects of each acute, 
intermittent exercise stimulus. The molecular events regulating skeletal muscle adaptation are 
discussed below. 
 
 
Figure 2-1. Conceptual schematic depicting the series of molecular events from leading to 
alterations in cellular protein. A stimulus (i.e. exercise) is placed upon the muscle cell, 
perturbing it from homeostasis. Cellular signaling events then cue the transcription of specific 
mRNA in the nucleus. These mRNA are then transported to the cytoplasm, bound by a 
ribosome, and translated into functional proteins. 
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2. Cellular Signaling 
 The conversion of a stimulus (i.e., muscle contraction, change in physiological state) into 
the molecular events altering skeletal muscle phenotype is largely accomplished through the 
activation of a variety of complex cellular signaling pathways (72). These signaling pathways are 
comprised of networks of molecules (largely proteins) that coordinate to control one or more cellular 
functions, such as the transcription of new mRNA or translation of mRNA into protein. While specific 
signaling pathways within skeletal muscle are beyond the scope of this review, activators of skeletal 
muscle signaling include mechanotransduction, ATP turn-over, production of reactive oxygen 
species, redox balance, and others (64). Overall, signaling events represent the initial regulator of 
transcriptional and translational activity during muscle adaptation. For a review of specific signaling 
pathways that have a role in regulating the response of skeletal muscle to exercise, see these 
reveiws (41, 47, 207). 
 
3. Transcription 
 Gene expression, known as transcription, is the process through which the genetic material 
of DNA is read and interpreted. Thus, transcription is often thought of as the “blueprint” or “intention” 
for eventual adjustments in protein composition (31). The end result of transcription is the formation 
of an RNA molecule that contains a specific sequence of nucleotides. The sequence of nucleotides 
in a RNA molecule is dictated by the sequence of nucleotides in the gene found in DNA. This 
process is initiated when the cell is signaled to produce more of a protein or enzyme. When 
stimulated, RNA polymerase reads a particular sequence of DNA (gene), specified by one or more 
transcription factors, and generates a complimentary single stranded RNA within the nucleus (208) 
(Fig. 2-1). Once the RNA polymerase encounters the terminator region of the gene, the formation 
of the RNA molecule is complete and it is exported into the cytosol where post-transcriptional 
modification such as alternative splicing, where exon sequences are rearranged to encode distinct 
proteins from a single mRNA (208). Consequently, “gene expression” most often refers to changes 
in the abundance of a particular mRNA molecule. 
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4. Translation 
Three versions of RNA exist: tRNA, rRNA, and mRNA. The RNA that provides the 
nucleotide sequence to form specific proteins is the mRNA. Once the mRNA is transported into the 
cytoplasm, it is bound by a ribosome that translates the specific base sequences of the mRNA into 
a specific sequence of amino acids to form a protein/polypeptide (Fig. 2-1). Following translation, 
the amino acid sequences typically undergoes post-translation modification enabling its proper 
function (208). Together, the translation of mRNA into new, functioning proteins is often referred to 
as protein synthesis. Skeletal muscle protein synthesis is a vital response following exercise and 
has been shown to persist for up to 48 hours following an exercise bout (190).  
5. Summary 
Collectively, the aforementioned molecular processes (cellular signaling, transcription, 
translation) are repeatedly and synchronously activated following each acute exercise session. 
Over time, the repeated stimulate of these molecular events ultimately leads produces alterations 
in cellular makeup (protein abundance) and function of skeletal muscle (72). 
III.  ULTRASONOGRAPHY AND MUSCLE ARCHITECTURE 
A.  History of Ultrasound Imaging 
 The technological foundation of ultrasound imaging dates back to 1880, when Jacques and 
Pierre Curie discovered the piezoelectric effect of quartz crystals (49-51). This discovery 
demonstrated the ability of quartz crystals to produce outward traveling sound waves when an 
electric current is applied. Subsequently these sound waves are able to generate an electric signal 
when they reverberate off an object and return to the crystals. Interestingly, the practical application 
of this discovery was popularized between World War I and World War II. During this period, 
reflectoscopes were developed as underwater “microphones”, utilizing the piezoelectric effect as a 
means of echolocation to detect submarines and identify damage on the hulls of ships (196). 
Subsequently, this technology was adapted and employed as a medical device in 1942 by Dr. Karl 
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Dussik in an attempt to visualize brain tumors (62). Today, modern ultrasound devices still utilize 
the piezoelectric effect with quartz crystals encapsulated in digital handheld probes paired to 
computers for real-time imaging feedback. 
The first reported use of ultrasound for musculoskeletal diagnostics was in 1958, when 
Donald and colleagues utilized ultrasound imaging to differentiate between cystic and solid masses 
in the abdomen (61). As technology improved, brightness mode (B-mode) ultrasound became 
capable of revealing differences in the echogenicity (brightness) of different tissues, which was 
considered to be associated with articular and periarticular injuries and diseases. With current 
ultrasound technology, anatomical compartments such as bone, muscle, connective tissue, and fat 
are easily distinguishable (Fig. 2-2).  
 
A single two-dimensional image of skeletal muscle can provide valuable insight into a 
skeletal muscle’s phenotype through the ability to quantify and measure muscle thickness (MT), 
pennation angle (PA) and fascicle length (FL). Similarly, a muscle’s composition can also be 
assessed through the measure of echogenicity (EG). These variables are routinely coupled with 
functional assessments of the muscle(s) and may serve as predictors of muscle strength and 
Figure 2-2.  B-mode ultrasound image in the longitudinal plane of 
the lateral quadriceps. Differences in echogenicity (brightness) 
allow for clear differentiation of several tissue compartments 
including skin, fat, muscle, connective tissue, and bone. 
Skin 
Vastus Lateralis 
Aponeurosis 
Femur 
Subcutaneous Fat 
Vastus Intermedius 
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function (5, 205, 270). The following sections address the use of ultrasound imaging (US) in the 
measurement of skeletal muscle size, architecture, and composition. Given the focus of this 
dissertation on imaging of only the quadriceps femoris (see Chapter 3), this review will focus on 
the quadriceps femoris muscle group, comprised of the vastus lateralis (VL), rectus femoris (RF), 
vastus intermedius (VI), and vastus medialis (VM). Please note that US has also been applied to 
the study of other skeletal muscle groups (67, 191). 
 
B.  Muscle Thickness 
 Skeletal muscle thickness (MT) is defined as the perpendicular distance between the two-
fascia surrounding a muscle. As an indicator of skeletal muscle mass, US-based muscle thickness 
measurements are strongly related to the cross-sectional area (CSA) of a muscle when measured 
via magnetic resonance imaging (MRI) (2). When compared with the manual measurement of 
quadriceps muscles from cadavers, US measurements of MT differed by only 0.03 cm, or 1% to 
1.5% of the average adult quadriceps thickness (80). US-based MT assessments has since been 
accepted as a valid alternative to more invasive techniques (i.e., muscle biopsy) or expensive 
approaches, such as MRI, computed tomography (CT), or dual-energy x-ray absorptiometry (DXA) 
(195). 
 A disadvantage of US is the relatively limited imaging area compared to the 
aforementioned imaging technologies. The area of an US image is dictated by the size of the 
transducer (the probe that emits and receives sound) which is typically ~4 cm in length. Thus, a 
single longitudinal US image (Fig. 2) only depicts the MT in a ~4cm region of a particular anatomical 
region. Therefore, it is not uncommon to acquire images from multiple sites along the same muscle, 
which is important since heterogeneity of MT within each muscle of the quadriceps has been well 
documented with US (13, 24, 25, 66, 152). In the VL and RF, MT decreases from proximal to distal, 
whereas in the VM, MT increases distally (13, 25, 66). While the MT of the anterior aspect of the 
VI appears fairly uniform across the length of the leg (25), the lateral aspect of the VI appears to 
decrease from proximal to distal (13, 25). Given that MT varies within the quadriceps muscles, care 
must be taken to ensure measures are taken at the same site to allow for appropriate comparisons. 
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Alternatively, variability may be reduced if measures are taken at multiple sites along the 
quadriceps. Thus, the ability for US to quickly assess MT at multiple sites on multiple muscles 
provides the ability observe within- and between-muscle responses to stimuli such as exercise 
training. 
 Following a resistance training program, increases in the CSA of the quadriceps muscles 
also differ at distinct regions along each muscle (176). Indeed, varying degrees of hypertrophy 
within a muscle have been demonstrated using US measures of MT at different sites longitudinally 
along a muscle (24, 66, 152). Far more common is the use of US to assess changes in MT at a 
single location on one or multiple muscles of the quadriceps following a chronic exercise routine 
(10, 11, 20, 24, 66, 105, 152, 169, 199, 203, 214, 232, 237, 258, 267). Documented changes in 
quadriceps MT range from increases of 5% to 47% from pre- to post-training. All but one study 
(169) included a resistance exercise intervention, whereas Murach et al. (169) observed no change 
in MT of the VL following 12 weeks of run training. Increases in MT following exercise training vary 
slightly between the four muscles of the quadriceps; VL: 5-17%, RF: 7-47%, VI: 9-15%, and VM: 
11-15%. Interestingly, while quadriceps MT is smaller in old versus young individuals (7, 236), the 
current body of literature indicates a similar degree of change in following training between young 
(< 50 yrs) and old (> 50 yrs) populations. Changes in MT following training in young are: VL: 5-
17%, RF: 7-47%, VI: 10-14%, VM: ~14%, while changes in the MT of older populations are: VL: 8-
15%, RF: 8-23%, VI: 9-15%, VM: 11-15% (Table 2-1). 
 Not only is MT examined as an indicator for hypertrophy, but also as a means to predict 
skeletal muscle function. Given the shared quadriceps tendon and functional role of the quadriceps 
muscles, the MT of the quadriceps muscles is commonly correlated to isolated actions of the knee 
joint such as isometric and isokinetic knee extension (KE). Several studies have demonstrated a 
moderate, positive relationship (r = 0.41 – 0.70) between the combined MT of several or all 
quadriceps muscles and peak KE force (3, 40, 78, 256, 261). Examining the relationship between 
the MT and peak KE force in a muscle specific manner reveals varying degrees of correlation 
amongst the four quadriceps muscles: VL: r = 0.54 – 0.84, RF: r = 0.19 – 0.88, VI: r = 0.42 – 0.82, 
VM: r = 0.39 – 0.92 (Table 2-1). Overall, the MT of each quadriceps muscle varies in its relation to 
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peak KE force. Furthermore, in the only study to directly compare between young (24 ± 4 yrs) and 
older (68 ± 5 yrs) participants, the relationships between the MT of each quadriceps muscle and 
peak KE were lower in old (236). The age-related reduction in the relationship between MT and KE 
force may indicate varying architectural or compositional differences that occur in skeletal muscle 
with advancing age, or differences in the ability of the tendon to transfer force (42). However, while 
the measurement of MT is effective in assessing muscle mass within and between muscles, US 
imaging enables other measurements capable of revealing architectural or compositional details of 
skeletal muscle. 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Freilich, 1995 
(75) 
18 - 50 Quad - - 
Isomet. KE; 
Men: r = 0.55 
Women: r = 0.56 
Cadore, 2012 
(40) 
66 ± 5 
VI 
 
 
 
 
VM 
 
 
 
 
Quad 
- - 
Isomet. KE: r = 0.42 
Isokin. KE (60/s): r = 0.53 
Isokin. KE (180/s): r = 0.51 
Isokin. KE (360/s): r = 0.52 
 
Isomet. KE: r = 0.42 
Isokin. KE (60/s): r = 0.55 
Isokin. KE (180/s): r = 0.62 
Isokin. KE (360/s): r = 0.60 
 
Isomet. KE: r = 0.43 
Isokin. KE (60/s): r = 0.57 
Isokin. KE (180/s): r = 0.63 
Isokin. KE (360/s): r = 0.61 
Fukumoto, 2012 
(78) 
70 ± 6 Quad - - Isomet. KE: r = 0.47 
Strasser, 2013 
(236) 
Y: 24 ± 4 
O: 68 ± 
5 
 
VL 
 
VI 
 
VM 
 
RF 
- - 
Isomet. KE; 
Y: r =0.838; O: r = 0.756 
 
Y: r =0.918; O: r = 0.815 
 
Y: r =0.920; O: r = 0.875 
 
Y: r =0.880; O: r = 0.834 
Wantanabe, 
2013 
(256) 
74 ± 6 Quad - - Isomet. KE: r = 0.411 
Abe, 2014 
(3) 
52 – 82 Quad - - Isomet. KE: r = 0.703 
  
1
7
 
 
Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Wilhelm, 2014 
(261) 
66 ± 5 Quad - - 
1RM: r = 0.656 
Isomet. KE: r = 0.620 
Ando, 2014 
(13) 
22 ± 1 
VL 
 
VI (lateral) 
 
VI (anterior) 
 
VM 
 
RF 
- - 
(ns) 
 
(ns) 
 
Isomet. KE: r = 0.74 
 
Isomet. KE: r = 0.39 
 
Isomet. KE: r = 0.19 
Tillquist, 2014 
(242) 
31 ± 8 Quad - -  
Lopez, 2017 
(148) 
66 ± 5 Quad - - 30sec Sit-to-stand: r = 0.51 
Raj, 2017 
(219) 
68 ± 5 
 
 
VL 
 
 
 
 
 
RF+VI 
- - 
Isomet. KE: r = 0.62 
Isokin. KE (60/s): r = 0.66 
Isokin. KE (120/s): r = 0.60 
Isokin. KE (240/s): r = 0.65 
Isokin. KE (360/s): r = 0.54 
 
Isomet. KE: r = 0.56 
Isokin. KE (60/s): r = 0.60 
Isokin. KE (120/s): r = 0.59 
Isokin. KE (240/s): r = 0.62 
Isokin. KE (360/s): r = 0.53 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Stock, 2017 
(234) 
12 ± 1 
VL 
RF 
- - 
VL: 
Sprint speed: r = -0.538 
Agility: r = -0.555 
Isomet KE: r = 0.422 
 
RF: 
Jump height: r = 0.400 
Sprint speed: r = -0.606 
Peak velocity: r = 0.491 
Agility: r = -0.646 
Isomet. KE: r = 0.564 
Blazevich, 2003 
(24) 
22 ± 2 
VL (distal) 
 
 
 
VL 
(proximal) 
 
 
 
RF (distal) 
 
 
 
RF 
(proximal) 
Weeks 1-4: 
3 sets of 10 LP, DL, LE 
2d/week 
 
Weeks 5-9: 
Squats (SQ) 
2d/week  
or 
Front hack squat (FHS) 
2d/week 
or  
sprint/jump (SJ) 
4d/week 
 
VL (distal): ↔ 
 
 
VL (proximal): 
↑ 11% (SQ) 
↑ 12% (FSH) 
 
 
RF (distal): ↔ 
 
 
RF (proximal): 
↑ 8% (SQ) 
↑ 11% (FSH) 
↑ 12% (SJ) 
- 
Alegre, 2006 
(11) 
22 ± 2 VL 
3-4 sets of 6-12 half squat @ 50-
60%1RM 
3d/week 
13 weeks 
↑ 7% Squat 1RM: r = 0.52 – 0.54 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Suetta, 2008 
(237) 
60 – 86 VL 
RT: KE and LP 
3d/week 
12 weeks 
 
ES: electrical stimulation for 1h 
@ 40Hz 
3d/week 
12 weeks 
 
SR: functional mobility exercises 
3d/week 
12 weeks 
RT: ↑ 15% 
 
ES: ↔ 
 
SR: ↔ 
- 
Reeves, 2009 
(203) 
74 ± 3 VL 
RT: 
2 sets of 10 @ 80% 5RM 
3d/week 
14 weeks 
 
Eccentric only RT (ECC): 
2 sets of 10 @ 80% 5RM 
3d/week 
14 weeks 
RT: ↔ 
 
ECC: ↔ 
- 
Baroni, 2013 
(20) 
24 ± 3 
VL 
 
 
RF 
3-5 sets of 10 ECC isokin. KE @ 
60/s 
2d/week 
12 weeks 
4 weeks: 
VL: ↑ 5% 
RF: ↑ 7% 
 
8 weeks: 
VL: ↑ 7% 
RF: ↑ 10% 
 
12 weeks: 
VL: ↑ 7% 
RF: ↑ 10% 
- 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Guilhelm, 2013 
(105) 
20 ± 3 VL 
ECC Isoload (IL): 
3-5 sets of 8 KE @ 120% 1RM 
20 sessions 
9 weeks 
 
ECC Isokin. (IK): 
3-5 sets of n reps (work-matched 
to IL) KE @ maximal effort 
20 sessions 
9 weeks 
IL: ↑ 10% 
 
IK: ↔ 
- 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Ema, 2013 
(66) 
27 ± 2 
VL (distal) 
VL 
(proximal) 
 
VI-Lateral 
(distal) 
VI-Lateral 
(proximal) 
 
VI-Medial 
(distal) 
VI-Medial 
(proximal) 
 
VM (distal) 
VM 
(proximal) 
 
RF (distal) 
RF 
(proximal) 
5 sets of 8 KE @ 80% 1RM 
12 weeks 
VL (distal): ↑ 
9% 
VL (proximal): 
↑ 8% 
 
VI-Lateral 
(distal): ↔ 
VI-Lateral 
(proximal): ↔ 
 
VI-Medial 
(distal): ↑ 14% 
VI-Medial 
(proximal): ↑ 
10% 
 
VM (distal): ↔ 
VM (proximal): 
↑ 14% 
 
RF (distal): ↑ 
22% 
RF (proximal): 
↑ 16%  
- 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Radaelli, 2013 
(199) 
60 – 74 
VL 
 
VI 
 
VM 
 
RF 
High volume (HV): 
3 sets per RE 
 
or 
 
Low volume (LV): 1 set per RE 
 
2d/week 
13 weeks 
HV: 
VL: ↑ 13% 
VI: ↑ 15% 
VM: ↑ 15% 
RF: ↑ 11% 
 
LV: 
VL: ↑ 8% 
VI: ↑ 9% 
VM: ↑ 11% 
RF: ↑ 8% 
- 
Scanlon, 2014 
(214) 
71 ± 7 
VL 
RF 
2-4 sets of 8-12 reps @ 70-85% 
1RM 
2d/week 
6 weeks 
VL: ↔ 
RF: ↔ 
- 
Wells, 2014 
(258) 
20 ± 1 VL 
Whole body progressive RE 
4d/week 
15 weeks 
VL0 (lateral): 
↔ 
VL5 (5cm 
medial): ↑ 10% 
Squat 1RM: 
VL0: r = 0.561 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Alegre, 2014 
(10) 
19 ± 2 VL 
3-4 sets of 5-7 isomet. KE @ 
either 50 KF (K50) or 90 KF 
(K90) 
2-3d/week 
8weeks 
K50: 
VL25 
(proximal): ↑ 
6% 
VL50 (middle): 
↑ 5% 
VL75 (distal): 
↔ 
 
K90: 
VL25 
(proximal): ↑ 
9% 
VL50 (middle): 
↑ 14% 
VL75 (distal): ↑ 
9% 
- 
Matta, 2015 
(152) 
19 ± 1 
RF 
(proximal, 
distal) 
3 sets of 10-11 isotonic (TON) or 
isokinetic (IK, 60/s) KE 
2d/week 
14 weeks 
TON: 
Proximal: ↑ 
14% 
Distal: ↑ 47% 
 
IK: 
Proximal: ↑ 
11% 
Distal: ↑ 32% 
- 
Murach, 2015 
(169) 
20 ± 1 VL 
Running 
4d/week 
12 weeks 
↔ - 
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Table 2-1 (pg. 16-24). Summary of ultrasound-derived muscle thickness measurements in the quadriceps: relationship to muscle 
function and changes with exercise training 
Author, Year 
(Reference) 
Age 
(yrs) 
Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Stansinaki, 2015 
(232) 
22 ± 2 VL 
Whole body RE 
3d/week 
6 weeks 
↑ 7-17% - 
Yoshiko, 2017 
(267) 
78 ± 8 RF 
Progressive rehab. program (RE 
& AE) 
12 months 
6mo.: ↔ 
12mo.: ↑ 23% 
- 
Quad, quadriceps; isomet, isometric; KE, knee extension; VI, vastus intermedius; VM, vastus medialis; isokin, isokinetic; Y, young; 
O, old; VL, vastus lateralis; RF, rectus femoris; RM, repetition maximum; LP, leg press; ns, not statistically significant; DL, dead lift; 
SQ, squat; FHS, front hack squat; SJ, sprint/jump training; RT, resistance training; ES, electrical stimulation; SR, standard 
rehabilitation; ECC, eccentric; IL, isoload training; IK, isokinetic training; HV, high volume; LV, low volume; RE, resistance exercise; 
KF, knee flexion; TON, isotonic training; ↔, p > 0.05; ↑ or ↓, p < 0.05. 
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 C. Pennation Angle and Fascicle Length 
 The function of skeletal muscle is governed, in part, based on the orientation of muscle 
fibers within the muscle (142, 203). Ultrasound imaging is capable of noninvasively assessing two 
hallmark architectural features of skeletal muscle, pennation angle and fascicle length. Pennation 
angle (PA) is defined as the angle between the orientation of a fascicle (bundle of muscle fibers) 
and the attached tendon (axis of forge generation) (Fig. 2-3). The degree of PA is directly related 
to force producing capacity of a muscle (143). Fascicle length (FL) is, in theory, a measurement of 
muscle fiber length. However, due to the difficulty to measure muscle fiber length in practice, FL is 
often measured from B-mode US images such as Fig. 2-3 instead. Defined as the distance between 
the intersection of the axis of force generation (tendon) and fascicle and the intersection of the 
opposing aponeurosis and fascicle, FL is proportional to the contractile velocity of a muscle (140). 
Due to geometrical constraints, a muscle with greater PA 
typically has shorter FL, and vice versa. Thus, variability 
in PA and FL between muscles largely explains the 
unique functional roles of varying muscles (143), even 
those with similar cross-sectional areas. 
Similar to MT, PA and FL not only vary across 
muscles, but also within muscles. Through US imaging, 
PA has been well documented to vary along different 
regions of all muscles of the quadriceps except the VI (24, 
25, 66, 152, 157). In the VL and RF muscles, PA typically 
decreases from proximal to distal (24, 25, 66, 152), 
whereas in the VM, PA increases proximal to distal (25, 
66). Although limited to one investigation, the PA of the 
VI appears somewhat constant along the length of the leg (25). The literature is limited regarding 
the heterogeneity of FL within each muscle of the quadriceps. Nonetheless, the simultaneous 
measurement of both PA and FL along multiple regions of a muscle can provide valuable insight 
into the functional characteristics of a muscle and how they are altered following various stimuli. 
Figure 2-3.  B-mode US image of 
the vastus lateralis (VL) and lateral 
vastus intermedius (VI). Pennation 
angle is measured as the angel 
between the fascicle and deep 
aponeurosis. Fascicle length is 
determined by extrapolating the 
superficial aponeurosis and fascicle 
to the right of the field of view until 
they intersect and measuring the 
distance from this intersection to 
the intersection with the deep 
aponeurosis. 
  26 
Exercise training is a powerful stimulus for skeletal muscle adaptation, and by assessing 
changes in PA and FL, one may better understand how a muscle is adapting following training. For 
instance, an increase in PA following training is likely the result of additional sarcomeres in parallel, 
or added contractile elements along the axis of force generation (172). This phenomenon of 
including more fibers along the force producing axis of a muscle is termed fiber packing (142). 
Conversely, the observation of increased FL following exercise training would infer that sarcomeres 
were added in series, resulting in greater contractile velocity (140). It is fairly common that PA and 
FL are measured simultaneously, however these variables often respond differently following 
chronic exercise training (Fig. 2-4). 
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Pre-training 
MT: 40mm 
PA: 30o 
Changes Following 
Exercise Training 
(Reference) 
PA: ↓ FL: ↑ MT: ↔ 
MT: 40mm 
PA: 25o 
(24) 
MT: 40mm 
PA: 45o 
PA: ↑ FL: ↓ MT: ↔ 
N/A 
MT: 60mm 
PA: 30o 
PA: ↔ FL: ↑ MT: ↑ 
 (11, 20, 204) 
MT: 80mm 
PA: 45o 
PA: ↑ FL: ↔ MT: ↑ 
 (10, 66, 105, 
232) 
Figure 2-4. Simplified schematic of possible combinations of MT, PA, and FL 
responses following chronic exercise training. Numerical values and changes 
are not actual. MT, muscle thickness; PA, pennation angle; FL, fascicle 
length; N/A, no reference available. 
N/A MT: 85mm 
PA: 45o 
PA: ↑ FL: ↑ MT: ↑ 
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Following an exercise training program, increases in quadricpes PA documented with US 
range from 4% following 12 weeks of knee extension resistance training (RT) (66) to 46% following 
9 weeks of RT emphasizing squats (24). Changes in PA have been documented with a little as 5 
weeks of knee extension training on a gravity-independent leg ergometer (220). All exercise training 
interventions included RT except for three studies, which included cycling (68), running (169), or 
functional mobility exercises (237). Functional mobility exercise was the only exercise training 
intervention to result in decreased PA (237), whereas cycling and running did not influence 
quadriceps PA (68, 169). Changes in PA also varied slightly between the muscles of the 
quadriceps. Increases in the PA of the VL ranged from 4% (66) to 36% following 14 weeks of RT 
(1), whereas changes in PA of the RF ranged from 13% (66) to 46% (24) both following 12 and 9 
weeks of RT, respectively. Interestingly, changes in PA of the VI and VM following exercise training 
have only been documented in one study (66), where increases ranged from 6 – 12% in the VI and 
4 – 7% in the VM following 12 weeks of RT. 
Changes in FL following chronic exercise training range from increases of 2% following as 
little as 1.5 weeks of knee extension training on a gravity-independent leg ergometer (220), to 83% 
following 9 weeks of squat-focused RT (24). Changes in FL within each muscle of the quadriceps 
is limited to the VL and RF, as there are no documented changes in the FL of the VI or VM following 
exercise training. Increases in the FL of the VL range from 2 – 80% following 1.5 weeks of knee 
extension training (220) and 9 weeks of squat-focused RT (24), respectively. Changes in the FL of 
the RF range from 14% following 12 weeks of eccentric RT (20) to 83% following 9 weeks of squat-
focused RT (24). 
Accompanying the aging-induced decrease in quadriceps MT (7, 236) is a similar decrease 
in PA and FL (175), which may account for up to half of the age-related loss in maximal contractile 
force and velocity (174). However, while the body of literature is limited, it appears exercise is a 
viable means to increase PA and FL in the quadriceps muscles of older populations. Only four 
studies (203, 204, 214, 237) have employed US to assess changes in PA and FL of the quadriceps 
muscles following exercise training. Three studies report no changes in PA following 12 weeks of 
electrical stimulation (237), 6 weeks of RT (214), or 14 weeks of eccentric RT (203). Yet, two 
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investigations demonstrate 8% and 20% increases in PA following 12 weeks (237) and 14 weeks 
of RT (204), respectively. While 6 weeks of RT was sufficient to induces changes in FL of the VL 
or RF of older individuals (214), increases in VL FL have been noted following 14 weeks of 
traditional (204) and eccentric RT (203). Surprisingly, exercise-induced changes in the PA or FL of 
the VI or VM have not been demonstrated in older populations. Collectively, it does appear that 
exercise is capable of inducing positive adaptations in the skeletal muscle architecture of older 
adults. 
 Similar to US-based MT measurements, PA and FL are commonly assessed to predict 
muscle function. Several studies have demonstrated a positive, moderate relationship (r = 0.341 – 
0.680) between PA and peak isometric KE torque (13, 219, 236). However, it appears that the PA 
of some, but not all of the quadriceps muscles exhibit this relationship with peak isometric KE. 
While Strasser et al. (236) demonstrated positive relationships between the PA of the VL , VI, and 
VM and peak isometric KE (r = 0.341, 0.680, 0.338; respectively), Ando and colleagues (13) 
showed that only the PA of the anterior VI was significantly correlated (r = 0.680) to peak isometric 
KE. Furthermore, an early study displayed no significant relationship between the PA of the VL or 
VI and peak isometric KE (209). Nonetheless, PA of the quadriceps has also been shown to be 
positively related to peak isometric squat (11) and 100m sprint performance (136). The relationship 
between FL and function of the quadriceps muscles has been less studied, with only one study 
demonstrating a significant relationship (r = -0.43) between FL of the VL and 100m sprint 
performance (136). In the only study to directly compare between young and old individuals, 
Strasser et al. (236) shows that only the PA of the VL, VI, and VM in the young are significantly 
related to peak isometric KE, whereas no significant relationships were revealed from the muscle 
architecture of the old. While it appears muscle architecture not only varies between muscles and 
age groups, so too does the relationship between muscle architecture and function. While more 
research examining muscle architecture in older populations is warranted, it is possible that 
quadriceps muscle function may be better predicted with a combination of US based 
measurements, including architecture, MT, and muscle composition. 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Kumagai, 
2000 
(136) 
NA VL - - 
100m sprint; 
PA: r = 0.34 
FL: r = -0.43 
Strasser, 2013 
(236) 
Y: 24 ± 4 
O: 68 ± 5 
 
VL 
 
VI 
 
VM 
- - 
Isomet. KE; 
PA: 
Y: r =0.341; O: r =0.322 (ns) 
 
Y: r =0.680; O: r =0.306 (ns) 
 
Y: r =0.338; O: r =0.253 (ns) 
Ando, 2014 
(13) 
22 ± 1 
 
VL 
 
 
VI 
(lateral) 
 
 
VI 
(anterior) 
 
 
VM 
 
 
RF 
- - 
Isomet. KE; 
 
PA: r = 0.15 (ns) 
FL: ns 
 
PA: r = 0.68 (ns) 
FL: ns 
 
PA: r = 0.68 
FL: ns 
 
PA: r = 0.35 (ns) 
FL: ns 
 
PA: r = 0.20 (ns) 
FL: ns 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Raj, 2017 
(219) 
68 ± 5 VL - - 
PA: 
Isomet. KE: r = 0.36 
Isokin. KE (60/s): r = 0.31 (ns) 
Isokin. KE (120/s): r = 0.26 (ns) 
Isokin. KE (240/s): r = 0.31 (ns) 
Isokin. KE (360/s): r = 0.28 (ns) 
 
FL: 
Isomet. KE: r = 0.04 (ns) 
Isokin. KE (60/s): r = 0.13 (ns) 
Isokin. KE (120/s): r = 0.11 (ns) 
Isokin. KE (240/s): r = 0.09 (ns) 
Isokin. KE (360/s): r = 0.00 (ns) 
 
Rutherford, 
1992 
(209) 
18 – 40 
VL 
 
 
VI 
4 sets of 6 KE @ 6RM 
3d/week 
12weeks 
FA: ↔ 
 
 
FA: ↔ 
Isomet. KE: No relation. 
Aagaard, 2001 
(1) 
27 ± 5 VL 
4-5 sets of 4-12 Squats, 
LP, KE 
2-3d/week 
14weeks 
PA: ↑ 36 ± 8% - 
  
3
2
 
 
 
Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Blazevich, 
2003 
(24) 
22 ± 2 
VL 
(distal) 
 
 
 
VL 
(proximal) 
 
 
 
RF 
(distal) 
 
 
 
RF 
(proximal) 
Weeks 1-4: 
3 sets of 10 LP, DL, LE 
2d/week 
 
Weeks 5-9: 
Squats (SQ) 
2d/week 
or 
Front hack squat (FHS) 
2d/week 
or 
sprint/jump (SJ) 
4d/week 
 
VL (distal) 
PA: ↔ 
FL: ↑ 80% w/ (SJ) 
 
VL (proximal) 
PA: ↓ 31% w/ (SJ) 
FL: ↑ 25% w/ (SJ) 
 
RF (distal) 
PA: ↑ 46% w/ (FHS) 
FL: ↑ 22% w/ (SQ) 
 
RF (proximal) 
PA: ↔ 
FL: ↑ 83% w/ (SQ); ↑ 
39% w/ (SJ) 
- 
Reeves, 2004 
(204) 
74 ± 4 VL 
2 sets of 10 KE and LP @ 
60-80% 5RM 
3d/week 
14 weeks 
PA: ↑ 8-10% 
FL: ↑ 28-35% 
- 
Alegre, 2006 
(11) 
22 ± 2 VL 
3-4 sets of 6-12 half squat 
@ 50-60%1RM 
3d/week 
13 weeks 
PA: ↔ 
FL: ↑ 10% 
PA: 
Isometric squat: r = 0.57 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Seynnes, 
2007 
(220) 
20 ± 2 VL 
KE on gravity-independent 
flywheel ergometer 
3d/week 
5 weeks 
1.5 weeks: 
PA: ↔ 
FL: ↑ 2% 
 
3 weeks: 
PA: ↔ 
FL: ↑ 6% 
 
5 weeks: 
PA: ↑ 8% 
FL: ↑ 10% 
 
- 
Suetta, 2008 
(237) 
60 – 86 VL 
RT: KE and LP 
3d/week 
12 weeks 
 
ES: electrical stimulation 
for 1h @ 40Hz 
3d/week 
12 weeks 
 
SR: functional mobility 
exercises 
3d/week 
12 weeks 
RT: 
PA: ↑ 22% 
 
ES: 
PA: ↔ 
 
SR: 
PA: ↓ 11% 
∆ PA w/ RT: 
∆ Isokin. KE (60/s): r = 0.619 
∆ Isokin. KE (180/s): r = 0.530 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Reeves, 2009 
(203) 
74 ± 3 VL 
RT: 
2 sets of 10 @ 80% 5RM 
3d/week 
14 weeks 
 
Eccentric only RT (ECC): 
2 sets of 10 @ 80% 5RM 
3d/week 
14 weeks 
RT: 
(previously reported: 
Reeves, 2004) 
 
ECC: 
PA: ↔ 
FL: ↑ 20% 
- 
Farup, 2012 
(68) 
23 ± 1 VL 
END: 30-40min cycling 
or 
RT: 3-5 sets of 4-10 
maximal reps 
3d/week 
10 weeks 
END: 
PA: ↔ 
 
RT: 
PA: ↑ 23% 
- 
Baroni, 2013 
(20) 
24 ± 3 
VL 
 
 
RF 
3-5 sets of 10 ECC isokin. 
KE @ 60/s 
2d/week 
12 weeks 
4 weeks: 
VL PA: ↔ 
VL FL: ↑ 5% 
RF PA: ↔ 
RF FL: ↑ 6% 
 
8 weeks: 
VL PA: ↔ 
VL FL: ↑ 17% 
RF PA: ↔ 
RF FL: ↑ 14% 
 
12 weeks: 
VL PA: ↔ 
VL FL: ↑ 19% 
RF PA: ↔ 
RF FL: ↑ 17% 
- 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Guilhelm, 
2013 
(105) 
20 ± 3 VL 
ECC Isoload (IL): 
3-5 sets of 8 KE @ 120% 
1RM 
20 sessions 
9 weeks 
 
ECC Isokin.: 
3-5 sets of n reps (work-
matched to IL) KE @ 
maximal effort 
20 sessions 
9 weeks 
IL: 
PA: ↑ 11% 
FL: ↔ 
 
 
IK: 
PA: ↔ 
FL: ↔ 
 
- 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Ema, 2013 
(66) 
27 ± 2 
VL 
(distal) 
VL 
(proximal) 
 
 
VI-Lateral 
(distal) 
VI-Lateral 
(proximal) 
 
 
VI-Medial 
(distal) 
VI-Medial 
(proximal) 
 
 
VM 
(distal) 
VM 
(proximal) 
 
 
RF 
(distal) 
RF 
(proximal) 
5 sets of 8 KE @ 80% 
1RM 
12 weeks 
PA: 
VL (distal): ↑ 4% 
VL (proximal): ↑ 11% 
 
VI-Lateral (distal): ↔ 
VI-Lateral (proximal): ↔ 
 
VI-Medial (distal): ↑ 12% 
VI-Medial (proximal): ↑ 
6% 
 
VM (distal): ↑ 4% 
VM (proximal): ↑ 7% 
 
RF (distal): ↑ 19% 
RF (proximal): ↑ 13% 
 
FL: 
VL (distal): ↔ 
VL (proximal): ↔ 
 
VM (proximal): ↔ 
 
RF (proximal): ↔ 
- 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Scanlon, 2014 
(214) 
71 ± 7 
VL 
RF 
2-4 sets of 8-12 reps @ 
70-85% 1RM 
2d/week 
6 weeks 
PA: 
VL: ↔ 
RF: ↔ 
 
FL: 
VL: ↔ 
RF: ↔ 
- 
Wells, 2014 
(258) 
20 ± 1 VL 
Whole body progressive 
RE 
4d/week 
15 weeks 
PA: 
VL0 (lateral): ↔ 
VL5 (5cm medial): ↔ 
 
FL: 
VL0 (lateral): ↑ 6% 
VL5 (5cm medial): ↔ 
- 
Alegre, 2014 
(10) 
19 ± 2 VL 
3-4 sets of 5-7 isomet. KE 
@ either 50 KF (K50) or 
90 KF (K90) 
2-3d/week 
8weeks 
PA: 
K50: ↔ 
K90: ↑ 12% 
 
FL: 
K50: ↔ 
K90: ↔ 
- 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
McMahon, 
2014 
(156) 
19 ± 3 
VL 
(proximal, 
middle, 
distal) 
Progressive RE of either 
longer length (LL, 40-90 
KE) or shorter length (SL, 
0-50 KE) 
3d/week 
8 weeks 
PA: 
LL(proximal): ↑ 14% 
SL (proximal): ↑ 12% 
LL(middle): ↑ 6% 
SL (middle): ↑ 7% 
LL(distal): ↑ 7% 
SL (distal): ↑ 11% 
 
FL: 
LL(proximal): ↑ 27mm 
SL (proximal): ↑ 18mm 
LL(middle): ↑ 21mm 
SL (middle): ↑ 9mm 
LL(distal): ↑ 24mm 
SL (distal): ↑ 12mm 
- 
Franchi, 2014 
(74) 
25 ± 3 VL 
4 sets of 8-10 concentric 
(CON) or eccentric (ECC) 
leg-press @ 80% 1RM 
3d/week 
10 weeks 
PA: 
CON: ↑ 30% 
ECC: ↑ 5% 
 
FL: 
CON: ↑ 5% 
ECC: ↑ 12% 
- 
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Table 2-2 (pg. 30-39). Summary of Ultrasound-Based Pennation Angle and Fascicle Length Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training Correlation to Muscle 
Function Exercise Outcome 
Matta, 2015 
(152) 
19 ± 1 
RF 
(proximal, 
distal) 
3 sets of 10-11 isotonic 
(TON) or isokinetic (KIN, 
60/s) KE 
2d/week 
14 weeks 
PA: 
TON Proximal: ↔ 
TON Distal: ↑ 20% 
 
KIN Proximal: ↔ 
KIN Distal: ↔ 
- 
Murach, 2015 
(169) 
20 ± 1 VL 
Running 
4d/week 
12 weeks 
PA: ↔ 
FL: ↔ 
- 
Stansinaki, 
2015 
(232) 
22 ± 2 VL 
Whole body RE 
3d/week 
6 weeks 
PA: ↑ 20-26% 
 
FL: ↔ 
- 
Quad, quadriceps; isomet, isometric; KE, knee extension; VI, vastus intermedius; VM, vastus medialis; isokin, isokinetic; Y, young; O, 
old; VL, vastus lateralis; RF, rectus femoris; RM, repetition maximum; LP, leg press; ns, not statistically significant; DL, dead lift; SQ, 
squat; FHS, front hack squat; SJ, sprint/jump training; RT, resistance training; ES, electrical stimulation; SR, standard rehabilitation; 
ECC, eccentric; IL, isoload training; IK, isokinetic training; HV, high volume; LV, low volume; RE, resistance exercise; KF, knee flexion; 
TON, isotonic training; ↔, p > 0.05; ↑ or ↓, p < 0.05 
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D. Echogenicity 
 B-mode US imaging enables the investigation of skeletal muscle mass and architecture 
from a single 2D image. However, what muscle mass and architecture fail to account for is the 
quality, or composition, of skeletal muscle. Echogenicity (EG) can be defined as the degree of 
sound reflection influenced by the acoustic impedance of tissues (191). In a 2D B-mode US image 
(Fig. 2-1), skeletal muscle has relatively low EG compared to the dense connective tissue of the 
aponeuroses and the border of the femur bone. The lower EG of skeletal muscle demonstrates that 
the impedance of sound through skeletal muscle is greater than that in connective tissue or bone. 
The early work of Heckmatt et al. (112) revealed that dystrophic and healthy muscles exhibited 
different levels of EG, indicating an alteration in the composition of dystrophic skeletal muscles. 
Since, EG has been correlated to the infiltration of fibrous (192) and adipose tissue (8, 269) into 
skeletal muscle. As more non-contractile tissue appears within skeletal muscle, the reflection of 
sound diminishes, and the EG increases. As a mean to assess intramuscular fat, primarily in the 
form of extramyocellular fat (between muscle fibers), US-based EG has been validated against the 
gold standard MRI (8, 269). However, while EG is limited in its ability distinguish between fibrous 
tissue and fat, it is a valid means to assess differences in skeletal muscle composition. 
Similar to MT, PA, and FL, EG also appears to vary across the four muscles of the 
quadriceps. In both studies that have assessed EG in all quadriceps muscles the EG of the 
superficial quadriceps (VL, RF, VM) appear similar while the EG of the VI appears to be consistently 
lower (236, 261). However, rather than a true anatomical difference, this may be due to a limitation 
in US where deeper tissues appear less echoic (lower EG) due to an attenuation of the US beam 
(191). 
 Exercise training is known to alter the composition of skeletal muscle (99). Reductions in 
skeletal muscle EG, indicating reduced non-contractile tissue, following exercise training range 
from 9%, following 6 months of combined AE and RE (267), to 21%, following 13 weeks of RT 
(199). In the few studies that have examined muscle EG following exercise training (199, 214, 258, 
267), none report EG to increase. The lack of increase in EG with exercise training indicates that 
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exercise training does not worsen muscle quality (i.e., resists infiltration of adipose and/or 
connective tissue into skeletal musce), when assessed via US. 
It is well understood that aging is associated with a progressive decline in the quality of 
skeletal muscle (101, 163). Further, the replacement of muscle tissue with fibrous and fatty tissue 
has been implicated as a major contributor to reduced muscle quality with aging (114, 151, 271). 
Only one study (236) has directly compared skeletal muscle composition of young and old using 
US-based EG. Strasser et al. (236) reports that the EG of the VL, VI, VM, and RF are higher in old 
compared to young individuals, indicating a greater abundance of non-contractile tissue in the 
quadriceps of older individuals. Interestingly, three of the four exercise training studies that 
assessed muscle EG were conducted in older populations (Table 1-3). While six weeks of RT did 
not appear sufficient to change EG of the VL or RF, improvements in EG of the RF have been 
documented following as little as 13 weeks of RT (199). All exercise training studies include some 
form of RT, thus further research assessing the influence of AE training on muscle EG is warranted. 
Skeletal muscle EG not only provides an indication as to muscle composition, but it has 
also been shown to relate to skeletal muscle function. EG of all quadriceps muscles are negatively 
correlated to peak isometric KE torque in both young [VL: r = -0.50, VI: r = -0.64, VM: r = -0.47, RF: 
r = -0.63 - -0.52; (234, 236)] and old [VL: r = -0.55, VI: r = -0.48, VM: r = -0.64, RF: r = -0.46 - -0.51; 
(40, 78, 256, 261)]. In addition, EG has also been shown to negatively correlate to more translatable 
functional tests such as the sit-to-stand (9, 148), 6-min walk (9), and jump height (234). Therefore, 
in addition to measure of MT, PA, and FL, EG serves as an additional US-based metric to predict 
muscle function.
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Table 2-3 (pg.42-44). Summary of Ultrasound-Based Echogenicity Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Cadore, 2012 
(40) 
66 ± 5 RF - - 
Isomet. KE: r = -0.51 
Isokin. KE (60/s): r = -0.48 
Isokin. KE (180/s): r = -0.64 
Isokin. KE (360/s): r = -0.67 
Fukumoto, 2012 
(78) 
70 ± 6 Quad - - Isomet. KE: r = -0.33 
Strasser, 2013 
(236) 
Y: 24 ± 4 
O: 68 ± 5 
 
VL 
 
VI 
 
VM 
 
RF 
- - 
Isomet. KE; 
Y: r =-0.500; O: r =-0.272 (ns) 
 
Y: r =-0.640; O: r =-0.339 (ns) 
 
Y: r =-0.470; O: r =-0.100 (ns) 
 
Y: r =-0.630; O: r = -0.301 (ns) 
Wantanabe, 
2013 
(256) 
74 ± 6 Quad - - Isomet. KE: r = -0.333 
Wilhelm, 2014 
(261) 
66 ± 5 
VL 
 
 
VI 
 
 
VM 
 
 
RF 
- - 
1RM: r = -0.562 
Isomet. KE: r = -0.551 
 
1RM: r = -0.501 
Isomet. KE: r = -0.484 
 
1RM: r = -0.656 
Isomet. KE: r = -0.640 
 
1RM: r = -0.498 
Isomet. KE: r = -0.460 
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Table 2-3 (pg.42-44). Summary of Ultrasound-Based Echogenicity Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Akima, 2017 
(9) 
M: 65 – 82 
F: 65 – 88 
VL 
 
 
 
 
RF 
- - 
Sit-to-stand; 
M: r = 0.518; F: r = 0.168 (ns) 
6-min walk; 
M: r = -0.519; F: r = 0.009 (ns) 
 
Sit-to-stand; 
M: r = 0.398; F: r = 0.511 
6-min walk; 
M: r = -0.36 (ns); F: r = -0.16 (ns) 
Lopez, 2017 
(148) 
66 ± 5 Quad - - 30sec Sit-to-stand: r = -0.56 
Stock, 2017 
(234) 
12 ± 1 
VL 
RF 
- - 
VL: 
Jump height: r = -0.436 
Peak velocity: r = -0.406 
Sprint speed: r = 0.436 
Agility: r = 0.359 
 
RF: 
Jump height: r = -0.331 
Sprint speed: r = 0.480 
Agility: r = 0.540 
Isomet. KE: r = -0.524 
Radaelli, 2013 
(199) 
60 – 74 RF 
High volume 
(HV): 
3 sets per RE 
 
or 
 
Low volume (LV): 
1 set per RE 
 
2d/week 
13 weeks 
HV: 
RF: ↓ 21% 
 
LV: 
RF: ↓ 12% 
- 
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Table 2-3 (pg.42-44). Summary of Ultrasound-Based Echogenicity Measurements in the Quadriceps. 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Training 
Correlation to Muscle Function 
Exercise Outcome 
Scanlon, 2014 
(214) 
71 ± 7 
VL 
RF 
2-4 sets of 8-12 
reps @ 70-85% 
1RM 
2d/week 
6 weeks 
VL: ↔ 
RF: ↔ 
- 
Wells, 2014 
(258) 
20 ± 1 VL 
Whole body 
progressive RE 
4d/week 
15 weeks 
↔ - 
Yoshiko, 2017 
(267) 
78 ± 8 RF 
Progressive 
rehab. program 
(RE & AE) 
12 months 
6mo.: ↓ 9% 
12mo.: ↔ 
- 
Quad, quadriceps; isomet, isometric; KE, knee extension; VI, vastus intermedius; VM, vastus medialis; isokin, isokinetic; Y, young; O, 
old; VL, vastus lateralis; RF, rectus femoris; RM, repetition maximum; LP, leg press; ns, not statistically significant; DL, dead lift; SQ, 
squat; FHS, front hack squat; SJ, sprint/jump training; RT, resistance training; ES, electrical stimulation; SR, standard rehabilitation; 
ECC, eccentric; IL, isoload training; IK, isokinetic training; HV, high volume; LV, low volume; RE, resistance exercise; KF, knee flexion; 
TON, isotonic training; ↔, p > 0.05; ↑ or ↓, p < 0.05 
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E. Reliability of Ultrasound-Derived Muscle Architecture Measurements 
 Accuracy in skeletal muscle US is highly dependent on operator ability. As a testament to 
this point, US specialists such as diagnostic medical sonographers have become more prevalent 
in various health professions. Skeletal muscle US is commonly utilized in chronic studies to assess 
changes in skeletal muscle characteristics that reflect changes in muscle function. Therefore, 
establishing the test-retest reliability of skeletal muscle US is imperative for the ability to detect 
changes over serial measurements.  
In the measurement of MT, common sources of variability include probe orientation relative 
to the skin and excessive force of the probe on the skin, causing deformations in the underlying 
tissues. While most studies restrict serial measurements to being made by the same sonographer, 
the inter-rate reliability of MT measures of the quadriceps appears to be good (ICCs: 0.73 – 0.99) 
(242). Perhaps more important, the test-retest reliability of US-obtained MT ranges from ICCs of 
0.77 to ICCS of 0.90 (Table 2-4), and ICCs appear to be similar for measurements in all quadriceps 
muscles (25, 66, 236). In addition, test-retest reliability of MT measures appears to be similar 
regardless of if repeated measures are performed on the same day (4, 25, 164, 241, 242) or on 
different days (7, 13, 20, 66, 236). Measures of MT are predominantly assessed with subjects either 
standing (4) or supine (268). Of the few studies that have assessed the reliability of MT 
measurements while standing (4, 241), test-retest reliability appears to be similar to when MT 
measures are collected supine (Table 2-4). Lastly, the test-retest reliability of MT measures 
appears to be slightly lower in older individuals, when the reliability within young and old are directly 
compared (7, 236). This suggests that the ability to detect changes in MT of older adults may be 
impeded due to increased day-to-day variability. Overall, US appears to be a reliable means to 
assess MT of the quadriceps across various approaches (supine vs. standing) and ages (young 
vs. old). 
Ultrasound measures of muscle architecture, including and PA and FL, are largely 
susceptible to sources of variability associated with US given relatively fine image detail (Fig. 2-3) 
required for such analyses. In addition, fascicles often extend past the visible field of view of an US 
image, limited by the width of the US transducer. This results in the extrapolation of FL based on 
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measurements of the MT and PA. Across all quadriceps muscles, the test-retest reliability of US 
measures of PA and FL range from 0.436 – 0.960 and 0.758 – 0.980, respectively (Table 2-4). 
While the reliability of FL measurements appear to be similar across all quadriceps (13, 25, 66), 
PA measurements in the VM appear less reliable compared to measures in the remaining 
quadriceps (236), which are similarly reliable (13, 25, 66). Concerning the two predominant 
approaches to skeletal muscle US, imaging when subjects stand versus lay supine, the reliability 
of PA and FL measurements have not been assessed when subjects were imaged standing. 
Studies are warranted to directly assess the influence of subject posture during imaging on the 
reliability of PA and FL measures of the quadriceps. Additionally, only one study (236) has 
examined the influence of age on the reliability of PA measures in the quadriceps. This study 
demonstrated lower reliability in the PA measurements of the VI and VM in old compared to young 
(236). To date, no studies have examined the reliability of FL measures in the quadriceps of older 
individuals. Collectively, the literature is limited concerning the reliability of PA and FL 
measurements collected in different subject postures and age groups. 
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Table 2-4 (pg.47-51). Summary of ultrasound-based quadriceps muscle architecture measurements with reported reliability 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Subject 
Position 
Type of 
Reliability 
Reliability 
Muscle Thickness 
Abe, 1994 
(4) 
18 – 50 Quad Stand Test-retest 
Mean Diff = -0.71 – 0.19 mm 
ICC = 0.97-0.99 
Blazevich, 2006 
(25) 
M: 20 ± 3 
F: 21 ± 3 
VL, VI, VM, RF Supine Test-retest 
Mean Diff = 0.74 – 0.97 mm 
ICC = 0.882 – 0.970 
Moreau, 2009 
(164) 
12 ± 4 
VL 
 
RF 
Supine Inter-rater 
ICC = 0.99 
 
ICC = 0.98 
Thoirs, 2009 
(241) 
22 + 50 Quad 
Supine 
 
Stand 
Test-retest 
ICC = 0.8 – 0.95 
 
ICC = 0.79 – 0.94 
Strasser, 2013 
(236) 
Y: 24 ± 4  
O: 68 ± 5  
VL 
 
 
VI 
 
 
VM 
 
 
RF 
Supine Test-retest 
Y: ICC = 0.957 
O: ICC = 0.852 
 
Y: ICC = 0.978 
O: ICC = 0.928 
 
Y: ICC = 0.979 
O: ICC = 0.949 
 
Y: ICC = 0.972 
O: ICC = 0.876 
Agyapong-
Badu, 2014 
(7) 
Y: 18 – 35  
 
 
O: 65 – 90  
Quad Supine Test-retest 
Y: ICC = 0.78 – 0.95 
MDC = 5.5 mm 
 
O: ICC = 0.77 – 0.94 
MDC = 5.9 mm 
Ando, 2014 
(13) 
22 ± 1  VL, VI, RF Supine Test-retest ICC = 0.966 
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Table 2-4 (pg.47-51). Summary of ultrasound-based quadriceps muscle architecture measurements with reported reliability 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Subject 
Position 
Type of 
Reliability 
Reliability 
Tillquist, 2014 
(242) 
31 ± 8  Quad Supine 
Test-retest 
 
 
Inter-rater 
ICC = 0.940 – 0.990 
Mean Diff. = 3.30 mm 
 
ICC = 0.730 – 0.990 
Mean Diff. = -2.80 mm 
Baroni, 2013 
(20) 
24 ± 3  
VL 
RF 
Supine Test-retest 
VL: ICC = 0.910 
RF: ICC = 0.960 
Ema, 2013 
(66) 
27 ± 2  
VL (distal) 
VL (proximal) 
 
 
VI-Lateral 
(distal) 
VI-Lateral 
(proximal) 
 
 
VI-Medial 
(distal) 
VI-Medial 
(proximal) 
 
 
VM (distal) 
VM (proximal) 
 
 
RF (distal) 
RF (proximal) 
Supine Test-retest 
VL (distal): ICC = 0.991 
VL (proximal): ICC = 0.976 
 
VI-Lateral (distal): ICC = 0.978 
VI-Lateral (proximal): ICC = 0.979 
 
VI-Medial (distal): ICC = 0.955 
VI-Medial (proximal): ICC = 0.951 
 
VM (proximal): ICC = 0.861 
 
RF (distal): ICC = 0.984 
RF (proximal): ICC = 0.985 
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Table 2-4 (pg.47-51). Summary of ultrasound-based quadriceps muscle architecture measurements with reported reliability 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Subject 
Position 
Type of 
Reliability 
Reliability 
Pennation Angle & Fascicle Length 
Blazevich, 2006 
(25) 
M: 20 ± 3  
F: 21 ± 3  
VL, VI, VM, RF Supine Test-retest 
PA: Mean Diff. = 0.24 – 1.22 
ICC = 0.899 – 0.991 
FL: Mean Diff. = 10.2 – 19.4 mm 
ICC = 0.758 – 0.863 
Moreau, 2009 
(164) 
12 ± 4  
VL 
 
 
RF 
Supine Inter-rater 
PA: ICC = 0.96 
FL: ICC = 0.88 
 
PA: ICC = 0.95 
FL: ICC = 0.95 
Strasser, 2013 
(236) 
Y: 24 ± 4  
O: 68 ± 5  
VL 
 
 
VI 
 
 
VM 
Supine Test-retest 
Y: ICC = 0.530 
O: ICC = 0.687 
 
Y: ICC = 0.783 
O: ICC = 0.741 
 
Y: ICC = 0.436 
O: ICC = 0.189 
Ando, 2014 
(13) 
22 ± 1  VL, VI, RF Supine Test-retest 
PA: ICC = 0.949 
FL: ICC = 0.836 
Baroni, 2013 
(20) 
24 ± 3  
VL 
 
 
RF 
Supine Test-retest 
PA: 
VL: ICC = 0.900 
RF: ICC = 0.950 
 
FL: 
VL: ICC = 0.910 
RF: ICC = 0.950 
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Table 2-4 (pg.47-51). Summary of ultrasound-based quadriceps muscle architecture measurements with reported reliability 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Subject 
Position 
Type of 
Reliability 
Reliability 
Ema, 2013 
(66) 
27 ± 2  
VL (distal) 
VL (proximal) 
 
VI-Lateral 
(distal) 
VI-Lateral 
(proximal) 
 
VI-Medial 
(distal) 
VI-Medial 
(proximal) 
 
VM (distal) 
VM (proximal) 
 
RF (distal) 
RF (proximal) 
Supine Test-retest 
PA: 
VL (distal): ICC = 0.931 
VL (proximal): ICC = 0.885 
 
VI-Lateral (distal): ICC = 0.919 
VI-Lateral (proximal): ICC = 0.943 
 
VI-Medial (distal): ICC = 0.948 
VI-Medial (proximal): ICC = 0.795 
 
VM (distal): ICC = 0.940 
VM (proximal): ICC = 0.945 
 
 
RF (distal): ICC = 0.921 
RF (proximal): ICC = 0.921 
 
FL: 
VL (distal): ICC = 0.966 
VL (proximal): ICC = 0.838 
 
VM (proximal): ICC = 0.902 
 
RF (proximal): ICC = 0.980 
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Table 2-4 (pg.47-51). Summary of ultrasound-based quadriceps muscle architecture measurements with reported reliability 
Author, Year 
(Reference) 
Age (yrs) Muscle 
Subject 
Position 
Type of 
Reliability 
Reliability 
Echogenicity 
Strasser, 2013 
(236) 
Y: 24 ± 4  
O: 68 ± 5  
VL 
 
 
VI 
 
 
VM 
 
 
RF 
Supine Test-retest 
Y: ICC = 0.623 
O: ICC = 0.297 
 
Y: ICC = 0.650 
O: ICC = 0.313 
 
Y: ICC = 0.624 
O: ICC = 0.209 
 
Y: ICC = 0.571 
O: ICC = 0.307 
Young, 2015 
(269) 
20 – 64  RF Supine Test-retest 
ICC = 0.91 
CV = 3.3% 
Varanoske, 
2017 
(252) 
20 ± 2  VL Supine Test-retest 
ICC = 0.718 
SEM = 3.117 AU 
MD = 8.641 AU 
CV = 4.6% 
MDC: minimal detectable change; Quad, quadriceps; isomet, isometric; KE, knee extension; VI, vastus intermedius; VM, vastus 
medialis; isokin, isokinetic; Y, young; O, old; VL, vastus lateralis; RF, rectus femoris; RM, repetition maximum; LP, leg press; ns, not 
statistically significant; DL, dead lift; SQ, squat; FHS, front hack squat; SJ, sprint/jump training; RT, resistance training; ES, electrical 
stimulation; SR, standard rehabilitation; ECC, eccentric; IL, isoload training; IK, isokinetic training; HV, high volume; LV, low volume; RE, 
resistance exercise; KF, knee flexion; TON, isotonic training. 
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IV.  Doxorubicin and Skeletal Muscle 
A. Overview of Doxorubicin 
Anthracycline class chemotherapeutics, which were derived from Streptomyces bacteria, 
were originally discovered in the 1960s (34). Anthracyclines have been utilized clinically for over 
50 years to aid in the treatment of many types of cancers, including leukemia, lymphoma, breast, 
and prostate (85). Danorubicin was the first anthracycline compound to be fully characterized and 
used in the treatment of leukemias (85). Soon thereafter, Doxorubicin (DOX) was developed (16) 
with a broader spectrum of applications and was considered one of the most effective 
chemotherapeutics (257). The anti-tumor effects of DOX vary, but include the inhibition of DNA 
replication by intercalating into DNA helixes and impairing topoisomerase II activity, and the 
generation of free radicals leading to DNA damage (211). Specifically, DOX enters cells through 
passive diffusion (224) whereupon it can displace nuclear proteins, bind to DNA, and result in 
conformational changes of the DNA structure (198). DOX also possesses a strong affinity for 
cardiolipin inside mitochondrial membranes, and when bound produces high amounts of reactive 
oxygen species (ROS) (233).  Collectively, these processes culminate into the primary task of DOX, 
which is to seize tumor cell growth and replication.  
While DOX, and anthracyclines as a whole, are widely regarded for their antitumor effects, 
their clinical utility is limited due to their negative side-effects in noncancerous tissues (94). Early 
reports of severe patient fatigue following DOX treatment (183) led to the revelation of DOX-
induced cardiotoxicitiy [see reviews (238, 250)]. In fact, a recent review concluded that 47% of 
studies assessing patient fatigue during and following anthracycline-based chemotherapy report 
fatigue that is “disabling and effecting physical capabilities of the patient” (94). While DOX has been 
widely shown to impact other off-target tissues (44), this review is focused on the impact of DOX 
on skeletal muscle. 
 
B. Impact of Doxorubicin on Skeletal Muscle Function 
 Individuals diagnosed with cancer experience general impairments in skeletal muscle 
function as a result of the disease (244). Cancer treatments, such as chemotherapy, are largely 
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believed to exacerbate functional impairments in the skeletal muscle of cancer patients. While the 
cardiotoxic effects of DOX have been known for some time (238, 250), the negative effects of DOX 
on peripheral tissues such as skeletal muscle has gained more recent attention.  In particular, 
maximal oxygen consumption (VO2peak) of breast cancer patients is reduced following DOX 
treatment despite no signs of impaired cardiac function (217). This suggests that DOX may result 
in direct impairments in skeletal muscle function.  
Preclinical models within the last decade demonstrate the negative effects of DOX on 
skeletal muscle function (Table 2-5). The systemic administration of DOX, through intraperitoneal 
injection, has been shown to induce contractile dysfunction in muscles of varying fiber type profiles, 
ranging from the predominantly slow-twitch soleus (33, 91, 111, 122) to the mainly fast-twitch 
extensor digitorum longus (EDL) (33, 90, 111, 122, 251), and even the diaphragm of mixed fiber 
type (92, 161). Thus, the skeletal muscle fiber type profile does not appear to impact the myotoxic 
effects of DOX on contractile function. 
A majority of the studies administer DOX through a single-bolus injection (33, 90-92, 111, 
122, 161). Administration of DOX in doses as low as 10 mg/kg and 12.5 mg/kg appear to increase 
fatigue and impair maximal twitch force in the soleus, but not the EDL (122). Therefore, single-
bolus injections have commonly been comprised of doses of at least 15 mg/kg. Interestingly, while 
DOX can accumulate in skeletal muscle for up to 24 hours following a dose of 15 mg/kg, functional 
impairments persist for up to 5 days following the injection (111). This suggests that DOX may 
induce structural damage to the contractile units within skeletal muscle that continue well after the 
tissue has been cleared of the drug. 
Nissinen et al. (186) administered DOX in smaller (6 mg/kg), sequential doses (4 doses 
every 2 weeks) over a longer period of time, similar to its use clinically. While this study did not 
assess the contractile function of a single muscle, it did demonstrate that a chronic, clinically-
relevant DOX regimen impairs running performance (186). However, whether the decrement in 
whole body functionality is caused by the most proximal dose to the exercise test or the cumulative 
effects of the DOX regimen is unknown. Future research is warranted to investigate the impact of 
chronic, clinically-relevant, low-dose DOX regimens on skeletal muscle function. 
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 Several studies have attempted to mitigate the DOX-induced impairments in skeletal 
muscle with a variety of countermeasures (Table 2-4). Many of the myotoxic effects of DOX are 
thought to stem from the generation of ROS (57). Works from Gilliam et al. postulated that DOX-
induced ROS generation are dependent on tumor necrosis factor (TNF) (90, 92). The authors have 
employed both a TNF receptor knockout mouse model (90) and an anti-TNF drug (Etanercept) (92) 
in preclinical models of DOX and both countermeasures have resulted in preserved specific force 
in the EDL and diaphragm, respectively. In addition, several studies have attempted to combat 
DOX-induced ROS through the administration of a targeted mitochondrial antioxidant (SS31) (161) 
or overexpression of the mitochondrial antioxidant, catalase (91). Both interventions were shown 
to be effective in mitigating DOX-induced impairments in skeletal muscle function (91, 161). These 
findings suggest that DOX-induced impairments in skeletal muscle function are ROS-mediated, 
and that ROS generation is a viable therapeutic strategy to preserve muscle function in the face of 
DOX. Given its resounding benefits for muscle function and robust capacity to stimulate 
antioxidants (217), exercise training represents a promising intervention to preserve muscle 
function following DOX treatment. To date, only one study has investigated the impact of exercise 
training on DOX-induced muscle dysfunction, in which rats completed resistance or aerobic training 
for 10 weeks prior to a single bolus of DOX (33). Aerobic exercise training reduced fatigue 
associated with DOX in the soleus and EDL, while resistance exercise training improved maximal 
twitch force in the soleus (33). Overall, exercise appears to be a viable strategy to preserve several 
aspects of muscle function following DOX treatment. However, future studies are needed to 
translate these findings into human cancer patients following DOX chemotherapy.  
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Table 2-5 (pg. 55-57). Summary of the Impact of Anthracyclines on Skeletal Muscle Function. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Function 
Intervention 
Countermeasure Outcome 
Gilliam, 2009 
(90) 
Mouse 
20 mg/kg; Single 
dose 
EDL 
↓ Abs. Force 
↓ Sp. Force 
↑ Fatigue 
TNFR1 knockout 
↑ Sp. Force 
↑ Fatigue 
van Norren, 
2009 
(251) 
Mouse 
50, 100, 175 µM; 
Incubation 
EDL 
50 µM: ↑ Relax. Time 
100 µM: ↓ Max Twitch Force,  
↑ Relax. Time 
175 µM: ↓ Max Twitch Force,  
↑ Relax. Time 
- - 
Gilliam, 2011 
(92) 
Mouse 
20 mg/kg; Single 
dose 
Diaphragm ↓ Sp. Force 
Etanercept (anti-TNF 
drug) 
↑ Sp. Force 
Hydock, 2011 
(122) 
Rat 
DOX1: 10mg/kg 
 
DOX2: 12.5 
mg/kg 
 
DOX3: 15mg/kg 
 
Single dose 
SOL; EDL 
SOL 
DOX1: ↑ Fatigue 
DOX2: ↓ Max Twitch Force,  
↑ Fatigue 
DOX3: ↓ Max Twitch Force,  
↑ Fatigue 
 
EDL 
DOX1: ↔ 
DOX2: ↔ 
DOX3: ↓ Max Twitch Force 
- - 
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Table 2-5 (pg. 55-57). Summary of the Impact of Anthracyclines on Skeletal Muscle Function. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Function 
Intervention 
Countermeasure Outcome 
Hayward, 2013 
(111) 
Rat 
15 mg/kg; Single 
dose 
SOL; EDL 
SOL 
1 day Post: ↔ 
3-day Post: ↓ Max Twitch 
Force, ↓ Rate force dev. 
5-day Post: ↓ Max Twitch 
Force, ↑ Rate force dec. 
 
EDL 
1 day Post: ↓ Max Twitch Force,  
↓ Rate force dev., ↑ Rate force 
dec. 
3-day Post: ↓ Max Twitch 
Force,  
↓ Rate force dev., ↑ Rate force 
dec. 
5-day Post: ↓ Max Twitch 
Force,  
↓ Rate force dev., ↑ Rate force 
dec. 
- - 
Min, 2015 
(161) 
Rat 
20 mg/kg; Single 
dose 
Diaphragm ↓ Sp. Force 
SS31 (Mito.-targeted 
anti-oxidant);  
SJA (Calpain-inhibitor) 
SS31: ↑ Sp. 
Force 
SJA: ↔ Sp. 
Force 
Gilliam, 2016 
(91) 
Mouse 
20 mg/kg; Single 
dose 
SOL ↓ Max Twitch Force 
Mito. Catalase 
Overexpression 
↑ Max 
Twitch 
Force 
Nissinen, 2016 
(186) 
Mouse 
24 mg/kg; 4 x 6 
mg/kg doses; 2 
wks 
SOL; GN; 
TA 
↓ Running performance 
sACVR2b-Fc (TGFβ 
activinin binding 
inhibitor) 
↔ Running 
performance 
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Table 2-5 (pg. 55-57). Summary of the Impact of Anthracyclines on Skeletal Muscle Function. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Function 
Intervention 
Countermeasure Outcome 
Bredahl, 2016 
(33) 
Rat 
15 mg/kg; Single 
dose 
SOL; EDL 
SOL 
↓ Max Twitch Force, ↓ Rate 
force dev., ↑ Rate force dec. 
 
EDL 
↓ Max Twitch Force 
Run: 30-60min/d, 
5d/wk, 10wks prior to 
DOX 
RT: elevated 
food/water, 10wks 
prior to DOX 
Run:  
↓ fatigue 
(SOL, EDL) 
 
RT: ↑ Max 
Twitch 
Force (SOL) 
 
EDL, extensor digitorum longus; Abs, absolute; TNFR1, tumor necrosis factor receptor 1; Relax, relaxation; TNF, tumor necrosis factor; 
DOX, doxorubicin; SOL, soleus; Sp, specific; Dev, development; Dec, decline; Mito, mitochondria; GN, gastrocnemius; TA, tibialis 
anterior; sACVR2b, soluble ligand binding domain of activinin receptor type IIb-Fc region; TGFβ, transforming growth factor beta; Run, 
run training; RT, resistance training; ↔, p > 0.05; ↑ or ↓, p < 0.05. 
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C. Impact of Doxorubicin on Skeletal Muscle Size 
 The risk of toxicity from chemotherapy treatments may be increased in cancer patients with 
reduced skeletal muscle mass (15), which is a vital concern considering the potentially comprised 
musculature due to cancer cachexia (243). Therefore, preserving skeletal muscle mass throughout 
chemotherapy is critical to reducing the risk of drug-induced dysfunction. Unfortunately, DOX has 
a direct, negative impact on skeletal muscle mass. When DOX is directly injected into skeletal 
muscle, as is done during myectomies to treat spasm, there is an abrupt (2 days) loss of muscle 
fibers (184). In addition, when C2C12 myotubes are incubated in physiologically-relevant 
concentrations of DOX (0.20 µM), myotube width is decreased (93). Therefore, DOX appears to 
diminish muscle cell size and number when directly administered. 
 Preclinical animal models have provided extensive evidence of the impact of systemic DOX 
administration on skeletal muscle size (Table 2-6). Whole muscle weights of the soleus, EDL, and 
gastrocnemius have been shown to be reduced following a single injection of DOX ranging from 4 
mg/kg to 20 mg/kg (32, 90, 91, 223). Concerning potential fiber type-specific differences in DOX-
induced muscle wasting, single-bolus administrations of DOX appear to reduce the cross-sectional 
area (CSA) of MHCI and MHCIIa fibers in the soleus (161), MHCI, MHCIIa, MHCIIb/x fibers in the 
plantaris (161), MHCIIb fibers in the tibialis anterior (32), and MHCI, MHCIIa, MHCIIb/x fibers in the 
diaphragm (161). Following a large, single-bolus administration of DOX, all muscle fiber types 
appear susceptible to DOX myotoxicity. 
 When DOX is administered in a clinically-relevant approach over smaller, sequential doses, 
whole muscle weights of the soleus (186), gastrocnemius (102, 186), and tibialis anterior (186) 
appear to be reduced. Chronic DOX regimens also appear to reduce CSA of MHCI and MHCIIa 
fibers in the soleus (58), MHCI, MHCIIb, MHCIIx fibers in the gastrocnemius (102), and all fiber 
types in the plantaris (186). Whether DOX-induced muscle wasting is a result of the last dose or of 
the cumulative dosage requires further investigation. Collectively, DOX, whether administered 
through a large, single-bolus or smaller, sequential doses, appears capable of reducing whole 
muscle weight and muscle fiber size in various skeletal muscles. While the literature is limited, 
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chemotherapy regimens containing DOX also appear to result in reduced CSA of MHCI and 
MHCIIa fibers in the soleus (159) and gastrocnemius (27) of cancer patients. 
 While the cellular mechanisms through which DOX may exert these deleterious effects on 
skeletal muscle remain to be fully understood, studies have demonstrated DOX-induced increases 
in the formation of ROS (91), inflammatory cytokines (90, 92), and proteolytic markers (130, 227) 
that may all contribute to skeletal muscle wasting. In addition, chronic DOX regimens have 
demonstrated that DOX may reduce protein synthesis (186), possibly through impaired mammalian 
target of rapamycin (mTOR) signaling (58), which would inevitably lead to muscle wasting. An 
interesting possibility that has been paid relatively little attention is the impact of DOX on skeletal 
muscle stem cells, termed satellite cells, that are largely important for maintaining skeletal muscle 
mass and regeneration (135). Exposure to DOX in vitro has been shown to interfere with myogenic 
processes associated with satellite cells, (137, 138), and to impair progression of myoblasts 
through the myogenic lineage (137, 179, 197). However, further research is needed to discern the 
impact of systemic DOX administration on satellite cells in relation to skeletal muscle mass. 
 Several studies have attempted to mitigate the DOX-induced impairments in skeletal 
muscle with a variety of countermeasures (Table 2-5). Interventions targeting the DOX-induced 
generation of ROS appear to be largely successful in preserving both whole muscle weight and 
muscle fiber CSA following DOX (90, 91, 93, 161, 223). Additionally, when muscle protein synthesis 
was sustained with a TGFβ activinin binding inhibitor (186), whole muscle weight of the soleus, 
gastrocnemius, and tibialis anterior, along with fiber CSA of the tibialis anterior were preserved 
following chronic DOX administration. The link between ROS and protein synthesis-mediated 
muscle wasting with DOX was bridged by Dickinson et al. who showed chronic DOX administration 
to increase the expression of the mTOR inhibitor, REDD1, which is responsive to oxidative stress 
(58). The same study also showed chronic high intensity treadmill running to limit REDD1 
expression, preserving mTOR signaling and CSA of MHCI and MHCIIa fibers in the soleus (58). 
Recently, Mijwel et al. demonstrated that 16 weeks of aerobic training or resistance training, both 
supplemented with high-intensity interval training, was successful in preserving MHCI and MHCI 
and MHCIIa fiber CSA, respectively during DOX treatment (159). Future studies investigating the 
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precise dose of exercise (mode, intensity) and time of exercise relative to DOX treatment (before, 
during, after) are warranted.  
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Table 2-6 (pg. 61-63). Summary of the Impact of Anthracyclines on Skeletal Muscle Size. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Size 
Intervention 
Countermeasure Outcome 
Bonifati, 2000 
(27) 
Human 
1.4 mg/kg; 
Schedule 
unknown 
GN 
↓ MHCI diameter (2/5 patients) 
↓ MHCII diameter (2/5 patients) 
- - 
Gilliam, 2009 
(90) 
Mouse 
20 mg/kg; Single 
dose 
EDL ↓ EDL weight TNFR1 knockout 
↔ EDL 
weight 
Gilliam, 2011 
(93) 
C2C12 
0.20 µM; 
Incubation  
Myotubes ↓ Myotube width 
SS31 (Mito.-targeted 
anti-oxidant) 
↑ 
Myotube 
width 
Braun, 2014 
(32) 
Mouse 
4 mg/kg; Single 
dose 
GN; TA 
GN: 
↓ GN weight 
TA: 
↓ MHCIIb fiber CSA 
GR knockout 
GN:  
↑ GN 
weight 
TA:  
↑ MHCIIb 
fiber CSA 
Gouspillou, 2015 
(102) 
Mouse 
40 mg/kg total; 4 x 
10 mg/kg doses, 
1d/3wks 
GN 
↓ GN weight 
↓ MHCI, MHCIIx, MHCIIb CSA 
- - 
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Table 2-6 (pg. 61-63). Summary of the Impact of Anthracyclines on Skeletal Muscle Size. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Size 
Intervention 
Countermeasure Outcome 
Min, 2015 
(161) 
Rat 
20 mg/kg; Single 
dose 
Diaphragm; 
SOL, PL  
Diaphragm: 
↓ MHCI, MHCIIa, MHCIIb/x CSA 
 
SOL: 
↓ MHCI, MHCIIa CSA 
 
PL: 
↓ MHCI, MHCIIa, MHCIIb/x CSA 
SS31 (Mito.-targeted 
anti-oxidant);  
SJA (Calpain-
inhibitor) 
SS31: 
↑ MHCI 
CSA 
(Dia., 
SOL);  
↑ MHCIIa 
CSA 
(Dia., 
SOL); 
↑ MHCIIb 
CSA (PL) 
 
SJA: 
↑ MHCI 
CSA 
(Dia., 
SOL);  
↑ MHCIIa 
CSA 
(SOL PL) 
Gilliam, 2016 
(91) 
Mouse 
20 mg/kg; Single 
dose 
SOL ↓ SOL weight 
Mito. Catalase 
Overexpression 
↔ SOL 
weight 
Nissinen, 2016 
(186) 
Mouse 
24 mg/kg; 4 x 6 
mg/kg doses per 2 
wks 
SOL, GN; 
TA 
↔ SOL weight; ↓ GN weight; ↓ 
TA weight; ↓ TA fiber CSA 
sACVR2b-Fc (TGFβ 
activinin binding 
inhibitor) 
↑ SOL 
weight;  
↑ GN 
weight; ↑ 
TA 
weight; ↑ 
TA fiber 
CSA 
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Table 2-6 (pg. 61-63). Summary of the Impact of Anthracyclines on Skeletal Muscle Size. 
Author, Year 
(Reference) 
Species Drug Regimen Muscle Size 
Intervention 
Countermeasure Outcome 
Sin, 2016 
(223) 
Mouse 
(young 
& old) 
18 mg/kg; Single 
dose 
GN 
Young: ↓ GN weight 
Old: ↓ GN weight 
Resveratrol 
Young:  
↑ GN 
weight 
Old:  
↑ GN 
weight 
Dickinson, 2017 
(58) 
Rat 
12 mg/kg total; 3 x 
4 mg/kg doses per 
2 wks 
SOL 
↓ MHCI fiber CSA; ↓ MHCIIa fiber 
CSA 
Run: 30-40min/d, 
5d/wk, 1wk prior to 
and during DOX 
↑ MHCI 
fiber CSA; 
↑ MHCIIa 
fiber CSA 
Mijwel, 2018 
(159) 
Human 
Anthracycline or 
Anthracycline + 
taxane therapy; 
Dosing schedule 
unknown 
VL 
↓ MHCI fiber CSA; ↓ MHCIIa fiber 
CSA 
RT+HIIT: 70-80% 
1RM + 3 x 3min 
intervals on cycle 
ergometer, 2d/wk, 
16wks 
 
AT+HIIT: 20min 
cycling or elliptical or 
rower + 3 x 3min 
intervals on cycle 
ergometer, 2d/wk, 
16wks 
RT+HIIT:  
↑ MHCI 
fiber CSA;  
↑ MHCIIa 
fiber CSA 
 
AT+HIIT: 
↑ MHCI 
fiber CSA 
GN, gastrocnemius; MHC, myosin heavy chain; EDL, extensor digitorum longus; TNFR1, tumor necrosis factor receptor 1; TA, tibialis 
anterior; GR, Glucocorticoid receptor; PL, plantaris; Mito, mitochondria; sACVR2b, soluble ligand binding domain of activinin receptor 
type IIb-Fc region; TGFβ, transforming growth factor beta; Run, run training; DOX, doxorubicin; RT, resistance training; HIIT, high-
intensity interval training; AT, aerobic training; ↔, p > 0.05; ↑ or ↓, p < 0.05. 
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D. Impact of Doxorubicin in Human Cancer Patients 
 While the most prominent side effect of DOX-based chemotherapy in cancer patients is 
the dose-dependent cardiotoxicity [see reviews (238, 250)], weakness and fatigue are commonly 
reported in patients following DOX treatment (94). In particular, 47% of patients receiving DOX 
report sever fatigue (94). In breast cancer patients, 4 doses of DOX resulted in impaired 12 min 
walk test and increased perceived ratings of fatigue (216). Perhaps more concerning are reports of 
muscle weakness and fatigue persisting 1-5 years following DOX treatment (65, 248, 253). More 
quantitative studies have shown reduced lower limb strength (159) and grip strength (235) from 
pre- to post-DOX treatment. Collectively, DOX treatment is associated with immediate reductions 
in muscular strength, that persist several years following treatment as perceived weakness and 
fatigue. 
 Less is known regarding the impact of DOX treatment on skeletal muscle mass in humans, 
likely due to the inability to isolate the impact of DOX amongst other consequences of cancer such 
as cachexia, malnutrition, and reduced physical activity. Several studies have documented 
reductions in MHCI and MHCIIa fiber CSA following the perfusion of DOX to a localized limb (27, 
159) or the systemic administration of DOX (27, 159). Each of these investigations examined lower 
limb muscles including the gastrocnemius (27, 159) and vastus lateralis (27, 159), thus future 
research investigating the impact of DOX on muscle mass of other vital muscles such as the 
diaphragm or erector spinae are warranted. 
 Exercise training has garnered attention as a potential therapy to alleviate the deleterious 
effects of DOX in skeletal muscle. The benefits of exercise to attenuate DOX-induced toxicity is 
strongly supported by the array of preclinical studies discussed above. When aerobic or resistance 
exercise training was performed during DOX treatment, CSA of MHCI and both MHCI and MHCIIa 
fibers was preserved, respectively (159). Even if cancer patients are unable to exercise during 
treatment due to increased fatigue, it appears that cancer survivors are still able to experience the 
benefits of exercise training following chemotherapy (48). In addition to the benefits of exercise 
training in skeletal muscle following DOX treatment, a wealth of cognitive and behavioral benefits 
from exercise training during chemotherapy have been reviewed recently (81). More research is 
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warranted to identify the optimal type and amount of exercise and to define the best time for 
exercise training relative to DOX treatment. 
 
V.  Divergent Exercise: High-Intensity Interval Exercise vs. Moderate-Intensity Exercise 
A. General Overview 
Skeletal muscle is a highly plastic tissue that is capable of adapting to changing functional 
and energetic demands from a variety of stimuli. Exercise represents a unique stimulus to skeletal 
muscle and is known to facilitate changes to the contractile, structural and metabolic properties 
within the muscle fibers, as well as to the extracellular environment (e.g., capillaries, connective 
tissue). The specific adaptive responses within skeletal muscle are dependent, in part, on the type 
of exercise performed. Aerobic and resistance exercise represent opposing ends of the exercise 
continuum and thus a majority of the literature investigating divergent exercise responses have 
focused on these two modes. Specifically, it is well documented that resistance exercise generally 
results in morphological alterations which confer increases in muscle size and strength (19, 108), 
whereas aerobic exercise improves oxidative capacity and fatigue resistance through the 
accumulation of mitochondrial proteins (70, 165). The distinct adaptations to each exercise are 
defined by the cumulative effect of the acute molecular responses to each exercise bout. The timing 
of the acute post-exercise mRNA bursts that drive changes in the functional protein pool typically 
peaks 4 to 8 hrs following exercise, with some mRNA responsive up to 24 hrs later (264). 
Collectively, understanding the unique adaptation of skeletal muscle to specific forms of exercise, 
and the underlying molecular responses, is important in utilizing targeted exercise strategies as a 
means to improve skeletal muscle. The focus the following sections are to highlight acute 
responses and chronic adaptations of skeletal muscle to different forms of aerobic exercise, 
particularly, moderate intensity continuous exercise (MOD) and high intensity interval exercise 
(HIIE).  
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B. Acute Skeletal Muscle Responses 
The acute molecular responses to traditional, moderate-intensity aerobic exercise have 
been well documented (46, 98, 116, 117). In particular, much attention has been given to the acute 
molecular responses governing mitochondrial biogenesis, a hallmark adaptation to aerobic 
exercise. The high ATP turnover associated with aerobic exercise is associated with the activation 
of two key signaling pathways that are understood to be central to mitochondrial biogenesis (64). 
Together, AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (MAPK) 
phosphorylate and activate peroxisome proliferator activated receptor 𝛾 coactivator-1α (PGC-1α) 
(46). In turn, PGC-1α regulates the activity of various transcription factors associated with the 
transcription of the nuclear and mitochondrial genome, eventually leading to increased 
mitochondrial content and functional capacity (46). Through perturbations in cellular oxygenation, 
aerobic exercise has also been shown to elicit acute increases in markers associated with 
capillarization and oxygenation (64). Acute angiogenic markers upregulated by aerobic exercise 
include hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor a (VEGFA), 
which together with PGC-1α, induce the transcription of genes associated with erythropoiesis and 
angiogenesis (64, 239). In addition, aerobic exercise has been shown to increase the transcription 
of a multitude of metabolic genes associated with the mobilization and metabolism of carbohydrate 
and fat (46, 264). Recently, we have highlighted the acute increase in the mRNA expression of 
estrogen-related γ (ERRγ; ESRRG) following aerobic exercise (59). Interestingly, ESRRG is 
associated with phenotypical changes typical of aerobic exercise training, including: improved 
mitochondrial function, greater oxidative capacity, increased vascularization, a reduced respiratory 
exchange ratio, and a shift from MHC II to MHC I fibers (82, 146, 177, 201). Therefore, acute 
increase in ESRRG may represent an important early adaptive response to aerobic exercise. 
 More recent efforts have aimed to achieve similar adaptations to traditional, moderate-
intensity aerobic exercise (MOD) with a lower time commitment. Low-volume, high-intensity interval 
exercise (HIIE) has garnered recent attention as an effective alternative to higher-volume, lower-
intensity aerobic exercise. Typically characterized by intermittent efforts of intense exercise, 
interspersed with periods of recovery, multiple variations of HIIE exist (Table 2-7). Interestingly, 
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common acute molecular responses in skeletal muscle to HIIE largely mimic those following MOD. 
A majority of the literature regarding the acute responses to HIIE have focused on markers 
associated with mitochondrial biogenesis. HIIE has commonly been observed to increase the 
activation of AMPK and MAPK (77, 87, 144, 158). In addition, the mRNA and protein abundances 
of PGC-1α, citrate synthase (CS), and cytochrome c oxidase (COX) appear to be acutely 
upregulated following HIIE (87, 144, 158). Aside from acute markers of mitochondrial adaptation, 
HIIE has also been shown to influence the activation of pathways associated with skeletal muscle 
insulin signaling (188) and angiogenesis (115, 239). While HIIE has been shown to acutely activate 
SCs (180), a response commonly associated with resistance exercise (229), signaling proteins 
commonly associated with myocellular growth do not appear to be activated (87), ate least in the 
initial 3 hrs following exercise. Collectively, HIIE appears to elicit similar acute skeletal muscle 
responses to MOD. However, all but one study (180) were conducted in young individuals, thus 
investigations of the acute molecular responses of skeletal muscle to HIIE in elderly and clinical 
populations are warranted. 
 Few studies have directly compared the acute skeletal muscle responses between HIIE 
and MOD (Table 2-7). Several studies have demonstrated greater activation of AMPK following 
HIIE versus MOD (103, 134). Granata et al. also reported that nuclear levels of PGC-1α protein 
were only increased following HIIE, whereas no increase was observed in response to MOD (103). 
Indeed, activation of PGC-1α appears to be intensity-dependent (63) which may suggest superior 
mitochondrial adaptations following chronic HIIE, compared to MOD. When examined in a fiber 
type-specific manner, activation of AMPK and MAPK in MHCII fibers was greater following HIIE 
compared to MOD (134), which may suggest intensity-dependent differences in fiber recruitment 
patterns between HIIE and MOD (113). Somewhat related is the finding of increased SC activation 
in older adults who performed HIIE, but not MOD (180).  While Nederveen et al. (180) did not 
assess fiber type-specific SC activation, the differential response in SC activation may also be due 
to greater recruitment of MHCII fibers (113). HIIE also appears to result in a greater stimulation of 
insulin signaling, as indicated by greater increase in insulin receptor substrate 1 (IRS1) 
phosphorylation and larger reduction in the phosphorylation of Akt substrate of 160kDa (AS160) 
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(188). While HIIE appears to augment the acute responses of several molecular process, HIIE may 
blunt acute angiogenic processes. Hoier et al. (115) demonstrated lower interstitial VEGF protein 
and endothelial cell proliferation following HIIE compared to MOD which may suggest that there is 
an upper limit of exercise intensity to achieve maximal angiogenesis (95). Overall, studies directly 
comparing the acute skeletal muscle responses between HIIE and MOD suggest that HIIE may 
induce superior initial adaptations, primarily related to mitochondrial adaptation. 
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Table 2-7 (pg. 69-70). Summary of Acute Skeletal Muscle Response: HIIE vs MOD 
Author, Year 
(Reference) 
Participants  
Muscle 
Biopsy 
Exercise 
Outcome 
Mode  Protocol 
Bartlett, 2012 
(21) 
Rec. Active; 
Young; 10m 
VL; Rest, 
immed. post, 
3h post 
Run 
MOD: 50min @ 70% VO2peak 
HIIE: 6 x 3min @ 90% VO2peak 
w/ 3min rest 
BOTH: ↑ AMPKThr172,  
↑ p38MAPKThr180/Tyr182 (immed. post); 
↑ PGC1α mRNA, ↑ HSP72 mRNA (3h 
post) 
Hoier, 2013 
(115) 
Trained; 
Young; 9m 
VL; Rest, 1h 
post, 3h post 
Cycle 
MOD: 60min @ 62% VO2peak 
HIIE: 24 x 1min @ 117% 
VO2peak w/ 1.5min rest 
BOTH: ↑ interstitial VEGF (MOD > 
HIIE); ↑ endothelial cell prolif. (MOD > 
HIIE) 
HIIE: ↑ VEGF mRNA (1h post), Timp1 
mRNA (3h post) 
 
Scribbans, 2014 
Rec. Active; 
Young, 6m 
VL; Rest, 
immed. post 
Cycle 
MOD: 30min @ 65% VO2peak 
HIIE:8 x 20sec @ 170% 
VO2peak, 1-sec rest 
BOTH: ↑ ACCSer79 
Kristensen, 2015 
(134) 
Rec. Active; 
Young; 9m 
VL; Rest, 
immed. post 
Cycle 
MOD: 30min @ 70% VO2peak 
HIIE: 6 x 90sec @ 95% 
VO2peak w/ 2.5min rest 
BOTH: ↑ ACCSer221 (MHCI fibers) 
↑ ACCSer221 (MHCII fibers; MOD < 
HIIE) 
HIIE: ↑ AMPKThr172 (MHCII fibers) 
Nederveen, 2015 
(180) 
Sed.; Old; 
22m 
VL; Rest, 24h 
post, 48h post 
Cycle 
MOD: 30min @ 55-60% 
VO2peak 
HIIE: 10 x 1min @ 90-95% 
VO2peak w/ 1min rest 
HIIE: ↑ MyoD+ SCs (24h post, 48h 
post) 
Granata, 2017 
(103) 
Rec. Active; 
Young; 19m 
VL; Rest, 
immed. post, 
3h post 
Cycle 
MOD: 24min @ 63% Wmax 
HIIE: 4 x 30sec @ Wingate w/ 
4min rest 
HIIE: ↑ nuclear p53Ser15 (immed. post, 
3h post); ↑ nuclear p38 
MAPKThr180/Tyr182 (immed. post), ↑ 
nuclear PGC1α protein (immed. post, 
3h post) 
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Table 2-7 (pg. 69-70). Summary of Acute Skeletal Muscle Response: HIIE vs MOD 
Author, Year 
(Reference) 
Participants  
Muscle 
Biopsy 
Exercise 
Outcome 
Mode  Protocol 
Parker, 2017 
(188) 
Rec. Active; 
Young; 6m, 
2f 
VL; Rest, 
immed. post, 
3h post 
Cycle 
MOD: 30min @ 50% Wmax 
HIIE: 5 x 4min @ 75% Wmax 
w/ 1min rest 
SIE: 4 x 30sec Wingate w/ 
4min rest 
ALL: ↑ IRS1Ser307 (immed. post; HIIE > 
MOD); ↑ p38MAPKThr180/Tyr182 (immed. 
post); ↓ AktSer473 (immed. post) 
HIIE & SIE: ↓ AS160Ser588 (immed. 
post, HIIE > SIE) 
SIE: ↑ NF-kBp65Ser536 (immed. post) 
Rec; recreationally; m, male; f, female; VL, vastus lateralis; immed, immediately post exercise; MOD, moderate intensity exercise; HIIE, 
high-intensity interval exercise; AMPK, 5' adenosine monophosphate-activated protein kinase; p38MAPK, p38 mitogen-activated 
protein kinases; PGC1α; peroxisome proliferator-activated receptor gamma coactivator 1-alpha; HSP72, heat shock protein 72; prolif, 
proliferation; VEGF, vascular endothelial growth factor; Timp1, tissue inhibitor of metalloproteinase 1; ACC, acetyl-CoA carboxylase; 
MHC, myosin heavy chain; sed, sedentary; MyoD, myogenic differentiation factor 1; SC, satellite cells; p53, tumor protein 53; SIE, sprint 
interval exercise; IRS1, insulin receptor substrate 1; Akt, protein kinase B; AS160, Akt substrate of 160 kDa; NF-kB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; ↑ or ↓, p < 0.05. 
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C. Chronic Skeletal Muscle Adaptations 
 Over the course of weeks or months, the cumulative effect of the acute skeletal muscle 
response to each exercise bout alters the skeletal muscle phenotype to meet new functional 
demands. The skeletal muscle adaptations to chronic aerobic exercise have been well documented 
(70, 110, 165). Traditional aerobic exercise training is characterized by periods of high volume, low 
to moderate intensity, continuous exercise, eliciting relatively minor mechanical strain on the 
skeletal muscle. Chronic aerobic exercise training results in morphological and metabolic 
adaptations to skeletal muscle. Increased mitochondrial abundance and oxidative capacity is a 
well-established adaptation to chronic aerobic exercise training (64), which ultimately leads to 
increased fatigue resistance (109). Similarly, chronic aerobic exercise is associated with increased 
substrate storage in the form of muscle glycogen (35) and intramuscular triglycerides (IMTG) (100). 
Substrate utilization is also altered following chronic aerobic exercise, where reliance on glycogen 
stores is reduced at a given submaximal workload and oxidation of IMTGs is increased (100, 215). 
Chronic aerobic exercise also results in a greater occurrence of MHCI muscle fibers (70, 166) and 
increases in skeletal muscle capillaries (110). Altogether, the hallmark adaptations to traditional 
aerobic exercise consist of improvements in mitochondrial capacity, oxygen and substrate delivery, 
and substrate storage and utilization, collectively contributing to an enhanced endurance capacity 
of skeletal muscle. 
  Low-volume, high-intensity interval training (HIIT) appears to induce similar skeletal muscle 
adaptations compared to traditional aerobic exercise training, albeit with a fraction of the exercise 
time. HIIT has been shown to result in increased PGC-1α protein (119, 145, 189, 213) and 
subsequent improvements in mitochondrial capacity, as indicated by increases in CS and COX 
activity (38, 119, 125, 145, 189). In fact, increased CS has been documented following as few as 
7 sessions of HIIT (189). The mitochondrial adaptations are accompanied by alterations in 
substrate storage. Increases in both muscle glycogen stores (38) and IMTGs (221) have been 
reported following 2 weeks and 6 weeks of HIIT, respectively. Concerning substrate storage, HIIT 
has also been shown to improve insulin sensitivity (119, 221) and GLUT4 abundance (119, 221). 
Similar to traditional aerobic exercise training, HIIT also appears capable of inducing a shift in 
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muscle fiber type, toward a greater distribution of MHCI muscle fibers (218, 254). An area that 
warrants further research is the impact of HIIT on capillarization. Although several studies have 
reported increased skeletal muscle capillaries following HIIT (53), Hoier et al. showed no change 
(115). In addition, investigation of the acute skeletal muscle responses to HIIE may indicate blunted 
angiogenesis (95), which could lead to negligible changes in skeletal muscle capillarization 
following HIIT. Finally, HIIT has also been documented to increase muscle fiber cross-sectional 
area (CSA) (254), an adaptation that is less associated with aerobic exercise yet still possible (107). 
 Studies that have directly compared skeletal muscle adaptations following HIIT and 
traditional aerobic exercise training (MOD) largely indicate similar adaptations are attained 
following each respective training modality (Table 2-8). However, a majority of the literature 
investigating skeletal muscle adaptations to HIIT have focused on mitochondrial adaptations, which 
may differ between HIIT and MOD. While both training modalities are effective in improving 
mitochondrial capacity, several studies report greater increases in mitochondrial respiration (104, 
218) and CS activity (149) following HIIT versus MOD. This may be a result of the higher exercise 
intensity associated with HIIT, as two of the studies demonstrating superior mitochondrial 
adaptations administered HIIT and MOD training protocols that were matched for total work (104, 
149). However, each of these studies employed rather short training periods of 2 weeks (149) and 
4 weeks (104). Therefore, it is also likely that MOD training may elicit similar adaptations when 
performed over a longer training period. Overall, HIIT appears to elicit similar skeletal muscle 
adaptations to tradition, high-volume, moderate-intensity aerobic exercise. The most obvious 
benefit to HIIT is the relatively minimal exercise time required, a common reason for poor exercise 
compliance (96). In addition to the array of benefits in skeletal muscle, HIIT has been well 
documented to induce a variety of positive adaptations to other tissues and physiological systems 
(128). HIIT also appears to be a viable exercise therapy for several clinical populations including 
those with obesity (18), COPD (254), cancer (159), and heart failure (14, 249). Future studies 
investigating the impact of HIIT on skeletal muscle growth, atrophy, and function are warranted, 
especially in aging and clinical populations. 
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Table 2-8 (pg. 73-74). Summary of Chronic Skeletal Muscle Adaptations: HIIT vs MOD 
Author, Year 
(Reference) 
Participants (n)  
Exercise Training Outcome 
Mode  Protocol  
Vogiatzis, 2005 
(254) 
COPD; Old; (HIIT: 
10, MOD: 9) 
Cycle; 
3d/wk; 10 
wks 
MOD: 30min @ 60% Wmax 
HIIT: 45 x 30sec @ 100% Wmax, 
30sec rest 
BOTH: ↓ MHCIIb dist.; ↑ MHCI 
CSA; ↑ MHCIIa CSA;  
↑ Cap.:fiber ratio 
MOD: ↓ PFK activity 
Gibala, 2006 
(86) 
Rec. Active; 
Young; (HIIT: 8m, 
MOD: 8m) 
Cycle; 
3d/wk; 2 wks 
MOD: 90-120min @ 65% 
VO2peak 
HIIT: 4-6 x 30sec Wingate 
BOTH: ↑ COX activity; ↑ COXII 
protein; ↑ COXIV protein; ↑ 
glycogen 
Burgomaster, 
2008 
(37) 
Rec. Active; 
Young; (HIIT: 5m, 
5f; MOD: 5m, 5f) 
Cycle; 
5d/wk; 6 wks 
MOD: 40-60min @ 65% VO2peak 
HIIT: 4-6 x 30sec Wingate, 
4.5min rest 
BOTH: ↑ CS activity; ↑ β-HAD 
activity; ↑ PGC1α protein 
Daussin, 2008 
(53) 
Sed.; Young; (7m, 
4f) 
Cycle; 
3d/wk; 8 wks 
MOD: 20-35min @ 61% Wmax 
HIIT: 4-7 x 1min @ 90% Wmax, 
4min rest  
(work matched) 
BOTH: ↑ Cap. density 
HIIT: ↑ Mito. Resp. 
Shepherd, 2012 
(221) 
Sed.; Young; 
(16m) 
Cycle; MOD: 
5d/wk; HIIT: 
3d/wk; 6 wks 
MOD: 40-60min @ 65% VO2peak 
HIIT: 4-6 x 30sec Wingate, 
4.5min rest 
BOTH: ↑ IMTG; ↑ PLIN2 protien  
↑ PLIN5 protien 
Scribbans, 
2014 
(218) 
Rec. Active; 
Young; (HIIT: 10, 
MOD: 9) 
Cycle; 
4d/wk; 6 wks 
MOD: 30min @ 65% VO2peak 
HIIT: 8 x 20sec @ 170% 
VO2peak, 10sec rest 
BOTH: ↑ MHCI dist.; ↓ MHCIIa/x 
dist.; ↑ SDH activity (all FT); ↑ 
Cap. density; ↑ GPD activity 
(MHCI) 
HIIT: ↑ GPD activity (MHCIIa) 
Joanisse, 2015 
(126) 
Rec. Active; 
Young; (HIIT: 10, 
MOD: 9) 
Cycle; 
4d/wk; 6 wks 
MOD: 30min @ 65% VO2peak 
HIIT: 8 x 20sec @ 170% 
VO2peak, 10sec rest 
BOTH: ↑ active SCs; ↑ diff. SCs; 
↑ terminally diff. SCs 
Baekkerud, 
2016 
(18) 
Overweight/Obese; 
Middle aged; 
(4HIIT: 5m, 7f; 
1HIIT: 3m, 6f; 
MOD: 4m, 5f) 
Run; 3d/wk; 
6 wks 
MOD: 45min @ 70% HRmax 
1HIIT: 10 x 1min @ 90% HRmax, 
1min rest 
4HIIT: 4 x 4min @ 89-95% 
HRmax, 3min rest 
ALL: ↑ CS activity 
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Table 2-8 (pg. 73-74). Summary of Chronic Skeletal Muscle Adaptations: HIIT vs MOD 
Author, Year 
(Reference) 
Participants (n)  
Exercise Training Outcome 
Mode  Protocol  
Granata, 2016 
(104) 
Rec. Active; 
Young; (HIIT: 11m, 
SIT: 9m, MOD: 
9m) 
Cycle; 
3d/wk; 4 wks 
MOD: 20-36min @ 65% Wmax 
HIIT: 4-7 x 4min @ 90% Wmax, 
2min rest 
SIT: 4-10 x 30sec Wingate, 4min 
rest 
SIT: ↑ Mito. resp.; ↑ PGC1α 
protein; ↑ p53 protein; ↑ PHF20 
protein 
Gillen, 2016 
(89) 
Sed.; Young; (HIIT: 
9m, MOD: 10m) 
Cycle; 
3d/wk; 12 
wks 
MOD: 45min @ 70% HRmax 
HIIT: 3 x 20sec Wingate, 2min 
rest 
BOTH: ↑ CS activity; ↑ ETC 
complexes 
MacInnis, 2017 
(149) 
Rec. Active; 
Young; (10m) 
Single-leg 
Cycle; 
3d/wk; 2 wks 
MOD: 30min @ 50% Wmax 
HIIT: 4 x 5min @ 65% Wmax, 
2.5min rest 
BOTH: ↑ COX IV protein; ↑ 
NDUFA9 protein; ↑ MFN2 
protein 
HIIT: ↑ CS activity 
COPD, chronic obstructive pulmonary disease; HIIT, high-intensity interval training; MOD, moderate intensity aerobic training; 
Wmax, maximal wattage; MHC, myosin heavy chain; Cap, capillary; PFK, phosphofructokinase; m, male; f, female; VO2peak, 
maximal oxygen consumption; COX, cytochrome c oxidase; PGC1α; peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha; Mito, mitochondria; Resp, respiration; Sed, sedentary; IMTG, intramuscular triglyceride; PLIN2, perilipin 
2; PLIN5, perilipin 5; SDH, succinate dehydrogenase; GPD, α-glycerophosphate dehydrogenase; SC, satellite cell; diff, 
differentiated; HRmax, maximal heart rate; CS, citrate synthase; p53, tumor protein 53; PHF20, plant homeodomain finger-
containing protein 20; ETC, electron transport chain; NDUFA9, NADH:ubiquinone oxidoreductase subunit A9; MFN2, 
mitofusion 2; ↑ or ↓, p < 0.05. 
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INTRODUCTION 
Skeletal muscle plays a fundamental role in an array of physiological processes that are 
imperative to the ability to perform both metabolic and physical functions. With respect to contractile 
characteristics, the functional performance of skeletal muscle is largely dictated by muscle fiber 
type profile (myosin heavy chain isoform) (272) and its architectural characteristics, such as fiber 
pennation angle (PA) and physiological cross-sectional area (pCSA) (143, 172). Additionally, the 
composition of skeletal muscle (i.e. the presence of non-contractile tissues within muscle) may 
have implications for proper functioning of contractile (114, 270) and metabolic (240) processes in 
skeletal muscle. Consequently, feasible strategies to accurately evaluate skeletal muscle 
architecture and composition could provide valuable insights for assessing and/or improving 
muscle function in the setting of both muscle performance and disease.  
Until recently, magnetic resonance imaging (MRI) has served as the gold-standard 
measurement for skeletal muscle architecture and composition. However, the utility of MRI is 
restricted by high costs, limited availability, and the necessity to position patients in a fixed prone 
or supine position. The emergence of real-time ultrasonography (US) has allowed for the 
examination of in vivo characteristics of skeletal muscle. Further, US presents minimal to no risk to 
the patient/subject, and it is extremely portable which provides access to a variety of populations, 
from bed-confined to ambulatory. In addition, US is an accurate and reliable means to measure 
muscle PA (139) and composition, the latter of which is indicated by the echogenicity (EG) or 
brightness of a tissue on US (192, 269). Since its emergence, US has also been accepted as a 
valid means of assessing age-induced changes in muscle size (17, 195, 236), PA (167, 236), and 
muscle composition (17, 236, 247). However, the current body of literature lacks consensus on a 
standardized method of assessment. This lack of standardization in skeletal muscle US is 
important, as it impedes the generalizability of findings across investigation. 
Currently, two predominate approaches to measure skeletal muscle characteristics with 
US are utilized. For one of these approaches images are captured while the patient is standing, 
whereas during the other approach images are captured while the patient is supine [for examples, 
see following reviews (5, 67)]. Each postural approach has its own unique advantages, especially 
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when the patient population may be limited in their ability to assume one posture over the other. 
For example, patients with congestive heart failure are reluctant to lay supine due to the increased 
incidences of dyspnea and pulmonary edema (178), while individuals who are bed-ridden may be 
unable to stand. To our knowledge only one study (241) has directly compared US-based measures 
of skeletal muscle acquired both supine and standing. Thoirs and colleagues (241) acquired repeat 
measurements of muscle thickness (MT) in young to middle-aged adults while standing and supine, 
demonstrating smaller absolute MT measurements when imaged supine versus standing. 
However, to what extent posture may influence other US-based measurements, such as PA and 
EG, and whether this impact occurs at different anatomical sites along the quadriceps have yet to 
be determined. These methodological considerations are important when identifying changes in 
US-derived skeletal muscle characteristics that may indicate changes in a muscle’s functional 
capacity. 
Given the relatively high reliance on operator ability with US, an important consideration 
for accurate measurements of muscle characteristics is the test-retest reliability of the measure. 
When utilizing skeletal muscle US, anatomical imaging sites are identified relative to bony 
landmarks (i.e. greater trochanter of femur, lateral condyle of knee). Considering the architecture 
and size of a muscle, particularly the quadriceps (25), changes along its length, variations in 
imaging site identification may introduce variability in US measurements. While a common strategy, 
particularly in exercise training studies, is to maintain a constant imaging site over time by marking 
the skin, a thorough assessment of the impact of variability in imaging site identification on the test-
retest reliability of skeletal muscle US has yet to be examined. Similarly, imaging posture has been 
shown to influence reliability (241), however the direct assessment of US reliability between 
postural approaches has also yet to be investigated. 
The purpose of this study was to determine 1) the influence of posture on US determined 
measures and 2) the test-retest reliability of distinct skeletal muscle US approaches (posture and 
imaging site identification) in a cohort of young and older males and females. Moreover, it is very 
well understood that advancing age is associated with changes to the size, architecture, and 
composition of skeletal muscle (56, 175, 236). Therefore, a secondary purpose of this study was 
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to determine how aging may influence differences between postures and the test-retest reliability 
of skeletal muscle US measures. Identifying the reliability of various approaches to skeletal muscle 
US is critical to increasing the ability to accurately assess changes in skeletal muscle 
characteristics in a variety of populations. Ultimately the objective of the current study is to improve 
the ability, through skeletal muscle US, identify individuals at risk for skeletal muscle decline and 
evaluate the progress of therapies aimed at improving skeletal muscle function. 
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MATERIALS AND METHODS 
Participants 
 Thirty healthy men and women from the greater Phoenix, AZ metropolitan area volunteered 
for this study. All subjects were considered recreationally active (performing ≤ 2 exercise sessions 
per week), but not engaged in a regularly scheduled exercise-training program. Screening was 
performed using an online survey (Qualtrics®), as well as a Physical Activity Readiness 
Questionnaire (PAR-Q). Subjects were eligible for inclusion if they were between 18 and 35 (young) 
or between 60 and 85 (old) yrs of age, and had a body mass index (BMI) ≤ 30 kg/m2 (non-obese) 
for the young and ≤ 32 kg/m2 for the old. Exclusion criteria included any acute or chronic illness, 
including but not limited to cardiac disease, uncontrolled hypertension, diabetes, or other metabolic 
disorders, arthritis of the knees or hips, a history of neuromuscular problems, lower limb injuries 
impeding function, or pregnancy. All subjects provided written informed consent prior to 
participation. Two subjects failed to complete the study due to reasons unrelated to the study and 
thus 28 subjects completed all aspects of the study (Table 3-1). All procedures were approved by 
the Institutional Review Board of Arizona State University, which is in compliance with the 
Declaration of Helsinki as revised in 1983. 
Study Design 
Subjects were studied on two separate occasions, separated by 6 ± 3 days. Both visits 
were identical except that during the first visit subject completed screening questionnaires and 
during the second visit subjects received a dual-energy x-ray absorptiometry (DXA) scan. Subjects 
were instructed to abstain from any heavy or unaccustomed physical activity for 48 h prior to each 
visit. During each visit, height and weight were recorded, ultrasound images of the quadriceps 
muscles of both legs were completed in both a supine and standing position, and the peak isometric 
torque of the quadriceps of each leg was assessed using an isokinetic dynamometer. US data 
collected from visit #1 was used to assess the influence of posture on US determined skeletal 
muscle characteristics, while US data collected from visit #1 and visit #2 was used to assess test-
retest reliability. 
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Skeletal Muscle Ultrasound Imaging 
 In vivo skeletal muscle architecture of the vastus lateralis (VL), rectus femoris (RF), and 
vastus intermedius (VI) were examined with two-dimensional (2D) brightness mode (B-mode) 
ultrasonography (Terason 3300, Teratech, Burlington, MA) using a 4.5 cm linear array transducer 
(4-15MHz) (Fig. 3-1). A preset for skeletal muscle imaging was used to obtain all images with 
setting of the focal zones, gain, and frequency held constant across all subjects.  Due to changes 
in muscle architecture and along the length of the leg, multiple imaging sites across the quadriceps 
were employed, as previously described (25). All imaging sites for a given leg were based on bony 
landmarks of the femur. Imaging sites on the lateral quadriceps were performed at 56% (L1), 39% 
(L2), and 22% (L3) of the distance 
from the lateral condyle of the knee 
to the head of the greater 
trochanter. Imaging sites on the 
anterior quadriceps were identified 
at 56% (A1) and 39% (A2) of this 
distance. Imaging sites were 
denoted on the skin with 
permanent marker by an “X” 
corresponding to the midline of the 
transducer. The transducer was 
coated in water-soluble gel to aid 
acoustic transmission and 
eliminate deformation of the skin 
and underlying tissues and 
oriented perpendicular to the skin 
to collect longitudinal images at 
each imaging site. Longitudinal images of the VL and lateral VI (VIL) were collected at sites L1, L2, 
and L3, while longitudinal images of the RF anterior VI (VIA) were collected at sites A1 and A2. 
VL 
VI 
SF 
B 
PA 
F 
A 
Fig 3-1. Longitudinal plane ultrasound scan of the 
vastus lateralis (VL) and lateral aspect of the vastus 
intermedius (VI). Pennation angle (PA, solid lines) was 
measured as the insertion angle of a fascicle (F) into the 
axis of force generation (A). Muscle thickness (dashed 
lines) was measured as the distance between the 
superior and deep muscle borders [i.e. deep 
aponeurosis and superficial border of femur (B)] at 3 
locations, corresponding to 10%, 50%, and 90% of the 
field of view width. Echogenicity (dotted line) was 
measured be tracing a region of interest within a muscle, 
avoiding connective tissue and subcutaneous fat (SF). 
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Imaging sites were identical for images collected during the supine and standing postures 
(described below).  
Participant posture during imaging.   
To determine the influence of posture on the test-retest reliability of MT, PA, and EG 
measurements, US images of the quadriceps of both legs were acquired, as described above, while 
the participant rested supine and standing. Each participant was randomly assigned to begin the 
ultrasound imaging in either the supine or standing posture, switching to the opposite posture 
immediately after collection of US measures in the first posture. This order was replicated for a 
given subject during the first and second visit, however, the posture order was counterbalanced 
between young and old participants. Prior to imaging, subjects rested in each posture for 20 mins 
to allow for any potential intramuscular fluid shifts to subside (22). In the supine posture (SUP), 
participants were laid on a medical examination bed with the hip flexion and rotation standardized 
using a custom-built positioning unit and a towel-roll placed under the knee to achieve natural knee 
flexion of approximately 10°. In the standing position (STAND), subjects stood on a cushioned mat 
without footwear and during imaging, transferred their body weight onto the opposite leg from that 
which was being imaged to avoid contraction-induced changes in muscle architecture (79). 
Influence of identifying imaging sites.   
To determine the day-to-day variability of US-determined muscle characteristics, one leg 
of each participant was randomly assigned to have the “marked” imaging sites kept constant until 
the next visit (marked leg, M) while the imaging sites on the opposite leg were removed during the 
first visit (unmarked leg, UM). Subjects were provided a surgical skin marker and instructed to 
maintain the five imaging sites only on the marked leg between the first and second visit. During 
the second visit, the sites on the marked leg were verified using measurements from the first visit 
while the imaging sites on the unmarked leg were reestablished as detailed above. 
Muscle function testing.   
To identify the relationship between US measurements of the quadriceps acquired in both 
postures and the function of the quadriceps muscles, we assessed the peak isometric torque of the 
knee extensors. Following ultrasound imaging, subjects completed a 5-min warm-up on a cycle 
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ergometer (Model 828, Monark, Varberg, Sweden) at approximately 60 watts. Subjects were then 
fitted to the isokinetic dynamometer (HUMAC Norm, CSMi, Stoughton, MA) to assess their peak 
isometric unilateral knee extension torque for each leg. The subjects performed three, 5-second 
maximal isometric unilateral knee extensions at 60° knee flexion, separated by 30 s of rest. Each 
leg was tested in a randomized order on both visits. The highest isometric knee extension torque 
across both visits was recorded to represent the peak muscle function of each leg. 
Dual-energy X-Ray Absorptiometry (DXA Scan).   
During the second visit, subjects underwent a whole-body DXA scan. Prior to the scan, 
subjects were instructed to void their bladder after which they rested supine for 20 mins to allow 
fluids to subside.  
Ultrasound image analysis.   
Ultrasound images were transferred as uncompressed .tiff files to a designated computer 
(iMac, Apple, Cupertino, CA, USA) for the analysis of muscle thickness, pennation angle, and 
echogenicity (Fig. 3-1). Image analysis was carried out using publicly available software (ImageJ, 
National Institutes of Health, USA). For the analysis of muscle thickness, ImageJ was first 
calibrated using the visible depth scale on each image. Muscle thickness (MT) of the VL and RF 
was measured as the perpendicular distance between the border of subcutaneous fat and muscle 
to the deep aponeurosis. In the VI, MT was measured as the perpendicular distance between the 
superficial aponeurosis and the superficial border of the femur. At each site, combined MT of the 
two visible muscles (VL+VI, RF+VI) was also examined, measured as the perpendicular distance 
between the subcutaneous fat and muscle border to the superficial border of the femur. To account 
for changes in MT across the field of view (FOV) in each image, MT measurements were made at 
three locations across the FOV, corresponding to 10%, 50%, and 90% from left to right (based on 
width of FOV). Measurements at the three locations across the FOV were averaged into one 
composite MT measurement for a given muscle and imaging site.  
 Pennation angle (PA) was measured by tracing the angle of insertion of a visible fascicle 
border into the aponeurosis corresponding to axis of force generation (VL: deep aponeurosis; VI: 
superficial aponeurosis) (Fig. 3-1). In a given image, one to three PA’s were measured, based on 
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the visibility of clear fascicular borders, and averaged to yield one PA measurement for a given 
muscle and image site. Due to the parallel orientation of fascicles to the aponeurosis in the RF 
(236), PA was not assessed in this muscle. 
 Echogenicity (EI) of the VL, RF, and VI was assessed using the gray-scale analysis 
function in ImageJ. First, images were converted to 8-bit grayscale in ImageJ, where EG resulted 
in a value ranging between 0 (black) to 255 (white). The EG of each muscle was assessed by 
tracing a region of interest in each muscle, carefully avoiding any surrounding bone or connective 
tissue. Special attention was paid to ensure the ultrasound unit settings of frequency, gain, and 
focal zone were kept constant across all subjects and visits. 
Statistical Analysis 
 All statistical analyses were performed using SPSS statistical software (v.24, IBM, Tokyo, 
Japan). For comparison of subject characteristics, independent t-tests were employed. To assess 
the impact of age, sex, and posture on the skeletal muscle architecture measurements, a linear 
mixed-model with fixed effects for age, sex, and posture was carried out only on measurements 
from the first visit. To assess the test-retest reliability of all skeletal muscle architecture 
measurements, change scores for the absolute [visit 2 value – visit 1 value] and relative [(visit 2 
value – visit 1 value) ÷ visit 1 value]*100 differences were first calculated. Next, a linear mixed 
model with fixed effects for sex, age, posture, and marking, and interactions among all terms was 
carried out on the absolute and relative test-retest differences. A Bonferroni correction was 
employed in all mixed model comparisons. Supplement pairwise analyses were used to discern 
differences in reliability between the four groups (age x sex), within the posture, leg, and leg x 
posture interactions. In addition, the agreement between ultrasound measurements made on each 
visit was determined within posture, marking, sex, and age using a 2-way random effects, single 
rater, absolute agreement intraclass correlation coefficient (ICC) analysis. 
 To examine which skeletal muscle architecture measurements best predict peak muscle 
function (peak isometric torque), a stepwise linear regression analysis (enter: P ≤ 0.05; remove: P 
≥ 0.10) was performed using MT, PA, and EG measurement averaged across the two visits for a 
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given subject and the highest peak isometric torque for each leg across visits. Significance for all 
analyses was set a priori at P < 0.05. All data are expressed as mean±SE unless noted otherwise.  
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RESULTS 
Subjects 
 Subject characteristics are displayed in table 3-1. Height and weight were similar between 
young and old (P > 0.05), but were greater in males versus females (163 ± 7 cm, 60 ± 9 kg) (P < 
0.001). Body mass index (BMI) was greater (P < 0.001) in old females compared to young females, 
whereas BMI was similar between young and old males (P > 0.05).  DXA-derived body fat 
percentage and fat mass were greater in old compared to young (P < 0.001). Lean mass was 
similar between young and old (P = 0.94), but was greater in males versus females (P < 0.001). 
Peak isometric torque (PIT) of the quadriceps was greater in young compared to old (P < 0.016) 
and in males versus females (P < 0.001). 
Measurement of Skeletal Muscle Parameters   
 The influence of sex and age on US determined muscle characteristics were determined 
using measurements of MT, PA, and EG collected during the first visit (Tables 3-2 to 3-12). 
Quadriceps MT was lower in old compared to young in 12 of the 15 measurements (Tables 3-2 to 
3-6), whereas PA was lower in old versus young in all 5 measurements (Table 3-7). In addition, the 
EG of the quadriceps was higher in old versus young in 7 of the 10 measurements (Tables 3-8 to 
3-12). Females exhibited smaller MT compared to males in 9 of the 15 measurements, 7 of which 
occurred along the lateral quadriceps (Tables 3-4 to 3-6). Females exhibited lower PA than males 
in 2 of the 5 measurements (Table 3-7). Quadriceps EG was higher in females versus males in all 
10 measurements (Tables 3-8 to 3-12). 
Influence of Posture on Skeletal Muscle Parameters 
 Postural differences in the measurements of MT, PA, and EG are visually displayed in 
figures 3-2 to 3-6. In addition, P-values for all main effects and interactions with posture are 
displayed in tables 3-57 to 3-61. All pairwise comparisons and values for MT, PA, and EG obtained 
in the standing and supine positions are displayed in tables 3-2 to 3-12.  
Posture during imaging largely affected the MT of the anterior quadriceps, where all 6 
anterior MT measurements were larger when measured standing versus supine (Fig. 3-2, Tables 
3-2 to 3-3). Conversely, MT of the VL at L1 was significantly smaller when measured standing 
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versus supine (Fig. 3-3, Table 3-4). Posture similarly influenced MT measurements in the young 
and old in all anterior measurements. However, the influence of posture on VL MT at L1 only 
occurred in young (Fig. 3-3, Table 3-4). Measurements of PA were minimally influenced by posture 
(Fig. 3-4, Table 3-7). An effect of posture on PA was only observed in young, in the measurement 
of VL PA at L2, where PA was lower when measured standing versus supine (Fig. 3-4, Table 3-7). 
Echogenicity measurements of the anterior quadriceps were lower when measured standing 
versus supine (Fig. 3-5, Tables 3-8 to 3-9). Along the lateral quadriceps, EG of the VI at L1 and L3 
was lower when measured standing versus supine only in old (Fig. 3-6, Tables 3-10 to 3-12). The 
influence of posture on MT, PA, and EG did not differ between females and males. 
Reproducibility of Skeletal Muscle Measurements 
 The absolute agreements between skeletal muscle measurements from the first and 
second visit are presented in tables 3-13 to 3-24. Intraclass correlation coefficients (ICCs) for MT 
across all groups ranged between 0.496 to 0.932 standing and 0.568 to 0.974 supine (Table 3-13, 
3-16). In addition, the marked leg resulted in higher ICCs in 5 of the 15 MT measurements when 
standing and in 12 of the 15 MT measurements when supine. Measurements of MT when standing 
yielded ICCs ranging between 0.298 to 0.955 in young (Tables 3-14, 3-17) and -0.018 to 0.955 in 
old (Tables 3-15, 3-18). When MT was measured supine, ICCs ranged between 0.239 to 0.972 in 
young and 0.545 to 0.971 in old. In young, the marked leg resulted in higher ICCs in 11 of the 15 
MT measurements when standing and 13 of the 15 MT measurements when supine. In the old, the 
marked leg yielded higher ICCs in 6 of the 15 MT measurements when standing and 7 of the 15 
MT measurements when supine. 
 Reproducibility of PA across all groups ranged between ICCs of 0.310 to 0.721 standing 
and 0.143 to 0.822 supine (Table 3-19 to 3-20). In addition, the marked leg resulted in higher ICCs 
in 2 of the 5 PA measurements when standing and in 4 of the 5 PA measurements when supine. 
Measurements of PA when standing yielded ICCs ranging between -0.806 to 0.749 in young (Table 
3-20) and -0.560 to 0.929 in old (Table 3-21). When PA was measured supine, ICCs ranged 
between -0.414 to 0.854 in young (Table 3-20) and -0.960 to 0.653 in old (Table 3-21). In young, 
the marked leg resulted in higher ICCs in 2 of the 5 PA measurements when standing and in 3 of 
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the 5 PA measurements when supine. In the old, the marked leg yielded higher ICCs in 2 of the 5 
PA measurements when standing and in 4 of the 5 PA measurements when supine. 
 Measurements of EG across all groups yielded ICCs between 0.265 to 0.751 standing and 
0.533 to 0.858 supine (Tables 3-22 to 3-24). In addition, the marked leg resulted in higher ICCs in 
2 of the 10 EG measurements when standing and in 5 of the 10 EG measurements when supine. 
Measurements of EG when standing yielded ICCs ranging between 0.226 to 0.824 in young (Table 
3-23) and -0.193 to 0.799 in old (Table 3-24). When EG was measured supine, ICCs ranged 
between 0.497 to 0.846 in young (Table 3-23) and 0.111 to 0.830 in old (Table 3-24). In young, the 
marked leg resulted in higher ICCs in 4 of the 10 EG measurements when standing and in 6 of the 
10 EG measurements when supine. In the old, the marked leg yielded higher ICCs in 5 of the 10 
EG measurements when standing and in 7 of the 10 EG measurements when supine. 
Test-Retest Reliability of Skeletal Muscle Measurements 
 P-values for all main effects and interactions with marking are displayed in tables 3-62 to 
3-71. All pairwise comparisons and day-to-day differences (absolute and relative) for MT, PA, and 
EG obtained in the standing and supine positions are displayed in tables 3-25 to 3-54. 
The day-to-day differences in MT measurements were not different between postures in 
young. However, in old 6 of the 15 MT measurements resulted in greater day-to-day differences (6 
absolute, 3 relative) when measurements were made standing compared to supine (Tables 3-25 
to 3-29). In young day-to-day differences in MT were greater in the unmarked versus the marked 
leg in 6 of the 15 measurements, 2 when measured standing (1 absolute, 1 relative) and 4 when 
supine (4 absolute, 4 relative). In old, day-to-day differences in MT were greater in the unmarked 
versus the marked leg at 2 of the 15 measurements, 1 when measured standing (absolute) and 1 
when supine (absolute). Conversely, day-to-day differences in MT of old were greater in the 
marked, versus the unmarked leg at 7 of the 15 measurements, 6 when measured standing (5 
absolute, 4 relative) and 1 when measured supine (relative). 
 The day-to-day differences in PA (Tables 3-40 to 3-44) of young at 2 of the 5 
measurements were lower (1 absolute, 2 relative) when standing versus supine, while supine 
resulted in lower day-to-day differences at 1 of the 5 measurements (relative). In old, 2 of the 5 PA 
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measurements resulted in lower day-to-day differences (1 absolute, 1 relative) when standing 
versus supine. In young, day-to-day differences in PA were greater in the marked versus the 
unmarked leg at 1 of the 5 measurements (1 absolute, 1 relative). In old, the day-to-day differences 
in PA were not influenced by leg marking.  
The day-to-day difference in EG measurements was not different between postures in 
young. However, in old, 2 of the 10 EG measurements resulted in greater day-to-day differences 
(relative) when standing versus supine (Tables 3-45 to 3-54). In young, day-to-day differences in 
EG were greater in the unmarked versus the marked leg at 1 of the 10 measurements when 
measured standing (relative). In old, day-to-day differences in EG were greater in the unmarked 
versus the marked leg at 2 of the 10 measurements, both when measured standing (absolute). 
Conversely, day-to-day differences in EG of old were greater in the marked versus the unmarked 
leg at 1 of the 10 measurements when measured standing (relative). 
Relationship Between Skeletal Muscle Measurements and Muscle Function 
 To determine which US-derived skeletal muscle measurements best predict PIT of the 
quadriceps, stepwise linear regressions were performed. The best single-site predictors for young, 
old, and all subjects are displayed in table 3-55. Across all subjects, PIT was best predicted by the 
MT of the VIL at L2 when measured supine (R2 = 0.791, β = 56.5) and the MT of the VL+VI at L1 
when measured standing (R2 = 0.686, β = 32.9). In young, PIT was best predicted by the MT of the 
VL+VIL at L2 when measured supine (R2 = 0.620, β = 44.7) and the MT of the VIL at L2 when 
measured standing (R2 = 0.876, β =66.0). In old, PIT was best predicted by the EG of the VIL at L1 
when measured supine (R2 = 0.827, β = -1.60) and the EG of the VIL at L3 when measured standing 
(R2 = 0.996, β =1.20).  
The best combination of US measurements to predict PIT for young, old, and all subjects 
are displayed in table 3-56. Across all subjects, PIT was best predicted by a single MT 
measurement of the lateral quadriceps when measured supine (R2 = 0.791) and a combination of 
three MT measurements at the anterior and lateral quadriceps when measured standing (R2 = 
0.854). In the young, PIT was best predicted by a combination MT and EG measurements of the 
anterior and lateral quadriceps when measured supine (R2 = 0.969) and a single MT measurement 
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of the lateral quadriceps when measured standing (R2 = 0.876). In the old, PIT was best predicted 
by a single MT and EG measurement of the lateral quadriceps when measured supine (R2 = 0.966) 
and a single MT and EG measurement of the lateral quadriceps when measured when measured 
standing (R2 = 1.00). 
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DISCUSSION 
The current study sought to directly compare distinct methodological approaches to 
capturing US images for the measurement of quadriceps skeletal muscle MT, PA, and EG in young 
and old individuals. Several key findings resulted from this study. First, subject posture during US 
imaging influenced US-determined measurements only in the anterior quadriceps, where standing 
produced higher MT and lower EG values compared to supine. Second, reliability of MT measured 
while subjects were standing was lower compared to when measured supine. In contrast, we did 
not detect a systematic influence subject posture on the test-retest reliability for measures of PA, 
or EG in either age group. Third, while strategies to identify anatomical imaging sites did not 
influence reliability for any US measures, older age was associated with lower test-retest reliability 
for measures of MT and PA. Collectively, these results highlight several methodological 
considerations for US-based assessment of skeletal muscle characteristics that should be 
considered for improving reproducibility and generalizability of US to assess skeletal muscle 
characteristics or function. 
Influence of Posture 
Current strategies for skeletal muscle US include obtaining images from subjects in either 
the standing or supine position. However, it is understood that posture can influence fluid 
distribution throughout the body, and in particular, fluid accumulation in the interstitium of the lower 
legs is greater when standing compared to lying supine (155). Indeed, posture-induced fluid shifts 
cause noticeable changes in lower limb morphology when assessed with computerize tomography 
(CT) (22) and DXA (54). Consequently, US measurements of skeletal muscle may be influenced 
by the posture in which the subject is imaged. Therefore, a primary goal of this study was to 
examine whether collecting images while standing or supine influenced US-determined measures 
of MT, EG, and PA. In the current study, measurements collected while standing demonstrated 
greater MT in the anterior quadriceps than those collected in the supine position, whereas MT of 
the lateral quadriceps was not influenced by subject posture. Our findings are consistent with a 
previous study that measured the composite MT of the RF and VIA, demonstrating greater MT when 
standing vs supine (241). Further, the larger MT of the anterior quadriceps while standing was 
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accompanied by lower EG at the same anatomical sites. Fluid accumulation in soft tissue negatively 
impacts EG (123), indicating that differences in MT between postures are likely due to the 
accumulation of fluid in the anterior quadriceps while standing. Despite lower EG of the VIL in old 
when standing, which may be due to greater extracellular water content in elderly (73), age did not 
influence the impact of posture on measures of MT. Further, in the current study, subjects rested 
for 15 mins after changing postures prior to capturing US images for the first leg being measured. 
The influence of posture on measures of MT and EG was no different in the first or second leg that 
were measured following postural changes, indicating that the 15 mins allocated for fluid shifts to 
subside was sufficient. Collectively, these data suggest that subject posture is an important 
methodological consideration when utilizing skeletal muscle US, especially when examining the 
anterior quadriceps, and that 15 minutes of rest are warranted prior to capturing US images for 
assessment of (anterior) quadriceps characteristics. 
In contrast to MT and EG, measurements of PA were not influenced by posture. Compared 
to the supine position, the weight-bearing nature of standing affords the subject the possibility of 
contracting the quadriceps. The PA of a muscle is dynamic from a passive to contracted state (79), 
and thus subjects were instructed to relax the measured leg by distributing their body weight onto 
the contralateral limb. The absence of a postural effect on PA suggests that this approach is 
effective in avoiding contraction-induced changes in PA when skeletal muscle US is performed 
standing. 
Reliability of Skeletal Muscle US 
Compared to imaging modalities such as MRI and DXA, the user dependence of US in 
characterizing skeletal muscle is significant. Therefore, establishing reliable measurement 
approaches is vital to accurately assess changes in skeletal muscle characteristics over serial 
measurements. The current study aimed to assess differences in the reliability of US measures of 
MT, PA, and EG between standing and supine in young and old individuals. We demonstrate that 
the reproducibility of MT measurements across all muscles is slightly lower when standing (ICCs: 
0.541 – 0.932) compared to supine (ICCs: 0.773 – 0.974). Muscle thickness of the distal VL (site 
L3) exhibited the lowest reproducibility between visits in both postures, likely due to the proximity 
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of the imaging site to the musculotendinous junction. When excluding this measurement, our results 
are in accordance with previous studies of quadriceps MT while standing (241) and supine (66, 
236, 241). The diminished reliability in standing versus supine may be due to difficulty in 
maintaining consistent probe orientation on the skin, as the subjects’ legs are relatively more mobile 
compared to when supine. Further, independent of posture the reliability of MT measurements was 
generally lower in older individuals. An interesting finding was that age appeared to preferentially 
impact the relative (%) day-to-day difference in MT more so than the absolute (cm) difference. The 
influence of age revealed in the relative day-to-day differences may simply be the result of smaller 
MT measurements in the muscles of older compared to young. These findings indicate that 
detecting changes in quadriceps MT of older adults over time may be more difficult due to lower 
day-to-day reliability compared to young. 
Measurements of quadriceps PA resulted in low to good reproducibility, according to the 
Fleiss ICC classification (222), while reproducibility of EG measurements ranged from moderate to 
good. These findings are in agreement with the only other study to assess the reliability of PA and 
EG measurements in the quadriceps of young and old (236). Overall, the reliability of PA and EG 
measures were largely similar between postures and age groups. Our results concerning the 
reproducibility of PA are lower compared to previous investigation assessing test-retest reliability 
within the same visit (13, 25, 164). In addition to the longer time period between visits in the current 
study (~ 1 week), our results may be explained by our imaging approach. In the current study, 
imaging was performed with the goal of collecting a single image suitable for measurements of MT, 
PA, and EG. Thus, special care was taken to not compress the tissue with the transducer for the 
assessment of MT, and to not adjust image contrast settings necessary to accurately assess EG. 
While this approach is time efficient, it may cause difficulty in visualizing fascicular border, 
especially in deep muscles. Thus, it is conceivable that the reproducibility of PA measurements 
may be improved if US operators are able to apply force to the tissue and alter image contrast to 
better visualize fascicular borders. To the best of our knowledge, the current study is the first to 
directly compare the influence of subject posture on the reliability of US measures of PA and EG. 
These findings suggest that although the reproducibility of EG and PA measurements is generally 
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lower than that of MT, reliability of EG and PA does not appear to be influenced by the posture in 
which they are measured.  
Given the characteristics of skeletal muscle vary across the length of a muscle (), an 
important consideration for using US to assess skeletal muscle is the proper identification of 
anatomical imaging site. Therefore, it is important that images are captured at the same anatomical 
site for both cross-sectional and longitudinal comparison. To the best of our knowledge, a thorough 
assessment of the impact of imaging site identification on the reliability of skeletal muscle US has 
yet to be examined. Therefore, we sought to determine to what extent the reliability of skeletal 
muscle US measures differs when maintaining constant, marked imaging sites across two visits 
compared to reacquiring imaging sites based on measurements from bony landmarks. In the 
current study, we observed no systematic benefit of maintaining constant, marked imaging sites 
from one visit to the next for the reliability of MT, PA, or EG in either posture. Specifically, the 
reliability of only five of the thirty distinct US measurements collected each visit exhibited a benefit 
of maintaining marked imaging sites, all of which were measurements of MT or PA of the lateral 
quadriceps of the young age group.  Maintaining a marked imaging site is often used in longitudinal 
study designs assessing changes in skeletal muscle characteristics, such as exercise training 
studies in which images are collected before and after exercise training (11, 20, 105, 199, 204, 
237). However, our findings suggest that reacquiring anatomical imaging sites based on measures 
from bony landmarks does not reduce reliability, and thus is a suitable alternative to maintaining a 
marked imaging site. Collectively, as long as imaging sites are established relative to bony 
landmarks, as detailed in the current study, maintaining a marked imaging site may not be 
necessary for future studies or clinical diagnostics with serial measures aimed at assessing 
changes in skeletal muscle characteristics. 
Relationship to Muscle Function  
Skeletal muscle US can be utilized to assess changes in skeletal muscle characteristics 
that may indicate improvements or decrements in muscle function. Indeed, US-derived 
measurements of quadriceps MT [see review: (5)], PA (13, 219, 236), and EG (40, 78, 256, 261) 
are routinely associated with the peak functional capacity of the quadriceps in young and old 
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populations. However, given US images are commonly captured in either the supine and standing 
position, there remains a need to identify how the posture in which the images are collected 
influences how US can be used to examine changes in muscle function. Specifically, does the 
posture in which the images are collected impact which imaging site or which muscle characteristics 
will best predict function? In the current study, function of the quadriceps was assessed by peak 
isometric torque (PIT) of the knee extensors, which negates any influence of fiber-type or fiber 
length (140). As expected, PIT was 21% lower in old age group, compared to the young. 
Interestingly, subject posture had no influence on the relationship between US-determined 
characteristics of skeletal muscle and measures and PIT. Further, following stepwise regression 
analysis PA was not identified as a significant predictor of PIT in either age group or posture, which 
is consistent with previous work by Strasser et al. (236).  On the other hand, MT of the VIL and 
VL+VIL were the best single site predictors of PIT when measured supine and standing, 
respectively, in the young. This finding is in agreement with previous reports indicating VI MT is 
significant predictor of PIT (13, 236). In the old age group, EG of the VIL was the best single 
predictor of PIT when supine and standing. Lopez et al. (148) recently demonstrated EG of the 
quadriceps as the best single predictor of a 30-sec sit-to-stand test in older adults, which together 
with the findings of the current study, suggest skeletal muscle composition may be more relevant 
to function than muscle mass (MT) in older adults. Interestingly, within young and old, US 
measurements of the lateral quadriceps, in particular the VIL, were more predictive of muscle 
function. Collectively, given that US measures in the lateral quadriceps do not appear to be 
influenced by posture and also serve as shared predictors of muscle function between young and 
old, our findings suggest that the lateral compartment of the quadriceps may be the optimal region 
to assess for functionally relevant changes in skeletal muscle. 
Conclusions 
The results from the current study highlight sources of variability associated the use of US 
to examine skeletal muscle characteristics. The goal of this study was to thoroughly assess various 
US-based strategies for the measurement of MT, PA, and EG in young and old adults. Overall, our 
findings suggest that US measurements of the lateral quadriceps are ideal for assessing functional 
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changes in skeletal muscle, particularly given their collective relationship with muscle function and 
resistance to posture in both young and old. However, older age was associated with generally 
lower reliability which may impede the ability to accurately detect changes in the skeletal muscle of 
older adults. Future studies are warranted to identify the reliability of skeletal muscle US measures 
in clinical populations. The findings from this study can be used to improve reproducibility and 
generalizability across and within scientific investigations. This is particularly relevant given the 
emerging use of US to assess skeletal muscle characteristics in healthy and clinical populations. 
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Table 3-1. Subject Characteristics 
Group (n) 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
Body 
Fat (%) 
Body 
Fat (kg) 
Lean 
Mass (kg) 
Peak Isometric 
Torque (Nm) 
YM (8) 26 ± 4A 178 ± 7a 75 ± 8a 24 ± 2a 18 ± 1Aa 12 ± 1A 58 ± 7a 224 ± 69a 
YF (8) 25 ± 4B 166 ± 5Ba 57 ± 6a 21 ± 2Ba 24 ± 3Ba 13 ± 2B 42 ± 3a 157 ± 39Ba 
OM (7) 70 ± 7A 177 ± 6b 82 ± 12b 26 ± 5 28 ± 9A 23 ± 10A 56 ± 6b 182 ± 43b 
OF (5) 69 ± 8B 158 ± 6Bb 65 ± 11b 26 ± 3B 36 ± 5B 23 ± 7B 34 ± 5b 112 ± 21Bb 
 
Y (8f, 8m) 26 ± 4A 172 ± 9 66 ± 12 22 ± 2A 21 ± 4A 13 ± 2A 49 ± 10 194 ± 66A 
O (5f, 7m) 70 ± 7A 170 ± 11 75 ± 15 26 ± 3A 32 ± 8A 23 ± 8A 49 ± 10 153 ± 50A 
 
M (15) 47 ± 23 178 ± 7a 78 ± 11a 25 ± 3 24 ± 9 18 ± 9 56 ± 6a 205 ± 61a 
F (13) 42 ± 23 163 ± 7a 60 ± 9a 23 ± 3 29 ± 7 17 ± 7 41 ± 4a 138 ± 39a 
Data are mean ± SD. Capital letters = age effect; Lower case letters = sex effect; Same letters denote differences 
within effect. Significance set at p < 0.05. BMI, body mass index; Y, young; O, old; M, male; F, female. 
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Table 3-2. Muscle Thickness at A1 
Group 
RF  VI  RF + VI 
Stand** Supine**  Stand** Supine**  Stand** Supine** 
YM 2.38±0.11 2.04±0.11a  2.48±0.12A 1.81±0.11  4.97±0.19 3.94±0.19 
YF 2.28±0.11 1.72±0.11a  2.47±0.12B 1.73±0.11  4.90±0.19A 3.57±0.19 
OM 2.38±0.13 1.74±0.12  2.10±0.13A 1.55±1.12  4.69±0.20 3.42±0.20 
OF 2.15±0.16 1.63±0.16  1.97±0.17B 1.41±0.16  4.16±0.25A 2.99±0.24 
         
Y 2.33±0.08 1.88±0.08  2.47±0.08A 1.77±0.08B  4.93±0.14A 3.76±0.13B 
O 2.26±0.10 1.68±0.10  2.03±0.11A 1.47±0.10B  4.44±0.16A 3.20±0.16B 
         
M 2.38±0.09a 1.89±0.08  2.28±0.09 1.68±0.08  4.83±0.14 3.68±0.14 
F 2.21±0.10a 1.67±0.10  2.22±0.10 1.57±0.10  4.55±0.16 3.27±0.14 
Data are mean±SE. **Posture effect present in all comparisons; *Posture effect in pairwise 
comparisons; Capital letters = age effect; Lower case letters = sex effect; Same letters or 
symbols denote differences within effect. 
 
 
 
Table 3-3. Muscle Thickness at A2 
Group 
RF  VI  RF + VI 
Stand Supine  Stand** Supine**  Stand** Supine** 
YM 1.58±0.10A 1.37±0.10  2.22±0.13 1.51±0.13  3.96±0.20 3.01±0.20 
YF 1.72±0.10* 1.20±0.10*  2.40±0.13A 1.56±0.13A  4.22±0.20A 2.91±0.20A 
OM 1.88±0.11*A 1.23±0.11*  1.85±0.14 1.34±0.14  3.89±0.22 2.67±0.22 
OF 1.89±0.14* 1.05±0.13*  1.65±0.18A 1.06±0.14A  3.55±0.26A 2.23±0.26A 
         
Y 1.65±0.07*A 1.28±0.07*  2.30±0.09A 1.54±0.09B  4.09±0.14 2.96±0.14A 
O 1.89±0.09*A 1.13±0.09*  1.75±0.11A 1.20±0.11B  3.73±0.17 2.44±0.17A 
         
M 1.73±0.08* 1.30±0.08*  2.03±0.10 1.42±0.10  3.92±0.15 2.84±0.15 
F 1.81±0.09* 1.12±0.08*  2.02±0.11 1.31±0.10  3.89±0.16 2.56±0.16 
Data are mean±SE. **Posture effect present in all comparisons; *Posture effect in pairwise 
comparisons; Capital letters = age effect; Same letters or symbols denote differences within 
effect. 
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Table 3-5. Muscle Thickness at L2 
Group 
VL  VI  VL + VI 
Stand Supine  Stand Supine  Stand Supine 
YM 2.47±0.09Aa 2.68±0.09Aa  1.83±0.13A 1.76±0.13A  4.41±0.18Aa 4.56±1.18Aa 
YF 1.97±0.09*Ba 2.24±0.09*Ba  1.69±0.13B 1.62±0.13B  3.78±0.18Ba 3.98±1.18Ba 
OM 1.82±0.10A 1.69±0.10A  1.34±0.14A 1.28±0.14A  3.28±0.20A 3.09±0.20A 
OF 1.65±0.12B 1.51±0.12B  1.19±0.17B 1.04±0.17B  2.98±0.23B 2.60±0.23A 
         
Y 2.22±0.07*A 2.46±0.07*B  1.76±0.10A 1.69±0.10B  4.09±0.13A 4.27±0.13B 
O 1.73±0.08A 1.60±0.08B  1.26±0.11A 1.16±0.11B  3.12±0.15A 2.85±0.15B 
         
M 2.14±0.07a 2.18±0.07b  1.59±0.10 1.52±0.10  3.85±0.14a 3.82±0.14b 
F 1.81±0.08a 1.88±0.08b  1.44±0.11 1.33±0.11  3.37±0.15a 3.30±0.15b 
Data are mean±SE. *Posture effect in pairwise comparisons; Capital letters = age effect; Lower 
case letters = sex effect; Same letters or symbols denote differences within effect. 
 
 
 
Table 3-6. Muscle Thickness at L3 
Group 
VL  VI  VL + VI 
Stand Supine  Stand Supine  Stand Supine 
YM 1.43±0.10a 1.35±0.10  1.66±0.13A 1.85±0.13A  3.18±0.18 3.31±0.18A 
YF 1.07±0.10a 1.24±0.10  1.63±0.12 1.67±0.14B  2.86±0.17 3.00±0.19B 
OM 1.48±0.12 1.46±0.11a  1.16±0.15A 1.00±0.14A  2.76±0.21 2.55±0.20A 
OF 1.14±0.15 1.03±0.13a  1.26±0.20 0.91±0.17B  3.32±0.23 1.99±0.22B 
         
Y 1.25±0.07 1.30±0.07  1.64±0.09A 1.76±0.09B  3.02±0.13A 3.16±0.13B 
O 1.30±0.10 1.26±0.09  1.21±0.12A 0.95±0.11B  2.53±0.15A 2.27±0.15B 
         
M 1.46±0.08a 1.40±0.08b  1.41±0.10 1.43±0.10  2.97±0.14 2.93±0.13a 
F 1.09±0.09a 1.15±0.08b  1.44±0.12 1.29±0.11  2.58±0.14 2.49±0.14a 
Data are mean±SE. Capital letters = age effect; Lower case letters = sex effect; Same letters 
or symbols denote differences within effect. 
 
Table 3-4. Muscle Thickness at L1 
Group 
VL  VI  VL + VI 
Stand Supine  Stand Supine  Stand Supine 
YM 2.56±0.09Aa 2.78±0.09Ab  1.88±1.11 2.02±0.11A  4.53±0.19Aa 4.90±0.19Ab 
YF 1.91±0.09Ba 2.12±0.09Bb  1.75±0.11A 1.76±1.11B  3.78±0.19Ba 4.00±0.19Bb 
OM 1.77±0.10A 1.95±0.10A  1.62±0.13 1.45±0.12A  3.59±0.20A 3.50±0.50A 
OF 1.52±0.12B 1.70±0.12B  1.28±0.15A 1.17±0.15B  3.05±0.24B 2.93±0.24B 
         
Y 2.24±0.07*A 2.45±0.07*B  1.82±0.08A 1.89±0.08B  4.16±0.14A 4.45±0.14B 
O 1.65±0.08A 1.83±0.08B  1.45±0.10A 1.30±0.10B  3.32±0.16A 3.21±0.16B 
         
M 2.17±0.07*a 2.36±0.07*b  1.75±0.09 1.74±0.08a  4.06±0.14a 4.20±0.14b 
F 1.71±0.08a 1.91±0.08b  1.52±0.09 1.45±0.09a  3.42±0.15a 3.46±0.15b 
Data are mean±SE. *Posture effect in pairwise comparisons; Capital letters = age effect; Lower 
case letters = sex effect; Same letters or symbols denote differences within effect. 
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Table 3-7. Pennation Angle 
Group 
L1 VL  L1 VI  L2 VL  L2 VI  L3 VL 
Stand Supine  Stand Supine  Stand Supine  Stand Supine  Stand Supine 
YM 11.9±1.0 14.2±0.9A  11.1±0.9A 9.7±0.9A  13.8±10.9*A 16.6±0.9*Aa  10.2±1.1 12.4±1.0Aa  17.1±1.2a 17.7±1.1Aa 
YF 11.7±0.9 12.5±0.9B  9.0±0.9 10.0±0.9  11.0±0.9* 15.2±0.9*Ba  11.8±1.0* 8.6±1.1*a  12.5±1.3a 13.1±1.1a 
OM 9.3±1.0 9.8±1.0A  7.1±1.2A 5.8±1.1A  10.5±1.1A 9.4±1.0A  8.7±1.2 6.6±1.1A  13.7±1.2 12.4±1.2A 
OF 9.0±1.2 9.3±1.2B  7.0±1.5 6.5±1.9  9.6±1.2 8.3±1.2B  8.0±1.8 8.0±1.3  12.3±1.3 13.0±1.2 
               
Y 11.8±0.7A 13.4±0.7B  10.1±0.7A 9.9±0.7B  12.4±0.7*A 15.9±0.7*B  11.1±0.8A 10.5±0.8B  14.8±0.9 15.5±0.8A 
O 9.1±0.8A 9.6±0.8B  7.0±0.9A 6.4±1.1B  10.0±0.8A 8.9±0.8B  8.8±1.1A 7.2±0.9B  13.0±0.9 12.7±1.8A 
               
M 10.5±0.7 12.0±0.7  9.1±0.8 7.7±0.7  12.1±0.7 13.0±0.7  9.4±0.9 9.5±0.8  15.4±0.8a 15.1±0.8 
F 10.4±0.7 10.9±0.7  8.0±0.9 8.5±1.0  10.2±0.8 11.8±0.8  10.6±1.0 8.1±0.9  12.4±0.9a 13.1±0.8 
Data are mean±SE. *Posture effect in pairwise comparisons; Capital letters = age effect; Lower case letters = sex effect; Same letters or symbols 
denote differences within effect. 
  100 
 
 
 
Table 3-8. Echogenicity at A1 
Group 
RF  VI 
Stand Supine  Stand Supine 
YM 27.8±4.4Aa 31.9±4.2Aa  31.3±3.4Aa 35.7±3.3A 
YF 48.3±4.2a 51.8±4.2a  41.0±3.3a 42.7±3.3 
OM 42.0±5.1A 50.7±4.9A  46.7±4.0A 54.2±3.8A 
OF 45.3±6.0 56.9±5.6  47.4±4.7* 63.4±4.4* 
      
Y 38.1±3.0 41.8±3.0A  36.2±2.4A 39.2±2.3B 
O 43.8±3.9 53.6±3.7A  47.3±3.1*A 58.5±2.9*B 
      
M 34.9±3.4a 41.3±3.2b  38.7±2.6 45.2±2.5 
F 47.0±3.6a 54.0±3.5b  44.7±2.8* 52.6±2.7* 
Data are mean±SE. *Posture effect in pairwise comparisons; Capital 
letters = age effect; Lower case letters = sex effect; Same letters or 
symbols denote differences within effect. 
 
 
Table 3-9. Echogenicity at A2 
Group 
RF  VI 
Stand Supine  Stand Supine 
YM 28.1±4.1a 31.7±4.1Aa  28.5±3.6 35.2±3.6A 
YF 44.3±4.1a 49.9±4.1Aa  38.3±3.6 41.9±3.6B 
OM 37.5±4.8 49.8±5.0  37.8±4.2 48.5±4.4A 
OF 43.1±5.2 49.1±5.2  44.1±4.6* 58.0±4.6*B 
      
Y 36.2±2.9 40.8±2.9  33.4±2.6 38.5±2.6A 
O 40.2±3.5 49.4±3.6  41.0±3.1* 53.1±3.2*A 
      
M 32.9±3.1a 40.5±3.2  33.1±2.8*a 41.9±2.8*b 
F 43.4±3.3a 49.8±3.2  41.4±2.9*a 49.7±2.9*b 
Data are mean±SE. *Posture effect in pairwise comparisons; 
Capital letters = age effect; Lower case letters = sex effect; Same 
letters or symbols denote differences within effect. 
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Table 3-10. Echogenicity at L1 
Group 
VL  VI 
Stand Supine  Stand Supine 
YM 32.4±4.4a 30.7±4.4Aa  38.2±4.5 35.2±4.5A 
YF 47.7±4.4a 46.3±4.4Ba  46.6±4.5 46.9±4.5B 
OM 42.3±5.3 50.4±5.1A  38.2±5.4 52.1±5.1A 
OF 54.7±5.9 60.2±5.6B  50.3±5.9 61.3±5.6B 
      
Y 40.1±3.1 38.5±3.1A  42.4±3.2 41.0±3.2A 
O 48.4±4.0 55.4±3.8A  44.2±4.0* 56.8±3.8*A 
      
M 37.4±3.4a 40.5±3.4b  38.3±3.5a 43.5±3.4b 
F 51.1±3.6a 53.4±3.5b  48.3±3.7a 54.3±3.6b 
Data are mean±SE. *Posture effect in pairwise comparisons; 
Capital letters = age effect; Lower case letters = sex effect; Same 
letters or symbols denote differences within effect. 
 
Table 3-11. Echogenicity at L2 
Group 
VL  VI 
Stand Supine  Stand Supine 
YM 30.1±4.0Aa 29.4±4.0Aa  37.0±4.4 35.0±4.4Aa 
YF 51.1±4.0a 52.1±4.0a  45.9±4.4 47.6±4.4Ba 
OM 42.9±1.7A 46.2±4.7A  42.6±5.1 51.7±5.1A 
OF 43.1±5.1 53.1±5.1  48.1±5.6* 64.0±5.6*B 
      
Y 40.7±2.9 40.8±2.9A  41.4±3.1 41.3±3.1 
O 43.1±3.5 49.6±3.5A  45.3±3.8* 57.8±3.8* 
      
M 36.4±3.1a 37.9±3.1b  39.7±3.4 43.4±3.4a 
F 47.3±3.2a 52.5±3.2b  47.1±3.5 55.7±3.5a 
Data are mean±SE. *Posture effect in pairwise comparisons; 
Capital letters = age effect; Lower case letters = sex effect; Same 
letters or symbols denote differences within effect. 
 
Table 3-12. Echogenicity at L3 
Group 
VL  VI 
Stand Supine  Stand Supine 
YM 34.7±6.0a 30.9±5.6a  24.8±4.1 20.5±4.0A 
YF 54.3±5.2a 58.5±5.4a  32.7±3.6 30.7±4.0B 
OM 43.6±6.9 45.7±6.9  34.8±4.7 41.5±4.7A 
OF 41.8±7.9 54.7±6.6  28.5±5.4* 53.3±4.5*B 
      
Y 44.6±4.0 44.7±3.9  29.0±2.8 25.5±2.9A 
O 42.7±5.3 50.2±4.8  32.0±3.7* 47.5±3.3*A 
      
M 39.2±4.3 38.4±4.5a  29.5±3.2 31.3±3.1a 
F 48.2±4.7 56.6±4.3a  31.5±3.2* 41.8±3.1*a 
Data are mean±SE. *Posture effect in pairwise comparisons; 
Capital letters = age effect; Lower case letters = sex effect; Same 
letters or symbols denote differences within effect. 
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Table 3-13. Test-Retest Intraclass Correlation Coefficients for Anterior Muscle Thickness 
 A1  A2 
 RF VI RF+VI  RF VI RF+VI 
Supine 
M 
0.940 0.784 0.910  0.853 0.945 0.936 
(0.871-0.972) (0.573-0.897) (0.817-0.957)  (0.703-0.930) (0.883-0.974) (0.867-0.970) 
UM 
0.901 0.781 0.924  0.743 0.653 0.694 
(0.798-0.954) (0.573-0.894) (0.842-0.964)  (0.509-0.874) (0.376-0.824) (0.441-0.845) 
Standing 
M 
0.785 0.853 0.780  0.818 0.932 0.904 
(0.580-0.896) (0.699-0.931) (0.572-0.894)  (0.640-0.913) (0.858-0.969) (0.802-0.954) 
UM 
0.865 0.809 0.887  0.722 0.876 0.836 
(0.710-0.940) (0.606-0.913) (0.766-0.947)  (0.475-0.863) (0.745-0.943) (0.682-0.922) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus 
femoris; VI, vastus intermedius. 
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Table 3-14. Test-Retest Intraclass Correlation Coefficients for Anterior Muscle Thickness in Young 
 A1  A2 
 RF VI RF+VI  RF VI RF+VI 
Supine 
M 
0.948 0.865 0.888  0.912 0.908 0.930 
(0.858-0.981) (0.655-0.951) (0.715-0.959)  (0.767-0.969) (0.759-0.967) (0.814-0.975) 
UM 
0.942 0.749 0.900  0.849 0.833 0.830 
(0.843-0.979) (0.413-0.905) (0.745-0.964)  (0.628-0.944) (0.594-0.938) (0.578-0.937) 
Standing 
M 
0.942 0.872 0.897  0.851 0.948 0.931 
(0.846-0.979) (0.672-0.953) (0.730-0.963)  (0.628-0.945) (0.859-0.981) (0.817-0.975) 
UM 
0.822 0.853 0.876  0.763 0.955 0.894 
(0.554-0.936) (0.607-0.949) (0.629-0.959)  (0.455-0.909) (0.875-0.984) (0.729-0.962) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus 
femoris; VI, vastus intermedius. 
Table 3-15. Test-Retest Intraclass Correlation Coefficients for Anterior Muscle Thickness in Old 
 A1  A2 
 RF VI RF+VI  RF VI RF+VI 
Supine 
M 
0.934 0.684 0.905  0.767 0.942 0.910 
(0.766-0.983) (0.112-0.912) (0.706-0.972)  (0.327-0.932) (0.798-0.984) (0.717-0.973) 
UM 
0.853 0.767 0.926  0.586 0.545 0.598 
(0.543-0.958) (0.328-0.932) (0.763-0.978)  (0.051-0.866) (-0.002-0.850) (0.087-0.863) 
Standing 
M 
0.602 0.784 0.552  0.782 0.824 0.827 
(0.006-0.877) (0.327-0.942) (-0.075-0.859)  (0.402-0.935) (0.473-0.949) (0.506-0.947) 
UM 
0.939 0.709 0.898  0.650 0.682 0.733 
(0.730-0.987) (0.163-0.925) (0.674-0.971)  (0.120-0.892) (0.137-0.910) (0.287-0.916) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus 
femoris; VI, vastus intermedius. 
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Table 3-16. Test-Retest Intraclass Correlation Coefficients for Lateral Muscle Thickness 
 L1  L2  L3 
 VL VI VL+VI  VL VI VL+VI  VL VI VL+VI 
Supine 
M 
0.927 0.785 0.904  0.948 0.974 0.985  0.773 0.949 0.923 
(0.847-0.966) (0.585-0.895) (0.805-0.954)  (0.891-0.975) (0.889-0.975) (0.968-0.993)  (0.542-0.896) (0.883-0.978) (0.830-0.996) 
U
M 
0.903 0.875 0.900  0.907 0.837 0.920  0.568 0.740 0.677 
(0.799-0.955) (0.746-0.941) (0.795-0.952)  (0.811-0.956) (0.677-0.921) (0.835-0.962)  (0.237-0.780) (0.484-0.879) (0.389-0.844) 
Standing 
M 
0.756 0.592 0.705  0.683 .859 0.883  0.541 0.780 0.496 
(0.541-0.879) (0.285-0.788) (0.453-0.852)  (.425-0.839) (0.718-0.932) (0.763-0.944)  (0.188-.773) (0.535-0.905) (0.124-0.784) 
U
M 
0.840 0.768 0.852  0.816 0.720 0.915  0.715 0.871 0.687 
(0.674-0.926) (0.547-0.889) (0.702-0.930)  (0.641-0.910) (0.483-0.859) (0.826-0.960)  (0.424-0.871) (0.719-0.944) (0.395-0.852) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
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Table 3-17. Test-Retest Intraclass Correlation Coefficients for Lateral Muscle Thickness in Young 
 L1  L2  L3 
 VL VI VL+VI  VL VI VL+VI  VL VI VL+VI 
Supine 
M 
0.937 0.557 0.837  0.940 0.937 0.972  0.822 0.944 0.940 
(0.833-0.977) (0.121-0.817) (0.601-0.940)  (0.839-0.979) (0.833-0.978) (0.924-0.990)  (0.547-0.937) (0.838-0.981) (0.822-0.980) 
U
M 
0.832 0.763 0.752  0.857 0.788 0.744  0.239 0.494 0.311 
(0.583-0.938) (0.450-0.910) (0.425-0.905)  (0.646-0.947) (0.486-0.916) (0.402-0.903)  (-0.311-0.654) (-0.051-0.807) (-0.278-0.717) 
Standing 
M 
0.838 0.699 0.842  0.832 0.867 0.931  0.492 0.697 0.376 
(0.593-0.940) (0.339-0.882) (0.615-0.941)  (0.589-0.938) (0.665-0.951) (0.814-0.975)  (0.008-0.793) (0.284-0.892) (-0.143-0.735) 
U
M 
0.746 0.298 0.649  0.658 0.462 0.816  0.664 0.901 0.753 
(0.420-0.903) (-0.244-0.688) (0.235-0.862)  (0.245-0.867) (-0.013-0.771) (0.560-0.931)  (0.236-0.874) (0.507-0.973) (0.421-0.909) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
Table 3-18. Test-Retest Intraclass Correlation Coefficients for Lateral Muscle Thickness in Old 
 L1  L2  L3 
 VL VI VL+VI  VL VI VL+VI  VL VI VL+VI 
Supine 
M 
0.826 0.902 0.869  0.812 0.915 0.971  0.733 0.855 0.845 
(0.468-0.950) (0.674-0.973) (0.604-0.961)  (0.489-0.941) (0.735-0.975) (0.905-0.992)  (0.170-0.933) (0.503-0.965) (0.499-0.959) 
U
M 
0.932 0.927 0.940  0.819 0.813 0.923  0.909 0.780 0.944 
(0.766-0.981) (0.754-0.980) (0.806-0.982)  (0.479-0.945) (0.488-0.942) (0.761-0.977)  (0.647-0.977) (0.306-0.941) (0.805-0.984) 
Standing 
M 
0.388 0.483 0.457  -0.018 0.710 0.698  0.795 0.894 0.840 
(-0.199-0.773) (-0.129-0.821) (-0.148-0.808)  (-0.625-0.557) (0.263-0.907) (0.218-0.904)  (0.311-0.954) (0.504-0.981) (0.433-0.965) 
U
M 
0.894 0.923 0.955  0.845 0.824 0.919  0.937 0.743 0.444 
(0.620-0.975) (0.727-0.980) (0.844-0.988)  (0.565-0.952) (0.517-0.945) (0.746-0.976)  (0.676-0.989) (0.199-0.942) (-0.282-0.842) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
  106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-19. Test-Retest Intraclass Correlation Coefficients for Pennation Angle 
 L1  L2  L3 
 VL VI  VL VI  VL 
Supine 
M 
0.822 0.573  0.779 0.197  0.751 
(0.646-.915) (0.124-0.789)  (0.580-0.891) (-0.257-0.605)  (0.510-0.882) 
U
M 
0.533 0.143  0.771 0.439  0.568 
(0.189-0.761) (-0.513-0.658)  (0.555-0.890) (-0.156-0.791)  (0.155-0.813) 
Standing 
M 
0.442 0.602  0.446 0.599  0.373 
(0.074-0.702) (0.182-0.836)  (0.105-0.696) (-0.018-0.884)  (-0.126-0.718) 
U
M 
0.674 0.310  0.678 0.387  0.721 
(0.404-0.835) (-0.140-0.699)  (0.404-0.840) (-0.218-0.767)  (0.418-0.880) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, 
lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
Table 3-20. Test-Retest Intraclass Correlation Coefficients for Pennation Angle Young 
 L1  L2  L3 
 VL VI  VL VI  VL 
Supine 
M 
0.841 0.436  0.580 -0.077  0.840 
(0.605-0.941) (-0.161-0.790)  (0.149-0.829) (-0.676-0.558)  (0.582-0.945) 
U
M 
0.439 -0.414  0.620 0.854  0.788 
(-0.078-0.764) (-0.998-0.425)  (0.167-0.855) (0.193-0.984)  (0.340-0.947) 
Standing 
M 
0.599 0.493  0.285 0.420  0.341 
(0.149-0.844) (-0.119-0.825)  (-0.261-0.681) (-0.502-0.873)  (-0.435-0.806) 
U
M 
0.703 0.326  0.749 -0.806  0.745 
(0.325-0.886) (-0.187-0.769)  (0.410-0.905) (-1.157-0.103)  (0.252-0.930) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, 
lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
Table 3-21. Test-Retest Intraclass Correlation Coefficients for Pennation Angle Old 
 L1  L2  L3 
 VL VI  VL VI  VL 
Supine 
M 
0.653 -0.048  0.586 -0.298  0.523 
(0.094-0.895) (-0.962-0.718)  (0.030-0.862) (-0.520-0.476)  (-0.106-0.847) 
U
M 
0.319 0.541  0.514 -0.960  0.140 
(-0.356-0.773) (-0.193-0.956)  (-0.069-0.840) (-1.247- -0.197)  (-0.640-0.723) 
Standing 
M 
0.191 -0.560  0.591 0.929  0.225 
(-0.463-0.683) (-1.163-0.582)  (-0.017-0.870) (0.202-0.998)  (-0.631-0.786) 
U
M 
0.474 0.099  0.332 0.727  0.683 
(-.147-0.818) (-0.936-0.903)  (-0.367-0.770) (-0.090-0.957)  (0.111-0.912) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; L1, lateral quadriceps 56%; L2, 
lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
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Table 3-22. Test-Retest Intraclass Correlation Coefficients for Echogenicity 
 A1 A2 L1 L2 L3 
 RF VI RF VI VL VI VL VI VL VI 
Supine 
M 
0.742 0.631 0.661 0.752 0.735 0.836 0.540 0.807 0.533 0.653 
(0.507-0.874) (0.340-0.813) (0.377-0.830) (0.517-0.880) (0.504-0.869) (0.670-0.922) (0.204-0.761) (0.622-0.907) (0.166-0.768) (0.338-0.836) 
U
M 
0.586 0.700 0.594 0.638 0.761 0.794 0.605 0.729 0.858 0.750 
(0.266-0.790) (0.417-0.856) (0.284-0.793) (0.339-0.820) (0.540-0.884) (0.600-0.901) (0.294-0.799) (0.492-0.866) (0.700-0.936) (0.490-0.888) 
Standing 
M 
0.552 0.437 0.569 0.643 0.577 0.675 0.542 0.546 0.265 0.416 
(0.209-0.772) (0.077-0.699) (0.250-0.777) (0.352-0.820) (0.246-0.786) (0.392-0.841) (0.212-0.762) (0.212-0.764) (-0.222-0.639) (-0.042-0.727) 
U
M 
0.587 0.467 0.380 0.542 0.663 0.751 0.608 0.629 0.703 0.665 
(0.253-0.797) (0.076-0.730) (-0.003-0.662) (0.210-0.762) (0.373-0.834) (0.517-0.881) (0.302-0.800) (0.335-0.811) (0.393-0.868) (0.334-0.850) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, 
lateral quadriceps 22%; RF, rectus femoris; VI, vastus intermedius; VL, vastus lateralis. 
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Table 3-23. Test-Retest Intraclass Correlation Coefficients for Echogenicity in Young 
 A1 A2 L1 L2 L3 
 RF VI RF VI VL VI VL VI VL VI 
Supine 
M 
0.684 0.613 0.692 0.746 0.619 0.846 0.497 0.780 0.527 0.591 
(0.295-
0.878) 
(0.203-0.844) (0.326-0.879) (0.425-0.902) (0.184-0.849) (0.583-0.945) (0.003-0.792) (0.477-0.917) (0.024-0.813) (0.101-0.849) 
UM 
0.555 0.587 0.604 0.634 0.742 0.803 0.595 0.817 0.871 0.519 
(0.100-
0.818) 
(0.158-0.832) (0.185-0.840) (0.236-0.853) (0.402-0.902) (0.579-0.937) (0.153-0.838) (0.562-0.932) (0.657-0.956) (-0.075-0.835) 
Standing 
M 
0.488 0.571 0.560 0.630 0.644 0.722 0.599 0.663 0.226 0.468 
(-0.01-0.788) (0.111-0.827) (0.093-0.822) (0.232-0.851) (0.234-0.859) (0.383-0.892) (0.152-0.840) (0.261-0.868) (-0.386-0.683) (-0.067-0.799) 
UM 
0.587 0.431 0.434 0.496 0.647 0.824 0.576 0.742 0.763 0.684 
(0.116-
0.840) 
(-0.101-0.767) (-0.086-0.761) (0.015-0.790) (0.228-0.862) (0.568-0.935) (0.122-0.829) (0.403-0.902) (0.391-0.921) (0.232-0.892) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; L1, lateral quadriceps 56%; L2, lateral 
quadriceps 39%; L3, lateral quadriceps 22%; RF, rectus femoris; VI, vastus intermedius; VL, vastus lateralis.  
Table 3-24. Test-Retest Intraclass Correlation Coefficients for Echogenicity in Old 
 A1 A2 L1 L2 L3 
 RF VI RF VI VL VI VL VI VL VI 
Supine 
M 
0.810 0.538 0.488 0.646 0.749 0.692 0.522 0.770 0.577 0.111 
(0.427-0.945) (-0.051-0.850) (-0.052-0.824) (0.132-0.889) (0.320-0.925) (0.171-0.907) (-0.021-0.839) (0.333-0.933) (-0.134-0.888) (-0.647-0.708) 
UM 
0.502 0.720 0.382 0.489 0.706 0.643 0.510 0.348 0.830 0.665 
(-0.182-0.850) (0.234-0.921) (-0.272-0.799) (-0.193-0.845) (0.251-0.910) (0.150-0.887) (-0.115-0.841) (-0.331-0.775) (0.460-0.955) (0.110-0.905) 
Standing 
M 
0.799 0.336 0.644 0.642 0.378 0.589 0.228 0.182 0.636 0.193 
(0.404-0.945) (-0.169-0.758) (0.150-0.887) (0.144-0.887) (-0.233-0.792) (0.043-0.875) (-0.384-0.708) (-0.365-0.672) (-0.284-0.940) (-0.812-0.837) 
UM 
0.595 0.485 0.244 0.602 0.666 0.327 0.730 0.232 0.300 0.524 
(-0.01-0.889) (-0.214-0.855) (-0.458-0.729) (0.008-0.877) (0.081-0.906) (-0.420-0.784) (0.254-0.920) (-0.421-0.717) (-0.473-0.807) (-0.309-0.886) 
Data are ICC (95% confidence interval). M, marked leg; UM, unmarked leg; A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; L1, lateral quadriceps 56%; L2, lateral 
quadriceps 39%; L3, lateral quadriceps 22%; RF, rectus femoris; VI, vastus intermedius; VL, vastus lateralis. 
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Table 3-25. Muscle Thickness for A1 Rectus Femoris 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS (cm) REL (%)  ABS (cm) REL (%)  ABS (cm) REL (%)  ABS (cm) REL (%) 
YM 0.10±0.06A 5.94±3.21  0.14±0.06 6.20±3.43  0.11±0.06 5.36±3.21  0.10±0.06 4.55±3.21 
YF 0.10±0.06 4.43±3.21#  0.25±0.06 15.2±3.21#  0.10±0.06 6.05±3.21  0.13±0.06 8.09±3.21 
OM 0.38±0.06*#Aa 15.1±3.43  0.17±0.08# 6.58±4.54  0.16±0.07* 10.7±3.70  0.21±0.06 11.3±3.43 
OF 0.15±0.08
a 7.10±4.54  0.12±0.08 5.85±4.54  0.12±0.08 6.36±5.54  0.26±0.08 16.5±4.54 
            
Y 0.12±0.04A 5.16±2.27  0.20±0.04 10.7±2.35  0.10±0.04 5.71±2.27  0.23±0.05 6.32±2.27B 
O 0.27±0.05A 11.1±2.84  0.15±0.06 6.21±3.21  0.14±0.05 8.55±2.93  0.11±0.04 13.9±2.84B 
            
M 0.26±0.04*a 10.5±2.35  0.16±0.05 6.39±2.84  0.13±0.05* 8.05±2.45  0.15±0.04 7.91±2.35 
F 0.13±0.05a 5.77±2.78#  0.19±0.05 10.5±2.78#  0.11±0.05 6.20±2.78  0.19±0.05 12.3±2.78 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-
day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-26. Muscle Thickness for A1 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.22±0.07 10.5±3.60  0.16±0.08A 6.33±3.85B  0.12±0.07 6.58±3.60B  0.11±0.07 5.86±3.60 
YF 0.13±0.07 4.72±3.60  0.16±0.07 7.57±3.60  0.11±0.07 5.66±3.60  0.12±0.07 6.90±3.60 
OM 0.31±0.08 14.2±3.85  0.43±0.09A 22.8±4.60Bb  0.34±0.09 21.1±4.15B  0.24±0.08 12.8±3.85 
OF 0.05±0.12 2.76±5.87  0.18±0.10 9.16±5.09
b  0.20±0.10 13.8±5.09  0.17±0.10 14.8±5.09 
            
Y 0.17±0.05 7.63±2.54  0.16±0.05 6.95±2.63B  0.12±0.05 6.12±2.54B  0.13±0.05 6.38±2.54 
O 0.18±0.07 8.47±3.51  0.31±0.07 16.0±3.41B  0.27±0.07 17.5±3.28B  0.21±0.07 13.8±3.19 
            
M 0.27±0.05 12.4±2.63a  0.30±0.06 14.6±2.98  0.23±0.06 13.8±2.75  0.18±0.05 9.33±2.63 
F 0.09±0.07 3.74±3.44a  0.17±0.06 8.36±3.12  0.16±0.06 9.75±3.12  0.140.06 10.8±3.12 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; same letters or symbols denote differences within 
effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
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Table 3-27. Muscle Thickness for A1 RF+VI 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.32±0.11 6.67±2.49  0.34±0.13 4.39±2.66  0.21±0.11 5.63±2.49  0.20±0.11 4.99±2.49 
YF 0.13±0.11 2.61±2.49  0.31±0.11 8.51±2.49  0.20±0.11 5.60±2.49  0.20±0.11 5.75±2.49 
OM 0.59±0.12 12.1±2.66  0.34±0.13 8.39±2.87  0.36±0.12 10.4±2.66  0.31±0.12 8.15±2.66 
OF 0.22±0.15 5.17±3.52  0.08±0.14 2.07±3.15  0.20±0.14 5.93±3.15  0.17±0.14 5.81±3.15 
            
Y 0.22±0.08 4.64±1.76  0.26±0.08 6.45±1.82  0.21±0.08 5.62±1.76  0.20±0.08 5.37±1.76 
O 0.40±0.10 8.64±2.20  0.21±0.09 5.23±2.13  0.28±0.09 8.17±2.06  0.24±0.09 6.98±2.06 
            
M 0.45±0.08a 9.39±1.82b  0.28±0.09 6.39±1.96  0.29±0.08 8.02±1.82  0.26±0.08 6.57±1.82 
F 0.17±0.09a 3.89±2.15b  0.20±0.09 5.29±2.01  0.20±0.09 5.77±2.01  0.18±0.09 5.78±2.01 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes 
marking effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; 
relative day-to-day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-28. Muscle Thickness for A2 Rectus Femoris 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.20±0.06 16.5±4.51  0.29±0.06 21.6±4.51  0.11±0.06 9.68±4.51  0.20±0.06 15.7±4.50 
YF 0.16±0.06 8.71±4.51  0.18±0.06A 11.9±4.51  0.11±0.06 9.12±4.51  0.15±0.06 15.4±4.51 
OM 0.26±0.07 14.4±4.82  0.17±0.07a 9.40±4.82  0.25±0.07 20.3±5.20  0.24±0.07 16.2±5.20 
OF 0.21±0.09
# 11.0±6.37  0.47±0.09*#Aa 24.2±6.37  0.09±0.08 9.12±5.70  0.14±0.08* 13.0±5.70 
            
Y 0.18±0.05 12.6±3.19  0.24±0.05 16.7±3.19  0.11±0.05 9.40±3.19  0.18±0.05 15.5±3.19 
O 0.23±0.06 12.7±3.99  0.32±0.06 16.8±3.99  0.17±0.06 14.7±3.86  0.19±0.06 14.6±3.86 
            
M 0.23±0.05 15.5±3.30  0.23±0.05 15.5±3.30  0.18±0.05 15.0±3.44  0.22±0.05 15.9±3.44 
F 0.18±0.06 9.88±3.90  0.33±0.06* 18.0±3.90  0.10±0.05 9.12±3.63  0.15±0.05* 14.2±3.63 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day 
difference; Y, young; O, old; M, male; F, female. 
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Table 3-29. Muscle Thickness for A2 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.22±0.08 12.1±3.40  0.12±0.08 6.60±3.40  0.09±0.08 6.48±3.40  0.13±0.08A 7.25±3.40 
YF 0.07±0.08 3.39±3.40B  0.16±0.08 7.54±3.40  0.10±0.08 5.81±3.40  0.09±0.08 6.02±3.40 
OM 0.20±0.09 12.9±3.63  0.31±0.09 14.3±3.63  0.10±0.09# 7.82±3.92  0.37±0.09#A 16.6±3.90 
OF 0.23±0.12 14.9±4.80
B  0.20±0.13 11.7±5.54  0.07±0.10 6.45±4.29  0.17±0.10 12.6±4.29 
            
Y 0.14±0.06 7.76±2.40  0.14±0.06 7.07±2.40  0.10±0.06 6.15±2.40  0.11±0.06 6.64±2.40B 
O 0.22±0.08 13.9±3.01  0.25±0.08 13.0±3.31  0.09±0.07 7.13±2.91  0.27±0.07 14.6±2.91B 
            
M 0.21±0.06 12.5±2.49  0.21±0.06 10.5±2.49  0.10±0.06 7.15±2.59  0.25±0.06 11.9±2.59 
F 0.15±0.07 9.13±2.94  0.18±0.08 9.61±3.25  0.08±0.07 6.13±2.74  0.13±0.07 9.29±2.74 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; same letters denote differences within 
effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-30. Muscle Thickness for A2 RF+VI 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.34±0.12 9.99±2.73  0.26±0.12 6.92±2.73  0.17±0.12 5.69±2.73  0.24±0.12 8.03±2.73 
YF 0.21±0.12 4.99±2.73  0.36±0.12 10.4±2.73  0.13±0.12 4.22±2.73  0.27±0.12 9.81±2.73 
OM 0.35±0.13 9.74±2.92  0.44±0.13 10.3±2.92  0.23±0.13 8.21±2.92  0.50±0.13 12.6±2.92 
OF 0.26±0.15 7.05±3.45  0.34±0.15 10.4±3.45  0.13±0.15 5.12±3.45  0.20±0.15 7.84±3.45 
            
Y 0.27±0.08 7.49±1.93  0.31±0.08 8.68±1.93  0.15±0.08 4.96±1.93  0.25±0.08 8.92±1.93 
O 0.31±0.10 8.39±2.26  0.39±0.10 10.4±2.26  0.18±0.10 6.66±2.26  0.25±0.10 10.2±2.26 
            
M 0.35±0.09 9.86±2.00  0.35±0.09 8.62±2.00  0.20±0.09 6.95±2.00  0.37±0.09 10.3±2.00 
F 0.23±0.10 6.02±2.20  0.35±0.10 10.4±2.20  0.13±0.10 4.67±2.20  0.23±0.10 8.83±2.20 
Data are mean±SE; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, 
male; F, female. 
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Table 3-31. Muscle Thickness for L1 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.19±0.06# 7.25±4.30  0.38±0.06#Aa 18.2±4.30  0.14±0.06 5.07±4.30  0.28±0.06 10.7±4.30 
YF 0.20±0.06A 12.0±4.30B  0.17±0.06a 9.29±4.30  0.12±0.06 5.57±4.30  0.12±0.06 5.92±4.30 
OM 0.28±0.07 15.6±4.59b  0.16±0.08A 7.22±4.96  0.16±0.07 8.10±4.59  0.13±0.07 7.32±4.59 
OF 0.46±0.08*
#A 35.1±5.44*#Bb  0.13±0.09# 10.1±6.08#  0.20±0.09* 14.1±6.08*  0.19±0.09 12.4±6.08 
            
Y 0.20±0.04A 9.62±3.04B  0.27±0.04 13.8±3.04  0.13±0.04 5.32±3.04  0.20±0.04 8.32±3.04 
O 0.37±0.05*#A 25.3±3.56#B  0.14±0.06# 8.65±3.92#  0.18±0.06* 11.1±3.81  0.16±0.06 9.85±3.81 
            
M 0.23±0.05 11.4±3.15b  0.27±0.05 12.7±3.28  0.15±0.05 6.58±3.15  0.21±0.05 9.01±3.15 
F 0.33±0.05*# 23.5±3.46*#b  0.15±0.05# 9.68±3.72#  0.16±0.05* 9.84±3.72*  0.15±0.05 9.15±3.72 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day 
difference; Y, young; O, old; M, male; F, female. 
 
Table 3-32. Muscle Thickness for L1 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.24±0.09 11.7±5.67b  0.25±0.09 15.7±5.67  0.37±0.09A 20.8±5.67B  0.30±0.09 14.1±5.67 
YF 0.20±0.09 10.4±5.67  0.21±0.09 12.6±5.67  0.11±0.09 6.47±5.67B  0.13±0.09 8.80±5.67 
OM 0.48±0.10* 31.2±6.06*b  0.23±0.11 14.7±6.55  0.06±0.10*A 3.80±6.06*Bb  0.19±0.10 15.1±6.06 
OF 0.30±0.12 24.0±7.18  0.06±0.13 5.20±8.02  0.32±0.13 31.3±8.02
Bb  0.12±0.13 10.6±8.02 
            
Y 0.22±0.07 11.1±4.01B  0.23±0.07 14.2±4.01  0.24±0.07 13.6±4.01  0.21±0.07 11.4±4.01 
O 0.39±0.08# 27.6±4.70#B  0.14±0.09# 9.96±5.18#  0.19±0.08 17.6±5.03  0.16±0.08 12.9±5.03 
            
M 0.36±0.07 21.5±4.15  0.24±0.07 15.2±4.33  0.21±0.07 12.3±4.15  0.25±0.07 14.6±4.15 
F 0.25±0.08 17.2±4.57  0.14±0.08 8.91±4.91  0.22±0.08 18.9±4.91  0.12±0.08 9.69±4.91 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-
day difference; Y, young; O, old; M, male; F, female. 
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Table 3-33. Muscle Thickness for L1 VL+VI 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.39±0.13 7.97±3.89B  0.59±0.13a 15.9±3.89b  0.37±0.13 7.81±3.89  0.48±0.13 10.0±3.89 
YF 0.24±0.13A 6.18±3.89B  0.18±0.13a 5.01±3.89b  0.22±0.13 5.46±3.89  0.20±0.12 5.50±3.89 
OM 0.70±0.14*# 20.2±4.16*#B  0.26±0.15# 7.44±4.49#  0.23±0.14* 6.43±4.16*  0.29±0.14 9.42±4.16 
OF 0.73±0.16
A 27.0±4.92#B  0.24±0.16 7.95±4.92#  0.41±0.16 15.9±4.92  0.21±0.16 8.63±4.92 
            
Y 0.31±0.09A 7.08±2.75B  0.39±0.09 10.5±2.75  0.29±0.09 6.63±2.75  0.34±0.09 7.75±2.75 
O 0.72±0.11*#A 23.6±3.22*#B  0.25±0.11# 7.70±3.33#  0.32±0.11* 11.1±3.22*  0.25±0.11 9.02±3.22 
            
M 0.54±0.10 14.1±2.85  0.42±0.10 11.7±2.97  0.30±0.10 7.12±2.85  0.39±0.10 9.71±2.85 
F 0.49±0.10 16.6±3.14#  0.21±0.10 6.48±3.14#  0.31±0.10 10.7±3.14  0.21±0.10 7.07±3.14 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-
day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-34. Muscle Thickness for L2 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.27±0.07 11.3±4.83  0.20±0.07 7.62±4.83  0.11±0.07 4.27±4.83  0.21±0.07 7.84±4.83 
YF 0.14±0.07 7.11±4.83  0.24±0.07 13.3±4.83  0.15±0.07 6.88±4.83  0.16±0.07 7.60±4.83 
OM 0.33±0.08# 21.5±5.16  0.11±0.08# 7.11±5.16  0.16±0.08 10.0±5.16  0.21±0.08 14.1±5.16 
OF 0.25±0.09 15.0±6.11  0.11±0.09 7.46±6.11  0.15±0.09 10.5±6.11  0.20±0.09 15.1±6.11 
            
Y 0.21±0.05 9.20±3.42  0.22±0.05 10.5±3.42  0.13±0.05 5.58±3.42  0.19±0.05 7.72±3.42 
O 0.29±0.06# 18.3±4.00  0.11±0.06# 7.28±4.00  0.15±0.06 10.2±4.00  0.20±0.06 14.6±4.00 
            
M 0.30±0.05*# 16.4±3.54  0.15±0.05# 7.36±3.54  0.13±0.05* 7.14±3.54  0.21±0.05 11.0±3.54 
F 0.20±0.06 11.1±3.89  0.17±0.06 10.4±3.89  0.15±0.06 8.67±3.89  0.18±0.06 11.4±3.89 
Data are mean±SE. *Denotes posture effects; #Denotes marking effects; same letters or symbols denote differences 
within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, 
female. 
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Table 3-35. Muscle Thickness for L2 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.22±0.08 10.5±5.26A  0.31±0.08 18.8±5.62  0.10±0.08 5.36±5.26  0.23±0.08 13.6±5.26 
YF 0.16±0.08 10.2±5.26  0.25±0.08 14.5±5.26  0.19±0.08 12.5±5.26  0.25±0.08 16.9±5.26 
OM 0.29±0.08 30.0±5.62#A  0.14±0.08 6.65±5.62#a  0.21±0.08 18.5±5.62  0.23±0.08 20.3±5.62 
OF 0.21±0.10 19.7±6.65  0.34±0.10 23.8±6.65
a  0.13±0.10 15.9±6.65  0.20±0.10 15.2±6.65 
            
Y 0.19±0.05 10.4±3.72A  0.28±0.05 16.7±3.72  0.14±0.05 8.95±3.72  0.24±0.05 15.2±3.72 
O 0.25±0.06 24.9±4.36A  0.24±0.06 15.2±4.36  0.17±0.06 17.2±4.36  0.22±0.06 17.8±4.36 
            
M 0.26±0.06 20.3±3.85  0.23±0.06 12.7±3.85  0.16±0.06 11.9±3.85  0.23±0.06 16.9±3.85 
F 0.19±0.06 15.0±4.24  0.30±0.06 19.2±4.24  0.16±0.06 14.2±4.24  0.23±0.06 16.1±4.24 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; #Denotes marking effects; same letters 
or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; 
Y, young; O, old; M, male; F, female. 
 
Table 3-36. Muscle Thickness for L2 VL+VI 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.20±0.08 4.27±2.01  0.30±0.08 6.80±2.01  0.14±0.08# 2.99±2.01#  0.41±0.08# 9.23±2.01# 
YF 0.27±0.08 7.30±2.01a  0.16±0.08 4.00±2.01  0.19±0.08 5.16±2.01  0.31±0.08 8.45±2.01 
OM 0.37±0.09* 9.09±2.15  0.19±0.09 6.33±2.15  0.12±0.09* 4.12±2.15  0.31±0.09 9.39±2.15 
OF 0.43±0.10 14.7±2.54
a  0.33±0.10 10.2±2.54  0.23±0.10 9.59±2.54  0.12±0.10 5.19±2.54 
            
Y 0.23±0.06 5.78±1.42A  0.23±0.06 5.40±1.42  0.17±0.06# 4.08±1.42#  0.36±0.06# 8.84±1.42# 
O 0.40±0.07* 11.9±1.66*A  0.26±0.07 8.25±1.66  0.18±0.07* 6.85±1.66*  0.21±0.07 7.29±1.66 
            
M 0.29±0.06 6.68±1.47a  0.25±0.06 6.57±1.47  0.13±0.06# 3.56±1.47#  0.36±0.06# 9.31±1.47# 
F 0.35±0.07 11.0±1.62a  0.24±0.07 7.09±1.62  0.21±0.07 7.37±1.62  0.22±0.07 6.82±1.62 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes 
marking effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; 
relative day-to-day difference; Y, young; O, old; M, male; F, female. 
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Table 3-37. Muscle Thickness for L3 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.42±0.09* 23.9±7.00  0.38±0.09A 36.6±7.00B  0.13±0.08*# 14.5±7.00#  0.38±0.08# 35.8±6.55#B 
YF 0.21±0.08 18.5±6.55  0.20±0.08 19.4±6.55  0.20±0.09 10.1±6.55  0.28±0.08 23.9±6.66 
OM 0.17±0.11 10.5±8.28  0.04±0.12A 3.10±9.26B  0.26±0.11 16.4±8.28  0.17±0.10 13.4±7.56B 
OF 0.12±0.14 10.2±10.7  0.11±0.14 10.9±10.7  0.11±0.12 10.8±9.26  0.10±0.12 10.9±9.26 
            
Y 0.31±0.06 21.2±4.79  0.29±0.06A 28.0±4.79B  0.17±0.06 12.3±4.79#  0.33±0.06A 29.9±4.63#B 
O 0.15±0.09 10.3±6.76  0.08±0.09A 6.98±7.07B  0.19±0.08 13.6±6.21  0.13±0.08A 12.1±5.98B 
            
M 0.30±0.07 17.2±5.42  0.21±0.08 19.9±5.80  0.20±0.07 13.3±5.28  0.27±0.06 24.6±5.00 
F 0.16±0.08 14.3±6.27  0.16±0.08 15.1±6.27  0.16±0.08 12.6±5.80  0.19±0.07 17.4±5.70 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-
day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-38. Muscle Thickness for L3 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.32±0.11 10.7±5.26  0.20±0.11 13.0±5.26  0.07±0.09# 4.25±4.56#B  0.41±0.10#A 17.6±4.87# 
YF 0.24±0.09 18.2±4.56  0.14±0.09 9.60±4.56  0.16±0.11 12.1±5.26  0.21±0.10 14.7±4.87 
OM 0.15±0.12 15.5±5.77  0.24±0.12 16.5±5.77  0.25±0.12 25.9±5.77#B  0.07±0.11A 7.37±5.26# 
OF 0.04±0.18 3.74±9.12  0.05±0.15 4.01±7.45  0.12±0.13 13.8±6.45  0.21±0.13 23.1±6.45 
            
Y 0.28±0.07 14.5±3.48  0.17±0.07 11.3±3.48  0.12±0.07# 8.16±3.48B  0.31±0.07# 16.2±3.45 
O 0.10±0.11 9.62±5.39  0.15±0.09 10.3±4.71  0.18±0.09 19.9±4.33B  0.14±0.08 15.2±4.16 
            
M 0.23±0.08 13.1±3.91  0.22±0.08 14.7±3.90  0.16±0.07 15.1±3.68  0.24±0.07 12.5±3.59 
F 0.14±0.10 11.0±5.10  0.10±0.09 6.81±4.37*  0.14±0.08 12.9±4.16  0.21±0.08 18.9±4.04* 
Data are mean±SE. Capital letters = age effect; *Denotes posture effects; #Denotes marking effects; same letters or 
symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, 
young; O, old; M, male; F, female. 
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Table 3-39. Muscle Thickness for L3 VL+VI 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 0.61±0.16a 12.5±4.05  0.42±0.16 15.5±4.05  0.20±0.15# 5.89±3.79#  0.69±0.16#A 19.4±4.05#B 
YF 0.12±0.15a 4.16±3.79  0.20±0.15 7.90±3.79*  0.16±0.17 4.96±4.37#  0.52±0.16 20.2±4.05*# 
OM 0.21±0.19 7.04±4.79  0.36±0.21 11.0±5.36  0.36±0.19 12.1±4.79  0.13±0.17A 5.26±4.37B 
OF 0.22±0.25 10.5±6.18  0.32±0.19 14.0±4.79  0.21±0.19 10.7±4.79  0.19±0.19 8.89±4.79 
            
Y 0.36±0.11 8.32±2.77  0.31±0.11 11.7±2.77*  0.18±0.12# 5.43±2.89#  0.60±0.11#A 19.8±2.86*#B 
O 0.22±0.16 8.75±3.91  0.34±0.14 12.5±3.59  0.28±0.14 11.4±3.39  0.16±0.13A 7.07±3.24B 
            
M 0.41±0.13 9.76±3.14  0.39±0.13 13.2±3.36  0.28±0.12 8.98±3.05  0.41±0.12 12.3±2.98 
F 0.17±0.15 7.31±3.63  0.26±0.12 10.9±3.05  0.18±0.13 7.83±3.24  0.35±0.13 14.5±3.14 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-
day difference; Y, young; O, old; M, male; F, female. 
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Table 3-40. Pennation Angle L1 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 2.85±0.80 33.3±8.61*  2.48±0.75* 23.5±8.05*  1.51±0.75# 9.26±8.05*#  5.45±0.75*#Aa 48.7±8.05*#a 
YF 2.78±0.75 26.7±8.05  2.67±0.75 23.1±8.05  2.29±0.75 18.9±8.05  2.22±0.75a 18.3±8.05a 
OM 4.34±0.80 51.9±8.61*  2.93±0.80 29.4±8.61  2.30±0.80 26.3±8.61*  1.90±0.87A 25.6±9.30 
OF 3.69±0.95 39.2±10.2  2.85±0.95 31.8±10.2  2.27±1.06 27.6±11.4  2.86±1.06 26.1±11.4 
            
Y 2.81±0.55 30.0±5.89  2.57±0.53 23.3±5.69  1.90±0.53# 14.1±5.69#  3.84±0.53# 33.5±5.69# 
O 4.02±0.62 45.6±6.67  2.89±0.62 30.6±6.67  2.29±0.67 26.9±7.14  2.38±0.68 25.9±7.35 
            
M 3.59±0.57* 42.6±6.09*  2.71±0.55 26.4±5.89  1.91±0.55*# 17.8±5.89*#  3.68±0.57# 37.2±6.15# 
F 3.24±0.61 32.9±6.49  2.76±0.61 27.5±6.49  2.25±0.65 23.3±6.97  2.54±0.65 22.2±6.97 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day 
difference; Y, young; O, old; M, male; F, female. 
 
Table 3-41. Pennation Angle L1 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 3.87±0.92 47.6±15.8  4.16±1.12 36.6±19.3  2.83±1.00 34.6±17.3  4.33±1.00 51.6±17.3 
YF 2.15±0.92 22.0±15.8A  2.27±1.00 25.7±17.3  2.71±0.79 32.8±13.6  4.14±1.30 27.6±22.3 
OM 1.87±1.30 55.0±22.3  4.00±1.59 42.0±27.3  1.67±1.12 31.4±19.3  2.87±1.12 57.5±19.3 
OF 3.88±1.59 86.7±27.3
A  1.70±1.59 41.8±27.3  2.51±1.30 61.5±22.3  - - 
            
Y 3.01±0.65 34.8±11.1  3.22±0.75 31.2±12.9  2.77±0.64 33.7±11.0  4.23±0.82 39.6±14.1 
O 2.87±1.02 70.8±17.6  2.85±1.12 41.9±19.3  2.09±0.86 46.5±14.7  2.87±1.12 57.5±19.3 
            
M 2.87±0.79 51.3±13.6  4.08±0.97 39.3±16.7  2.25±0.75 33.0±12.9  3.60±0.75 54.6±12.9 
F 3.01±0.92 54.3±15.8  1.98±0.94 33.8±16.2  2.61±0.76 47.1±13.1  4.14±1.30 27.6±22.3 
Data are mean±SE. Capital letters = age effect; same letters or symbols denote differences within effect; ABS, 
absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
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Table 3-42. Pennation Angle L2 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.63±0.87 31.3±8.78  2.36±0.87 19.2±8.78  3.37±0.87 19.5±8.78  3.08±0.87 31.1±8.78 
YF 3.04±0.87 28.3±8.78  2.99±0.87 33.6±8.78  1.88±0.87 12.9±8.78A  3.05±0.93 22.2±9.39 
OM 2.21±0.93 28.8±11.1  2.98±1.01 32.8±10.1  2.10±0.93 25.8±9.39  1.92±1.01 17.3±10.1 
OF 3.23±1.11 20.0±9.39  3.49±1.11 43.5±11.1  3.52±1.11 49.5±11.1
A  1.33±1.11 19.6±11.1 
            
Y 3.83±0.62 29.8±6.21  2.67±0.62 26.4±6.21  2.63±0.62 16.2±6.21A  3.07±0.64 26.6±6.43 
O 2.72±0.72 24.4±7.27  3.23±0.75 38.1±7.52  2.81±0.72 37.7±7.27A  1.63±0.75 18.4±7.52 
            
M 3.42±0.64 25.7±6.43  2.67±0.67 26.0±6.71  2.74±0.64 22.7±6.43  2.50±0.67 24.2±6.71 
F 3.14±0.70 28.5±7.08  3.24±0.70 38.5±7.08  2.70±0.70 31.2±7.08  2.19±0.72 20.9±7.27 
Data are mean±SE. Capital letters = age effect; same letters or symbols denote differences within effect; ABS, 
absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
 
 
Table 3-43. Pennation Angle L2 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.47±1.41 50.4±24.1  1.88±2.00 21.4±34.0  3.60±1.26 21.9±21.5  1.53±2.00 18.7±34.0 
YF 1.21±2.00 10.4±34.0  3.30±1.26 30.8±21.5  3.80±1.26 68.6±21.5  2.21±1.63 26.0±27.8 
OM 0.66±1.63 11.7±27.8  2.07±1.41 23.2±24.1  2.16±1.41 24.1±24.1  3.35±1.41 76.8±24.1 
OF - -  2.43±2.00 23.1±34.0  2.55±2.00 29.8±34.0  2.80±1.41 31.1±24.1 
            
Y 2.84±1.22 30.4±20.8  2.59±1.18 26.1±20.1  3.70±0.89 45.2±15.2  1.87±1.29 22.3±22.0 
O 0.66±1.63 11.7±27.8  2.25±1.22 23.1±20.8  2.36±1.22 26.9±20.8  3.07±1.00 54.0±17.0 
            
M 2.57±1.08 31.0±18.4  1.98±1.22 22.3±20.8  2.88±0.95 23.0±16.1  2.44±1.22 47.8±20.8 
F 1.21±2.00 10.4±34.0  2.87±1.18 26.9±20.1  3.17±1.18 49.2±20.1  2.50±1.08 28.5±18.4 
Data are mean±SE; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, 
male; F, female. 
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Table 3-44. Pennation Angle L3 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.75±1.19 51.0±13.2*  2.95±1.19 19.4±13.2  2.02±1.01 12.9±11.1*  2.73±1.34 16.0±14.7 
YF 3.58±1.34 23.2±14.7  3.83±1.19 37.1±13.2  2.16±1.01 21.5±11.1  3.35±1.19 23.0±13.2 
OM 2.59±1.34 23.8±14.7  2.13±1.09 14.9±12.0  3.06±1.09 25.3±12.0  5.03±1.34 47.9±14.7 
OF 2.41±1.34 21.3±14.7  2.38±1.34 21.8±14.7  3.24±1.19 26.9±13.2  4.36±1.19 28.2±13.2 
            
Y 4.17±0.90 37.1±9.88  3.39±0.84 28.3±9.32  2.09±0.71 17.2±7.87  3.04±0.90 19.5±9.88 
O 2.50±0.94 22.5±10.4  2.26±0.86* 18.4±9.51  3.15±0.81 26.0±8.92  4.69±0.90* 38.1±9.88 
            
M 3.67±0.90 37.4±9.88  2.54±0.81 17.2±8.92  2.54±0.74 19.0±8.20  3.88±0.94 32.0±10.4 
F 3.00±0.94 22.2±10.4  3.11±0.90 29.5±9.88  2.70±0.78 24.2±8.63  3.86±0.84 25.6±9.32 
Data are mean±SE. *Denotes posture effects; same letters or symbols denote differences within effect; ABS, absolute 
day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
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Table 3-45. Echogenicity for A1 Rectus Femoris 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 6.02±3.15 20.8±5.40  4.70±3.41 15.3±5.84  3.06±3.15A 8.92±5.42  6.34±3.15 19.7±5.05 
YF 8.26±2.95 16.9±5.05  9.26±2.95 14.8±5.05  10.6±2.95 17.4±5.05  9.50±2.95 20.8±5.05 
OM 7.68±3.41 17.8±5.84  7.52±3.73 15.0±6.39  12.4±3.41A 24.1±5.84  9.29±3.41 16.7±5.84 
OF 3.56±4.17 10.8±7.15  10.9±4.17 28.6±7.15  6.63±3.73 11.2±6.39  11.9±4.17 20.6±7.15 
            
Y 7.14±2.16 18.9±3.70  6.98±2.25 15.1±3.86  6.82±2.16 13.2±3.70  7.92±2.16 20.2±3.70 
O 5.62±2.69 14.3±4.61  9.23±2.80 21.8±4.79  9.53±2.53 17.7±4.33  10.6±2.69 18.7±4.61 
            
M 6.85±2.32 19.3±3.98  6.11±2.56 15.2±4.33  7.75±2.32 16.5±3.98  7.82±2.32 18.2±3.98 
F 5.91±2.56 13.9±4.38  10.1±2.56 21.7±4.38  8.61±2.38 14.3±4.07  10.7±2.56 20.7±4.38 
Data are mean±SE. Capital letters = age effect; same letters or symbols denote differences within effect; ABS, 
absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
 
 
Table 3-46. Echogenicity for A1 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 8.54±3.76 23.5±7.32  8.43±4.06 29.6±7.91  6.72±3.76 16.7±7.32  8.65±3.76 23.6±7.32 
YF 7.01±3.52 17.1±6.85  9.30±3.52 18.9±6.85  11.4±3.52 23.2±6.85  11.3±3.52 31.7±6.85 
OM 18.1±4.06 37.0±7.91  11.1±4.45 18.3±8.67  12.7±4.06 20.9±7.91  9.91±4.06 18.2±7.91 
OF 8.45±4.97 15.2±9.69  5.48±4.97 14.0±9.69  8.30±4.45 15.1±8.67  11.3±4.97 21.0±9.69 
            
Y 7.77±2.57 20.3±5.01  8.86±2.69 24.3±5.23  9.06±2.57 19.9±5.01  9.99±2.57 27.7±5.01 
O 13.3±3.21 26.1±6.25  8.28±3.34 16.1±6.50  10.5±3.01 18.0±5.87  10.6±3.21 19.6±6.25 
            
M 13.3±2.77 30.2±5.39  9.76±3.01 23.9±5.87  9.73±2.77 18.8±5.39  9.28±2.77 20.9±5.39 
F 7.73±3.04 16.1±5.93  7.39±3.04 16.5±5.93  9.85±2.83 19.1±5.52  11.3±3.04 26.3±5.93 
Data are mean±SE; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, 
male; F, female. 
  
 12
1
 
 
Table 3-47. Echogenicity for A2 Rectus Femoris 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.46±3.14a 14.9±7.82  4.17±3.14A 13.3±7.82A  3.10±3.14a 9.03±7.82  7.79±3.14 25.8±7.82 
YF 14.7±2.94a 34.6±7.31  10.9±2.94 26.7±7.31  13.3±2.94a 21.1±7.31  7.64±2.94 19.6±7.31 
OM 6.66±3.39 16.2±8.45#  15.7±3.39A 45.5±8.45*#A  11.1±3.39 22.1±8.45  8.98±3.71 18.8±9.25* 
OF 10.2±3.71 23.6±9.25  9.76±3.71 25.5±9.25  13.2±3.71 28.6±9.25  14.7±3.71 34.5±9.25 
            
Y 9.61±2.15 24.8±5.35  7.52±2.15 19.9±5.35  8.18±2.15 15.1±5.35  7.72±2.15 22.7±5.35 
O 8.42±2.51 19.9±6.26  12.7±2.51 35.5±6.26  12.2±2.51 25.4±6.26  11.8±2.63 26.6±6.54 
            
M 5.56±2.31a 15.6±5.75  9.92±2.31 29.4±5.75  7.12±2.31 15.6±5.75  8.38±2.43 22.3±6.06 
F 12.5±2.37a 29.1±5.90  10.3±2.37 26.1±5.90  13.2±2.37 24.9±5.90  11.2±2.37 27.0±5.90 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; #Denotes marking 
effects; same letters or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-
to-day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-48. Echogenicity for A2 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 5.76±3.21 18.2±6.81  5.22±3.21 13.7±6.81  5.64±3.21 12.5±6.81  8.99±3.21 24.0±6.81 
YF 11.1±3.00 26.7±6.37  8.77±3.00 20.2±6.37  4.46±3.00 14.5±6.37  9.05±3.00 19.9±6.37 
OM 11.0±3.47 25.5±7.35  11.6±3.47 31.9±7.35  4.46±3.47 9.13±7.35  8.34±3.80 14.9±8.05 
OF 5.93±3.80 13.6±8.05  6.55±3.80 18.9±8.05  12.5±3.80 22.3±8.05  11.2±3.80 23.4±8.05 
            
Y 8.44±2.20 22.4±466  6.70±2.20 16.9±4.66  5.05±2.20 12.5±4.66  9.02±2.20 22.0±4.66 
O 8.44±2.57 19.6±5.45  9.06±2.57 25.4±5.45  8.46±2.57 15.6±5.45  9.78±2.69 19.2±5.70 
            
M 8.36±2.36 21.8±5.01  8.40±2.36 22.8±5.01  5.05±2.36 10.8±5.01  8.67±2.49 19.5±5.27 
F 8.52±2.42 20.2±5.13  7.66±2.42 19.6±5.13  8.46±2.42 18.4±5.13  10.1±2.42 21.7±5.13 
Data are mean±SE; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, 
male; F, female. 
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Table 3-49. Echogenicity for L1 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.41±3.04 12.4±5.66  5.03±3.04 14.5±5.66A  2.92±3.04 9.68±5.66#  8.25±3.04 30.1±5.66#a 
YF 3.88±2.85 8.13±5.29  11.3±2.85 21.6±5.29  8.62±2.85 18.1±5.29  7.52±2.84 14.9±5.29a 
OM 10.9±3.60 24.9±6.70  12.4±3.29 31.0±6.11A  9.54±3.29 22.7±6.11  9.32±3.29 15.4±6.11 
OF 9.44±3.60 20.5±6.70  10.2±4.02 14.8±7.49  12.9±3.60 22.2±6.70  6.57±3.60 11.6±6.70 
            
Y 4.14±2.08 10.3±3.88A  8.16±2.08 18.0±3.88  5.77±2.08 13.9±3.88  7.88±2.08 22.4±3.88 
O 10.2±2.55 22.7±4.74A  11.8±2.60 22.9±4.83  11.3±2.44 22.5±4.53  7.94±2.44 13.5±4.53 
            
M 7.65±2.36 18.6±4.38  9.21±2.24 22.7±4.17  6.23±2.24 16.2±4.17  8.78±2.24 22.7±4.17 
F 6.60±2.29 14.3±4.27  10.8±2.46 18.2±4.59  10.8±2.29 20.2±4.27  7.04±2.29 13.3±4.27 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; #Denotes marking effects; same letters or 
symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, 
young; O, old; M, male; F, female. 
 
Table 3-50. Echogenicity for L1 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 9.27±3.50 20.7±8.00  4.88±3.50 11.5±8.00A  7.97±3.50 22.9±8.00  7.81±3.50 21.7±8.00 
YF 9.28±3.27 23.7±7.49  9.58±3.27 22.7±7.49  7.92±3.27 17.6±7.29  10.7±3.27 18.3±7.49 
OM 12.8±4.14 33.8±9.47  14.7±3.78 42.7±8.64*Aa  9.60±3.78 18.6±8.64  9.13±3.78 14.6±8.64* 
OF 8.82±4.14 18.5±9.47  6.52±4.63 11.5±10.6
a  8.73±4.14 14.8±9.47  7.33±4.14 11.7±9.47 
            
Y 9.27±2.40 22.2±5.48  7.2±2.40 17.1±5.48  7.95±2.40 20.2±5.48  9.27±2.40 20.0±5.48 
O 11.3±2.93 26.1±6.70  10.6±2.99 27.1±6.83  9.17±2.80 16.7±6.41  8.23±2.80 13.2±6.41 
            
M 11.5±2.71 27.2±6.20  9.79±2.58 27.1±5.89  8.79±2.58 20.8±5.89  8.47±2.58 18.2±5.89 
F 9.05±2.64 21.1±6.04  8.00±2.84 17.1±6.48  8.33±2.64 16.2±6.04  9.03±2.64 15.0±6.04 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; *Denotes posture effects; same letters 
or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; 
Y, young; O, old; M, male; F, female. 
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Table 3-51. Echogenicity for L2 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 2.55±4.12 7.38±6.71  5.68±4.12 15.2±6.71  1.94±4.12A 7.76±6.71A  7.00±4.12 21.7±6.71 
YF 10.9±3.85 17.0±6.28  10.90±3.85 18.6±6.28  11.7±3.85 18.3±6.28  13.7±3.85 22.8±6.28 
OM 10.8±4.45 25.0±7.25  10.4±4.45 23.2±7.25  15.6±4.45A 34.3±7.25Aa  6.51±4.45 20.6±7.25 
OF 8.35±4.87 20.0±7.94  6.27±4.87 16.1±7.94  4.82±4.87 8.27±7.94
a  13.8±4.87 25.1±7.94 
            
Y 6.73±2.82 12.2±4.59  8.29±2.82 16.9±4.59  6.84±2.82 13.0±4.59  10.4±2.82 22.2±4.59 
O 9.58±3.30 22.5±5.37  8.34±3.30 19.6±5.37  10.2±3.30 21.3±5.37  10.1±3.30 22.8±5.37 
            
M 6.68±3.03 16.2±4.94  8.05±3.03 19.2±4.94  8.77±3.03 21.0±4.94  6.76±3.03 21.1±4.94 
F 9.63±3.11 18.5±5.06  8.58±3.11 17.3±5.06  8.28±3.11 13.3±5.06  12.7±3.11 23.9±5.06 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect;; same letters denote differences within 
effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, female. 
 
Table 3-52. Echogenicity for L2 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 5.35±2.97A 15.5±7.10  4.26±2.97A 11.4±7.10A  7.66±2.97 18.4±7.10  7.80±2.97 22.5±7.10 
YF 11.2±2.78 23.8±6.64  5.57±2.78 14.6±6.64  5.91±2.78 14.4±6.64  8.52±2.78 18.4±6.64 
OM 17.6±3.21A 35.4±7.67  14.1±3.21A 40.9±7.67A  10.7±3.21 20.8±7.67  15.3±3.21 29.7±7.67 
OF 11.7±3.52 27.1±8.40  13.1±3.52 33.2±8.40  6.57±3.52 9.46±8.40  7.16±3.52 12.7±8.40 
            
Y 8.27±2.03A 19.6±4.9  4.91±2.03A 13.0±4.86A  6.79±2.03 16.4±4.86  8.16±2.03 20.5±4.86 
O 14.7±2.38A 31.2±5.69*  13.6±2.38A 37.1±5.69A  8.64±2.38 15.1±5.69*  11.2±2.38 21.2±5.69 
            
M 11.5±2.19 25.4±5.23  9.17±2.19 26.2±5.23  9.18±2.19 19.6±5.23  11.6±2.19 26.1±5.23 
F 11.532.24 25.4±5.36  9.35±2.24 23.9±5.36  6.24±2.24 11.9±5.36  7.84±2.24 15.5±5.36 
Data are mean±SE. Capital letters = age effect; *Denotes posture effects; same letters or symbols denote differences 
within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, 
female. 
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Table 3-53. Echogenicity for L3 Vastus Lateralis 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 8.29±6.12 22.4±8.40  3.25±6.12 9.79±8.40A  5.78±4.63 18.8±6.35  2.97±5.00 9.52±6.86 
YF 15.1±4.33 21.4±5.94  8.89±4.33 16.0±5.94  17.8±4.63 22.7±6.35  11.9±4.33 18.1±5.94 
OM 6.91±6.12 13.2±8.40#  14.8±5.48 38.4±7.52#A  6.56±6.12 13.7±8.40  9.04±5.48 20.7±7.52 
OF 6.84±8.66 22.0±11.9  6.72±7.07 16.8±9.70  11.6±5.48 25.7±7.52  11.3±5.48 19.3±7.52 
            
Y 11.7±3.75 21.9±5.15  6.07±3.75 12.9±5.15  11.8±3.27 20.7±4.49  7.45±3.31 13.8±4.54 
O 6.87±5.30 17.6±7.28  10.7±4.47 27.6±6.14  9.06±4.11 19.7±5.64  10.2±3.87 20.0±5.31 
            
M 7.60±4.33 17.8±5.94  9.00±4.11 24.1±5.64  6.17±3.84 16.2±5.27  6.00±3.71 15.1±5.09 
F 11.0±4.84 21.7±6.64  7.81±4.15 16.4±5.69  14.7±3.59 24.2±4.92  11.6±3.49 18.7±4.79 
Data are mean±SE. Capital letters = age effect; #Denotes marking effects; same letters or symbols denote differences 
within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; Y, young; O, old; M, male; F, 
female. 
 
Table 3-54. Echogenicity for L3 Vastus Intermedius 
Group 
Stand  Supine 
Marked  Unmarked  Marked  Unmarked 
ABS REL  ABS REL  ABS REL  ABS REL 
YM 4.06±2.58 18.5±10.2  1.64±4.58 8.82±10.2A  6.03±3.46 22.7±7.71  4.47±4.09 21.5±9.12 
YF 8.34±3.24 25.6±7.21A  9.13±3.24 20.7±7.21  9.74±3.74 24.0±8.32  9.22±3.46 25.3±7.71 
OM 11.1±4.58 23.7±10.2a  8.47±4.09 37.1±9.12A  15.4±4.58 37.0±10.2  8.36±4.09 21.2±9.12 
OF 11.5±6.47 59.9±14.4
#Aa  2.14±5.29 11.1±11.8#  15.6±4.09 29.9±9.12  7.88±4.09 14.8±9.12 
            
Y 6.20±2.80 22.0±6.24  5.38±2.80 14.8±6.24  7.89±2.55 23.3±5.67  6.84±2.68 23.4±5.97 
O 11.3±3.96 41.8±8.83  5.31±3.34 24.1±7.44  15.5±3.07 33.4±6.84  8.12±2.90 18.0±6.45 
            
M 7.59±3.24 21.1±7.21a  5.06±3.07 22.9±6.84  10.7±2.87 29.8±6.39  6.41±2.90 21.4±6.45 
F 9.93±3.62 42.8±8.06#a  5.63±3.10 15.9±6.90#  12.7±2.77 27.0±6.17  8.55±2.68 20.0±5.97 
Data are mean±SE. Capital letters = age effect; Lower case letter = sex effect; #Denotes marking effects; same letters 
or symbols denote differences within effect; ABS, absolute day-to-day difference; REL; relative day-to-day difference; 
Y, young; O, old; M, male; F, female. 
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Table 3-55. Best Single Site Predictors of Peak Isometric Torque of the Quadriceps 
Group Variable  R R2  Sig. Equation 
Supine 
Y MT L2 VL+VI  0.825 0.620  0.001 PIT = -45.6 + 44.7 * MT L2 VL+VI 
O EG L1 VI  0.909 0.827  0.012 PIT = 191.0 – 1.60 * EG L1 VI 
ALL MT L2 VI  0.889 0.791  0.03 PIT = 41.1 + 56.5 * MT L2 VI 
Standing 
Y MT L2 VI  0.936 0.876  0.019 PIT = 20.1 + 66.0 * MT L2 VI 
O EG L3 VI  0.998 0.996  0.041 PIT = 67.5 + 1.02 * EG L3 VI 
ALL MT L1 VL+VI  0.828 0.686  0.0001 PIT = -3.33 + 32.9 * MT L1 VL+VI 
Y, young; O, old; MT, muscle thickness; EG, echogenicity; L1, lateral site 56%; L2, lateral site 39%; 
L3, lateral site 22%; VL, vastus lateralis; VI, vastus intermedius; PIT, peak isometric torque. 
Table 3-56. Stepwise Linear Regression Predicting Peak Isometric Torque of the Quadriceps 
Group Model(s)  R2  Sig. Equation 
Supine 
Y 
1. X1: MT L2 VL+VI 
2. X1: MT L2 VL+VI, X2: MT A2 VI 
3. X1: MT L2 VL+VI, X2: MT A2 VI, X3: MT L3 VL+VI 
4. X1: MT L2 VL+VI, X2: MT A2 VI, X3: MT L3 VL+VI, X4: EG A1 RF 
 
0.620 
0.886 
0.938 
0.969 
 
0.001 
0.0001 
0.0001 
0.0001 
1. PIT = -45.6 + 44.7*X1 
2. PIT = 12.0 + 62.5*X1 – 89.8*X2 
3. PIT = 6.30 + 43.2*X1 – 109.4*X2 + 37.2*X3 
4. PIT = -53.5 + 50.9*X1 – 98.3*X2 + 29.9*X3 + 0.083*X4 
O 
1. X1: EG L1 VI 
2. X1: EG L1 VI, X2: MT L2 VI 
 
0.827 
0.966 
 
0.012 
0.006 
1. PIT = 191.0 – 1.60*X1 
2. PIT = 166.8 – 1.40*X1 + 14.1*X2 
ALL 1. X1: MT L2 VI  0.791  0.03 1. PIT = 41.1 + 56.5*X1 
Standing 
Y 1. X1: MT L2 VI  0.876  0.019 1. PIT = 20.1 + 66.0*X1 
O 
1. X1: EG L3 VI 
2. X1: EG L3 VI, X2: MT L3 VL 
 
0.996 
1.00 
 
0.041 
- 
1. PIT = 67.5 + 1.02*X1 
2. PIT = 65.2 + 0.68*X1 + 10.3*X2 
ALL 
1. X1: MT L1 VL+VI 
2. X1: MT L1 VL+VI, X2: MT A2 VI 
3. X1: MT L1 VL+VI, X2: MT A2 VI, X3: MT L3 VL+VI 
 
0.686 
0.764 
0.854 
 
0.0001 
0.0001 
0.0001 
1. PIT = -3.33 + 32.9*X1 
2. PIT = 28.3 + 43.6*X1 – 54.6*X2 
3. PIT = 23.3 + 28.6*X1 – 83.1*X2 + 37.0*X3 
Y, young; O, old; MT, muscle thickness; EG, echogenicity; A1, anterior site 56%; A2, anterior site 39%; L1, lateral site 56%; L2, lateral site 39%; L3, lateral site 22%; 
VL, vastus lateralis; VI, vastus intermedius; RF, rectus femoris; PIT, peak isometric torque. 
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Table 3-57. Mixed Model Results for Posture in Muscle Thickness- Anterior Sites 
Group 
A1  A2 
RF VI RF+VI  RF VI RF+VI 
Sex 0.037 0.373 0.020  0.534 0.551 0.330 
Age 0.143 0.000 0.000  0.580 0.000 0.006 
Posture 0.000 0.000 0.000  0.000 0.000 0.000 
Marking 0.871 0.287 0.535  0.537 0.784 0.628 
        
Age × Posture  0.390 0.442 0.819  0.017 0.291 0.619 
Sex × Posture 0.601 0.758 0.648  0.105 0.611 0.416 
Posture × Marking 0.817 0.736 0.969  0.801 0.643 0.681 
Age × Sex 0.810 0.648 0.400  0.686 0.087 0.138 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates 
significant (P < 0.05). A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; 
RF, rectus femoris; VI, vastus intermedius. 
 
 
Table 3-58. Mixed Model Results for Posture in Muscle Thickness- Lateral Sites 
Group 
L1  L2  L3 
VL VI VL+VI  VL VI VL+VI  VL VI VL+VI 
Sex 0.000 0.005 0.000  0.000 0.098 0.001  0.000 0.617 0.004 
Age 0.000 0.000 0.000  0.000 0.000 0.000  0.951 0.000 0.000 
Posture 0.008 0.698 0.531  0.427 0.407 0.733  0.981 0.504 0.650 
Marking 0.859 0.376 0.830  0.400 0.821 0.703  0.320 0.586 0.795 
            
Age × Posture  0.822 0.220 0.173  0.010 0.890 0.115  0.577 0.080 0.150 
Sex × Posture 0.991 0.760 0.715  0.830 0.839 0.867  0.456 0.405 0.858 
Posture × Marking 0.966 0.453 0.972  0.602 0.848 0.914  0.932 0.434 0.883 
Age × Sex 0.007 0.536 0.360  0.046 0.796 0.468  0.372 0.607 0.513 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 0.05). L1, lateral 
quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
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Table 3-59. Mixed Model Results for Posture in Pennation Angle- Lateral Sites 
Group 
L1    L2  L3 
VL VI  VL VI  VL 
Sex 0.384 0.807  0.045 0.904  0.004 
Age 0.000 0.000  0.000 0.003  0.009 
Posture 0.171 0.605  0.113 0.205  0.818 
Marking 0.563 0.894  0.134 0.950  0.800 
        
Age × Posture  0.420 0.795  0.003 0.548  0.537 
Sex × Posture 0.499 0.233  0.618 0.157  0.564 
Posture × Marking 0.130 0.654  0.949 0.589  0.179 
Age × Sex 0.745 0.443  0.448 0.324  0.020 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates 
significant (P < 0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; 
L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
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Table 3-60. Mixed Model Results for Posture in Echogenicity- Anterior Sites 
Group 
A1  A2 
RF VI  RF VI 
Sex 0.001 0.015  0.003 0.006 
Age 0.013 0.000  0.056 0.000 
Posture 0.051 0.009  0.035 0.003 
Marking 0.630 0.243  0.143 0.389 
      
Age × Posture  0.378 0.133  0.474 0.227 
Sex × Posture 0.919 0.799  0.848 0.933 
Posture × Marking 0.457 0.929  0.858 0.831 
Age × Sex 0.027 0.552  0.027 0.952 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates 
significant (P < 0.05). A1, anterior quadriceps 56%; A2, anterior quadriceps 
39%; RF, rectus femoris; VI, vastus intermedius. 
 
Table 3-61. Mixed Model Results for Posture in Echogenicity- Lateral Sites 
Group 
L1  L2  L3 
VL VI  VL VI  VL VI 
Sex 0.000 0.004  0.000 0.006  0.004 0.055 
Age 0.000 0.015  0.082 0.004  0.690 0.000 
Posture 0.442 0.116  0.301 0.079  0.402 0.060 
Marking 0.689 0.441  0.652 0.528  0.896 0.885 
         
Age × Posture  0.224 0.051  0.319 0.072  0.420 0.004 
Sex × Posture 0.892 0.914  0.552 0.476  0.301 0.176 
Posture × Marking 0.825 0.938  0.989 0.700  0.799 0.820 
Age × Sex 0.543 0.924  0.005 0.785  0.031 0.343 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant 
(P < 0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral 
quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
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Table 3-63. Mixed Model Results for Absolute Reliability in Muscle Thickness- Lateral Sites 
Group 
L1  L2  L3 
VL VI VL+VI  VL VI VL+VI  VL VI VL+VI 
Sex 0.373 0.082 0.063  0.534 0.984 0.926  0.079 0.335 0.104 
Age 0.911 0.792 0.578  0.930 0.855 0.780  0.009 0.228 0.197 
Posture 0.022 0.298 0.126  0.258 0.289 0.406  0.762 0.907 0.921 
Marking 0.412 0.214 0.159  0.666 0.219 0.640  0.975 0.889 0.324 
            
Sex × Marking  0.028 0.720 0.202  0.609 0.563 0.078  0.864 0.545 0.640 
Age × Marking 0.005 0.253 0.024  0.201 0.276 0.087  0.159 0.493 0.258 
Posture × Marking 0.320 0.408 0.243  0.085 0.661 0.020  0.193 0.171 0.319 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 0.05). L1, lateral 
quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
 
Table 3-62. Mixed Model Results for Absolute Reliability in Muscle Thickness- Anterior Sites 
Group 
A1  A2 
RF VI RF+VI  RF VI RF+VI 
Sex 0.703 0.067 0.057  0.388 0.223 0.271 
Age 0.035 0.009 0.239  0.227 0.054 0.311 
Posture 0.168 0.287 0.390  0.063 0.301 0.180 
Marking 0.743 0.892 0.401  0.192 0.155 0.099 
        
Sex × Marking  0.110 0.607 0.368  0.510 0.901 0.733 
Age × Marking 0.384 0.803 0.267  0.699 0.171 0.591 
Posture × Marking 0.473 0.454 0.722  0.946 0.464 0.516 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 0.05). 
A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus femoris; VI, vastus 
intermedius. 
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Table 3-65. Mixed Model Results for Relatively Reliability in Muscle Thickness- Lateral Sites 
Group 
L1  L2  L3 
VL VI Both  VL VI Both  VL VI Both 
Sex 0.374 0.349 0.573  0.976 0.785 0.206  0.191 0.835 0.516 
Age 0.106 0.250 0.037  0.085 0.037 0.026  0.003 0.418 0.509 
Posture 0.022 0.414 0.114  0.406 0.557 0.544  0.889 0.705 0.628 
Marking 0.235 0.173 0.133  0.756 0.866 0.769  0.266 0.693 0.075 
            
Sex × Marking  0.042 0.486 0.109  0.483 0.596 0.023  0.304 0.642 0.677 
Age × Marking 0.009 0.133 0.012  0.330 0.044 0.087  0.048 0.241 0.043 
Posture × Marking 0.299 0.553 0.277  0.152 0.333 0.022  0.303 0.338 0.492 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 0.05). L1, lateral 
quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; VL, vastus lateralis; VI, vastus 
intermedius. 
 
Table 3-64. Mixed Model Results for Relative Reliability in Muscle Thickness- Anterior Sites 
Group 
A1  A2 
RF VI RF+VI  RF VI RF+VI 
Sex 0.603 0.113 0.146  0.214 0.261 0.377 
Age 0.064 0.000 0.153  0.803 0.007 0.297 
Posture 0.803 0.914 0.939  0.745 0.390 0.497 
Marking 0.369 0.794 0.592  0.228 0.313 0.055 
        
Sex × Marking  0.049 0.337 0.252  0.362 0.680 0.205 
Age × Marking 0.456 0.739 0.251  0.406 0.288 0.880 
Posture × Marking 0.802 0.344 0.936  0.968 0.302 0.397 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 
0.05). A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus femoris; VI, 
vastus intermedius. 
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Table 3-66. Mixed Model Results for Absolute Reliability in Pennation Angle- Lateral Sites 
Group 
L1    L2  L3 
VL VI  VL VI  VL 
Sex 0.419 0.250  0.814 0.957  0.930 
Age 0.809 0.186  0.290 0.297  0.948 
Posture 0.352 0.946  0.258 0.561  0.897 
Marking 0.802 0.439  0.556 0.867  0.546 
        
Sex × Marking 0.326 0.392  0.581 0.501  0.606 
Age × Marking 0.086 0.693  0.853 0.154  0.839 
Posture × Marking 0.036 0.496  0.790 0.574  0.120 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 
0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 
22%; VL, vastus lateralis; VI, vastus intermedius. 
 
 
 
Table 3-67. Mixed Model Results for Relative Reliability in Pennation Angle- Lateral Sites 
Group 
L1    L2  L3 
VL VI  VL VI  VL 
Sex 0.259 0.553  0.387 0.857  0.969 
Age 0.123 0.151  0.381 0.780  0.921 
Posture 0.132 0.962  0.291 0.433  0.711 
Marking 0.785 0.758  0.857 0.952  0.976 
        
Sex × Marking 0.425 0.478  0.977 0.425  0.556 
Age × Marking 0.092 0.625  0.582 0.313  0.756 
Posture × Marking 0.016 0.378  0.605 0.788  0.265 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 
0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; 
VL, vastus lateralis; VI, vastus intermedius. 
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Table 3-68. Mixed Model Results for Absolute Reliability in Echogenicity- Anterior Sites 
Group 
A1  A2 
RF VI  RF VI 
Sex 0.191 0.688  0.008 0.480 
Age 0.318 0.344  0.062 0.341 
Posture 0.447 0.814  0.935 0.762 
Marking 0.497 0.664  0.845 0.479 
      
Sex × Marking 0.438 0.568  0.109 0.697 
Age × Marking 0.644 0.369  0.323 0.953 
Posture × Marking 0.917 0.614  0.691 0.276 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P 
< 0.05). A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus femoris; 
VI, vastus intermedius. 
 
 
Table 3-69. Mixed Model Results for Absolute Reliability in Echogenicity- Lateral Sites 
Group 
L1  L2  L3 
VL VI  VL VI  VL VI 
Sex 0.453 0.794  0.132 0.468  0.045 0.218 
Age 0.019 0.418  0.455 0.002  0.893 0.082 
Posture 0.877 0.625  0.597 0.405  0.935 0.388 
Marking 0.427 0.849  0.743 0.925  0.713 0.092 
         
Sex × Marking 0.618 0.702  0.703 0.899  0.437 0.867 
Age × Marking 0.250 0.968  0.448 0.586  0.198 0.146 
Posture × Marking 0.271 0.665  0.772 0.143  0.942 0.795 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P < 
0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral quadriceps 22%; 
VL, vastus lateralis; VI, vastus intermedius. 
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Table 3-70. Mixed Model Results for Relative Reliability in Echogenicity- Anterior Sites 
Group 
A1  A2 
RF VI  RF VI 
Sex 0.879 0.419  0.120 0.694 
Age 0.648 0.483  0.120 0.678 
Posture 0.934 0.987  0.453 0.295 
Marking 0.435 0.946  0.223 0.371 
      
Sex × Marking 0.288 0.547  0.171 0.589 
Age × Marking 0.745 0.190  0.373 0.624 
Posture × Marking 0.496 0.316  0.940 0.302 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P 
< 0.05). A1, anterior quadriceps 56%; A2, anterior quadriceps 39%; RF, rectus femoris; 
VI, vastus intermedius. 
 
 
Table 3-71. Mixed Model Results for Relative Reliability in Echogenicity- Lateral Sites 
Group 
L1  L2  L3 
VL VI  VL VI  VL VI 
Sex 0.308 0.296  0.996 0.263  0.499 0.799 
Age 0.168 0.794  0.115 0.020  0.266 0.178 
Posture 0.974 0.213  0.514 0.134  0.693 0.945 
Marking 0.504 0.760  0.449 0.536  0.969 0.120 
         
Sex × Marking 0.264 0.994  0.837 0.728  0.431 0.363 
Age × Marking 0.048 0.785  0.272 0.343  0.103 0.289 
Posture × Marking 0.459 0.980  0.593 0.385  0.500 0.935 
Data are P-values; Bonferroni adjusted when applicable. Bold indicates significant (P 
< 0.05). L1, lateral quadriceps 56%; L2, lateral quadriceps 39%; L3, lateral 
quadriceps 22%; VL, vastus lateralis; VI, vastus intermedius. 
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Figure 3-2. Skeletal muscle thickness of the anterior quadriceps measured while standing and 
supine. A1, anterior quadriceps 56% proximal from knee; A2, anterior quadriceps 39% proximal 
from knee; RF, rectus femoris; VI, vastus intermedius; MT, muscle thickness. 
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Figure 3-3. Skeletal muscle thickness of the lateral quadriceps measured while standing and 
supine. L1, lateral quadriceps 56% proximal from knee; L2, anterior quadriceps 39% proximal 
from knee; L3, lateral quadriceps 22% proximal from knee; VL, vastus lateralis; VI, vastus 
intermedius; MT, muscle thickness. 
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Figure 3-4. Skeletal muscle pennation angle of the lateral quadriceps measured while standing 
and supine. L1, lateral quadriceps 56% proximal from knee; L2, anterior quadriceps 39% 
proximal from knee; L3, lateral quadriceps 22% proximal from knee; VL, vastus lateralis; VI, 
vastus intermedius; PA, pennation angle. 
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Figure 3-5. Skeletal muscle echogenicity of the anterior quadriceps measured while standing 
and supine. A1, anterior quadriceps 56% proximal from knee; A2, anterior quadriceps 39% 
proximal from knee; RF, rectus femoris; VI, vastus intermedius; EG, echogenicity; OD, optical 
density. 
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Figure 3-6. Skeletal muscle echogenicity of the lateral quadriceps measured while standing 
and supine. L1, lateral quadriceps 56% proximal from knee; L2, anterior quadriceps 39% 
proximal from knee; L3, lateral quadriceps 22% proximal from knee; VL, vastus lateralis; VI, 
vastus intermedius; EG, echogenicity. 
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INTRODUCTION 
 
Doxorubicin (DOX) is an anthracycline-class chemotherapeutic agent that is very effective 
for treating various cancers (162). However, the clinical utility of DOX is limited due to well-known 
off-target effects (90, 130, 226-228), including the induction of skeletal muscle atrophy (27, 32) and 
dysfunction (33, 91, 111, 122). While the cellular mechanisms through which DOX may exert these 
deleterious effects on skeletal muscle remain to be fully understood, previous studies have 
demonstrated increased formation of reactive oxygen species (91), as well as increased 
inflammatory (90, 92) and proteolytic markers (130, 227) in skeletal muscle within days following 
the administration of a large, single bolus of DOX. When administering smaller doses of DOX over 
biweekly intervals, to mimic the clinical utility of DOX, we have recently shown reduced muscle fiber 
size to coincide with impaired skeletal muscle mammalian target of rapamycin (mTOR) signaling 
(58). Indeed, the mTOR pathway is implicated in a variety of cellular processes related to muscle 
size including protein translation, cell proliferation, and autophagy (212). Thus, a more precise 
characterization of the cellular response of skeletal muscle to chronic DOX administration may 
provide valuable therapeutic targets to reduce side effects and improve clinical utility. 
Since their discovery (129, 154), satellite cells have been purported to serve an essential 
role in skeletal muscle growth and regeneration (135). Indeed, in vitro exposure to DOX has been 
shown to interfere with myogenic processes associated with satellite cells, including repressed 
activity of a key myogenic regulatory factor, myogenic differentiation factor 1 (MyoD) (137, 138), 
and impaired progression of myoblasts through the myogenic lineage (137, 179, 197). Furthermore, 
the administration of a single bolus of DOX appears to exacerbate muscle fiber loss when injected 
during the peak satellite cell activation window following an injury (185). Moreover, satellite cells 
have also been reported to actively engage in unique crosstalk with neighboring capillaries to 
facilitate myogenic and angiogenic processes (6, 45). Interestingly, chronic administration of DOX 
also appears to reduce cardiac muscle capillaries by ~50% (12). While there appears to be a 
potential role for satellite cells and capillaries as therapeutic targets for attenuating DOX-induced 
toxicities in skeletal muscle, the impact of DOX on satellite cell and capillary content, and their 
relation to muscle fiber size has not been thoroughly investigated. 
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Recently, the dependence on satellite cells for the non-injurious maintenance of muscle 
fiber size in adulthood has garnered review (170). Specifically, the role of satellite cells in the 
maintenance of fiber size may differ between skeletal muscles of various fiber types (88, 132), 
functions (127) and capillarization (182). Thus, there not only remains a need to explore the impact 
of in vivo DOX administration on satellite cells and capillary contents in skeletal muscle, but in 
particular, there is a need to assess this relationship in skeletal muscles of varying fiber type and 
function. Therefore, the purpose of this study was to determine the impact of chronic biweekly DOX 
administration on satellite cell and capillary content in the soleus (SOL) and extensor digitorum 
longus (EDL) muscles. These muscles were selected as they differ substantially in fiber size (231), 
fiber type (231), and capillarization (171), and the function of these muscles appears to be 
differentially impacted by DOX (111, 122). We hypothesized that chronic DOX administration would 
be associated with reduced satellite cell and capillary content as well as reduced fiber size, in both 
muscles. 
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METHODS 
Study Design 
Eight-week-old ovariectomized female Sprague-Dawley rats were purchased (Charles 
River Labs, Wilmington, MA) and acclimated to the laboratory for 1 week as previously described 
(58). Rats included in the current study were randomized to receive either Doxorubicin (DOX, n = 
8) or a saline vehicle (VEH, n = 8). Rats were pair-housed with an animal in the same group, 
allowed access to food and water ad libitum, and maintained on a 12-h light-12-h dark cycle. All 
methods used in this investigation were approved by the Midwestern University Institutional Animal 
Care and Use Committee. 
 Rats were injected (I.P.) on three occasions with DOX (doxorubicin hydrochloride >99%; 
LC Laboratories, Woburn, MA) dissolved in 0.9% normal saline or vehicle (0.9% normal saline). 
Injections were separated by 2 week intervals. The dosing strategy was designed to closely mimic 
strategies used in the clinical treatment of human cancer patients (250) and has been previously 
detailed (58). Briefly, during each injection, DOX was administered in doses of 4mg∙kg-1; totaling 
12mg/kg received by each animal by the end the experimental protocol. Five days following the 
final injection, rats were anesthetized with isoflurane then decapitated. Upon euthanasia, the SOL 
and EDL muscles were removed from each leg. The muscles from one leg were immediately frozen 
in liquid nitrogen for RT-qPCR analysis while the muscles from the opposite leg were carefully 
embedded on a foil-wrapped cork in Tissue Tek optimal cutting temperature medium (OCT; Thermo 
Fisher Scientific, Rockford, IL) and frozen in liquid nitrogen-cooled isopentane for 
immunohistochemical analysis. All samples were stored at -80°C for subsequent analyses. 
 
Immunohistochemistry 
Seven-micron-thick sections were cut in a cryostat (HM525X; ThermoFisher, Waltham, 
MA), and sections were allowed to air dry for 1 h. Determination of cross-sectional area (CSA) was 
performed as previously described for these animals in which fiber type-specific CSA in the SOL 
has been previously reported (58). Briefly, unfixed slides were incubated for 90 min at room 
temperature with an antibody directed against laminin [2E8, IgG2a, supernatant; Developmental 
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Studies Hybridoma Bank (DSHB, Iowa City, IA)]. Following a series of washes in phosphate-
buffered saline (PBS), slides were incubated for 60 min at room temperature in goat anti-mouse 
IgG2a Alexa Fluor (AF) 633 (#A21136; Invitrogen, Grand Island, NY), washed in PBS, and mounted 
with fluorescent mounting media (Fluormount G, #0100-01; Southern Biotech, Birmingham, AL). 
For Pax7/laminin/DAPI staining (visualization of myonuclei and satellite cells), 
immunohistochemical procedures were adapted from Finnerty et al. (71). Briefly, slides were fixed 
in 4% paraformaldehyde followed by epitope retrieval using sodium citrate (10 mM, pH 6.5) at 92°C 
for 20 min. Endogenous peroxidases were blocked with 3% hydrogen peroxide in PBS, and then 
slides were incubated overnight at 4°C in anti-laminin (no. L9393; Sigma Aldrich, St. Louis, MO) 
and anti-Pax7 antibody (DSHB). The next day, slides were incubated for 70 min at room 
temperature in goat anti-rabbit AF488 (#A11034; Invitrogen, laminin) and goat anti-mouse 
biotinylated secondary antibody (no. 115-065-205; Jackson ImmunoResearch, West Grove, PA), 
and then reacted with streptavidin-horseradish peroxidase (HRP) and AF555 tyramide included 
with the tyramide signal amplification (TSA) kit (#T20932; Invitrogen). TSA-AF555 was used to 
visualize Pax7 antibody-binding. Slides were co-stained with 4’,6-diamidino-2-phenylindole (DAPI, 
no. D35471; Invitrogen) before being mounted with Vectashield fluorescent mounting media 
(Vector Laboratories, Burlingame, CA). 
For visualization of capillaries, slides were fixed for 10 min in ice-cold acetone (-20°C) and 
then blocked for 1 h in 2.5% normal horse serum (Vector Laboratories). Slides were incubated 
overnight at 4°C in antibody against CD31/PECAM (#550300, BD Biosciences, San Jose, CA). The 
next day, slides were incubated for 1 h at room temperature in goat anti-mouse AF555 (#A21127, 
Invitrogen) and AF488 conjugated-wheat germ agglutinin (WGA, #W11261, Invitrogen). 
Image acquisition and analysis 
Images were captured at 100x total magnification at room temperature with a Zeiss upright 
microscope equipped with an automated stage (AxioImager M1; Zeiss, Oberkochen, Germany). 
Muscle fiber CSA was analyzed from images of laminin staining using a semiautomated threshold 
analysis (ImageJ, NIH, Bethesda, MD) as previously detailed (58). Image analysis for satellite cells, 
myonuclei, and capillaries was performed using the AxioVision Rel software (v. 4.9) by a single 
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assessor blinded to group. Satellite cell abundance was assessed as previously described (71). 
Briefly, Pax7+/DAPI+ loci residing within the laminin border were counted as satellite cells. DAPI+ 
nuclei residing within the laminin border were counted as myonuclei. A nucleus was identified as a 
myonucleus if it met one of the following criteria: 1) it was clearly located within the laminin 
boundary; 2) it was on the laminin boundary facing inside the fiber; or 3) 50% of the area fell inside 
the laminin boundary. Cellular structures positive for CD31+ were counted as capillaries. All satellite 
cells, myonuclei, and capillary counts were normalized to muscle area (mm2). 
 
RNA Extraction and Semiquantitative real-time PCR  
RNA isolation, cDNA synthesis, and real-time quantitative PCR were performed as our 
laboratory has previously described (58). Briefly, frozen muscle tissue was weighed (mean ± SD, 
25.84 ± 6.5mg) at 4ºC and homogenized with a hand-held homogenizing dispenser (Bio-Gen 
PRO200, Pro Scientific, Oxford, CT) in 1 ml of Tri reagent (Molecular Research Center, Cincinnati, 
OH). RNA concentration was determined using a Take3 plate (Biotek, Winooski, VT) and Biotek 
H1 Synergy. RNA (5 μg) was DNase-treated using a commercially available kit (DNA-free, Ambion, 
Austin, TX). A total of 1 μg of RNA was reverse transcribed into cDNA according to the directions 
provided by the manufacturer (SensiFAST, Bioline, Taunton, MA). Real-time qPCR was carried out 
with a CFX Connect Real-Time PCR Detection System (BioRad). cDNA was analyzed with SYBR 
green fluorescence (iTaq Universal SYBR green supermix; BioRad). Primer sequences were 
designed using the National Center for Biotechnology Information database (265) to be mRNA 
specific and compatible with SYBR green chemistry. Primer pairs (Table 1) were purchased from 
Invitrogen (Carlsbad, CA) and carefully optimized as previously described (52). 2-Microglobulin 
was utilized as a normalization/housekeeping gene. Relative fold changes from VEH were 
determined from the Cq values using the 2–𝚫𝚫Ct method (147). 
Statistical Analyses 
 All data were tested for normality through skewness and kurtosis analyses and visual 
inspection of the normality plots using SPSS v.24 (IBM). Satellite cell, myonuclei, capillary, and 
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mRNA expression data were analyzed using an independent samples t-test. To account for multiple 
measures obtained from the same animal, all individual fiber CSA data from an individual animal 
were nested and data were analyzed using a multi-level mixed model (nested ANOVA) (58). This 
statistical model allows for the inclusion of the multiple measures (i.e., all fibers analyzed), but 
avoids treating each fiber as an independent observation and takes into account variability for 
measures obtained both within and between animals. Statistical analyses were conducted using 
SPSS v.24 (IBM). Significance was set a priori at P ≤ 0.05. Data are presented as mean ± standard 
error (SE) where individual data are not shown. 
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RESULTS 
Muscle fiber CSA 
To assess the impact of DOX administration on muscle fiber size, we examined SOL and 
EDL fiber CSA. Similar to the fiber type specific data previously reported (58), DOX administration 
was associated with ~26% smaller pooled-fiber CSA in the SOL (Fig. 1A; P = 0.022). Similarly, fiber 
CSA in the EDL was ~33% smaller in DOX animals (Fig. 1C; P = 0.009). The distribution of fiber 
CSA in each muscle displayed a clear leftward shift toward smaller fibers in both the SOL and EDL 
in DOX animals (Fig. 1B,D). The average number of SOL fibers analyzed per animal were 162 ± 5 
for VEH and 209 ± 15 for DOX, while the average EDL fibers analyzed per animal were 228 ± 74 
for VEH and 403 ± 100 for DOX. 
Satellite cell and myonuclei content 
 Representative immunohistochemical images of satellite cell and myonuclei analyses are 
shown in Figure 2. Pax7-positive satellite cell content in the SOL was ~39% lower in DOX animals 
(Fig. 3A; P = 0.002). Notably, the SC content in the SOL of all animals that were administered DOX 
was lower than every animal in VEH (Fig. 3A). On the other hand, SC content was not statistically 
impacted by DOX administration in the EDL (Fig. 3C; P = 0.18). Myonuclei content in the SOL (Fig. 
3B) and EDL (Fig. 3D) were not affected by DOX administration (P = 0.292 and P = 0.66, 
respectively). The muscle area (mm2) analyzed for SC and myonuclei content was similar for each 
muscle between groups (P > 0.05; SOL: VEH = 3.43 ± 0.35, DOX = 5.03 ± 0.98; EDL: VEH = 5.81 
± 0.74, DOX = 5.21 ± 0.53 mm2). 
Capillary content 
 Capillary content in the SOL was ~35% lower in DOX animals (Fig. 4A-D; P = 0.021). 
Notably, the SOL capillary content of all animals that were administered DOX was lower than every 
VEH animal (Fig 4D). Capillary content of the EDL was not impacted by DOX administration (Fig. 
4E-H; P = 0.959). The muscle area (mm2) analyzed for capillary content was similar for each muscle 
across treatments (P > 0.05; SOL: VEH= 1.23 ± 0.47, DOX = 5.50 ± 1.92; EDL: VEH = 3.64 ± 1.05, 
DOX = 2.89 ± 0.54 mm2). 
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Myogenic gene expression 
 The mRNA expression of MYF5 was higher in animals administered DOX only in the SOL 
(P = 0.026). MGF mRNA expression was lower in animals administered DOX only in the EDL (P = 
0.048). The mRNA expression of several other genes associated with myogenesis in the SOL and 
EDL were unaffected by DOX administration (Table 2). 
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DISCUSSION 
The purpose of the current study was to determine the impact of chronic DOX 
administration on satellite cell and capillary densities in different skeletal muscles. Several novel 
findings resulted from this study. First, chronic DOX administration was associated with lower 
skeletal muscle satellite cell density in the SOL muscle. The lower satellite cell density in the SOL 
of DOX animals coincided with lower capillary density and reduced muscle fiber CSA. Conversely, 
while chronic DOX administration was also associated with reduced CSA in the EDL, satellite cell 
and capillary densities were not impacted. These findings suggest that 1) DOX administration 
impacts satellite cell and capillary densities in a muscle-specific manner, 2) DOX impairs the 
regulation of muscle fiber CSA across multiple muscles of varying fiber type, 3) the role of satellite 
cells in the regulation of muscle fiber size may differ across muscles. 
We have previously reported reduced MHC I and MHC II fiber CSA in the SOL of animals 
that underwent chronic DOX administration (58). DOX has been shown to impact the function of 
both the SOL and EDL (111, 122), however, to what extent chronic DOX administration impacts 
fiber size in the EDL has not been investigated. In the current study, chronic DOX administration 
was associated with a similar relative reduction in fiber CSA in both the SOL and EDL muscles 
despite the fact that these muscles differ considerably in fiber type profile and fiber size (231), and 
may also differ in their accumulation of DOX (111). Nonetheless, these results indicate that DOX 
exerts an impact on muscle fiber size across different skeletal muscles. 
Satellite cells are understood to contribute to the regulation of muscle fiber size (131), 
however, the role of satellite cells in maintaining fiber size may differ depending on the muscular 
environment in which they reside. Therefore, to more precisely identify the impact of DOX on the 
regulation of muscle fiber size, we examined satellite cell density in the SOL and EDL following 
chronic DOX administration as these muscles are comprised of different fiber type profiles (88, 
132), functions (127) and capillarization (36). While chronic DOX administration reduced muscle 
fiber size in both the SOL and EDL, the reduced fiber size was accompanied by reduced satellite 
cell density only in the SOL, whereas satellite cell density was unaffected by DOX in the EDL. 
Indeed, the work of Kelly et al. (132) propose that fiber size in the SOL is more associated with 
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satellite cell fusion whereas fiber size in the EDL is more a product of cytoplasmic expansion. While 
satellite cells in the EDL were not affected by DOX administration, the EDL muscle of the DOX 
group exhibited reduced MGF mRNA expression which has been shown to be regulated by 
circulating growth hormone (124) and positively correlated to lean mass (193). Thus, it is likely that 
the role of satellite cells as a contributing factor to the maintenance of fiber size may differ between 
the SOL and EDL. Collectively, these data highlight that the mechanisms through which DOX 
administration impacts fiber size may vary between muscles of different phenotype. 
An interesting finding in the current study was that chronic DOX administration was 
associated with a muscle-specific reduction of satellite cell density in the SOL. However, despite 
reductions in satellite cell density, the myonuclear density was maintained in the SOL following 
DOX administration. Previous research has shown that a large, single bolus injection of DOX 
increases the occurrence of apoptotic myonuclei in the SOL (227). Importantly, maintenance of the 
myonuclear population is reliant on satellite cell fusion as the primary source of new myonuclei 
(168). In addition, DOX is a known inhibitor of cell proliferation (106), thus it is possible that satellite 
cell proliferation may also be blunted by DOX administration. Collectively, the reduced satellite cell 
density observed specifically in the SOL of the DOX group may be the result of a greater reliance 
on satellite cells to replenish apoptotic nuclei coupled with an impaired ability to maintain the 
satellite cell pool through blunted proliferation/self-renewal. Further, this interpretation is supported 
by increased mRNA expression of Myf5 in the SOL of DOX, which may be upregulated in an 
attempt to recuperate proliferation (266) and self-renewal (210) that may be compromised by DOX. 
Further research is needed to identify the precise mechanisms regulating satellite cell dynamics in 
otherwise sedentary skeletal muscle and how they are affected by myotoxic drugs such as DOX. 
Similar to previous studies (88, 132), we also detected reduced satellite cell density in the 
EDL compared to the SOL, supporting the notion that satellite cells may have unique roles within 
various skeletal muscles. Further, similar to satellite cell density, myonuclear density was also not 
impacted by chronic DOX administration in the EDL. Previous reports indicate satellite cells and 
myonuclei within the EDL are less mitotically and transcriptionally active, respectively, compared 
to those within SOL (97, 132). Previous research has also demonstrated that under non-injurious 
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conditions, the number of myonuclei in the EDL of satellite cell-ablated mice do not appear to differ 
from that of control mice (131). This latter observation would seem to indicate that satellite cells in 
the EDL may not measurably contribute to myonuclear number in the maintenance of muscle 
homeostasis. Thus, in the uninjured state (i.e., sedentary) the satellite cell pool in the EDL may be 
less susceptible to the deleterious effects of DOX. On the other hand, future research is necessary 
to determine the extent to which DOX administration impacts satellite cell in the EDL in the 
presence of a (damaging) stimulus that may accompany clinical treatment (i.e., 
exercise/rehabilitation). 
It is well known that muscle capillaries serve a vital role in maintaining skeletal muscle by 
delivering oxygen, substrates, and circulating factors. More recently, mounting evidence indicates 
that capillaries and satellite cells communicate through paracrine interactions to facilitate myogenic 
and angiogenic processes (6, 45). Indeed, satellite cells and capillaries appear to share a general 
proximity within skeletal muscle (45, 181). Given the vital role of skeletal muscle capillaries and 
their proposed relationship with satellite cells, we examined the impact of chronic DOX 
administration on capillary density in the SOL and EDL. Similar to our findings regarding satellite 
cell density, we also show that DOX administration was associated with lower capillary density in 
the SOL, but not the EDL. Our findings are consistent with a previous study (12) demonstrating 
reduced capillaries in the myocardium of diabetic rats following chronic DOX administration. 
Interestingly, myocardial capillary content was increased when stem cells were administered along 
with DOX administration (12). These findings indicate that stem cells may aid in the maintenance 
of capillary networks. Indeed, cell culture models demonstrate capillary density (200) and capillary 
growth (206) are greater in the presence of satellite cells. Therefore, it is interesting to speculate 
that in the current study the lower capillary density observed in the SOL of the DOX group may, in 
part, result from the reduction in satellite cell density in the same muscle. 
Consistent with the satellite cell data, capillary density in the EDL was unaffected by 
chronic DOX administration. Recently, Nissinen et al. (186) showed that chronic DOX 
administration did not impact capillary density of the tibialis anterior (TA) muscle in mice. Given the 
strikingly similar fiber type profiles between the TA and EDL (231), the findings from Nissinen et al. 
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(186) indirectly support our findings in the predominantly MHC II EDL. Similar to observations made 
in the SOL, it is interesting to speculate that the preservation of capillary density in the EDL following 
chronic DOX administration may be, in part, related to the lack of effect on satellite cell density. 
However, it is important to note that much of the work investigating the relationship between 
satellite cells and capillaries has occurred during times of active muscle repair (181, 182, 187), 
therefore more research is needed to clarify the relationship between satellite cells and capillaries 
in relation to uninjured, skeletal muscle maintenance as was employed in the current investigation 
(i.e., sedentary animals). Nonetheless, our findings further promote an intricately regulated 
connection between satellite cell and capillary populations across skeletal muscles. 
In conclusion, we show for the first time that chronic DOX administration is associated with 
reduced satellite cell and capillary densities in the SOL. On the other hand, while DOX 
administration was associated with reduced muscle fiber size in both the SOL and EDL, satellite 
cell and capillary density were unaffected by chronic DOX administration in the EDL. These findings 
indicate that varying skeletal muscles may rely on different mechanisms to maintain fiber size and 
that chronic DOX administration may impact fiber size of various skeletal muscles through different 
cellular mechanisms. While the current study did not examine functional parameters of these 
muscles, DOX appears to cause dysfunction in both the SOL and EDL (111, 122). Coupled with 
previous findings in which chronic DOX administration attenuated mTORC1 signaling (58) and 
mitochondrial dysfunction (102), these findings contribute to a growing body of literature 
highlighting the myotoxicity associated with DOX. Future studies are encouraged to examine 
skeletal muscle satellite cells and capillaries as therapeutic targets in mitigating the deleterious 
impact of DOX in skeletal muscle. 
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Table 4-1.  Primer sequences used for real-time PCR 
mRNA  Accession No. Primer Sequence (5’-3’) 
Product 
Size 
(bp) 
Id2 NM_013060.3 
Sense GGACAGAACCAAACGTCCAG 
94 
Antisense TAAGCTCAGAAGGGAATTCAGAC 
MGF NM_001082478.1 
Sense TGACATGCCCAAGACTCAGAAGT 
70 
Antisense CCTTCTCCTTTGCAGCTTCCT 
MYF5 NM_001106783.1 
Sense TGTCTGGTCCCGAAAGAACA 
103 
Antisense CAAGCAATCCAAGCTGGACA 
MYF6 NM_013172.2 
Sense CCCTTACAGCTACAAACCCAAG 
130 
Antisense TGCTCCTCCTTCCTTAGCAG 
MyoD NM_176079.1 
Sense GGAGACATCCTCAAGCGATGC 
104 
Antisense GCACCTGGTAAATCGGATTG 
Myogenin NM_017115.2 
Sense CAGTGAATGCAACTCCCACA 
85 
Antisense CAAATGATCTCCTGGGTTGG 
Myostatin NM_019151.1 
Sense GGCAGAGTATTGATGTGAAGAC 
119 
Antisense TGGGAAGGTTACAGCAAGATC 
Mdm2 NM_001108099.1 
Sense CCGAGCGAAATGGTCTCTCA 
93 
Antisense CTGCAGACCGCTGCTACTC 
Npm1 NM_012992.4 
Sense TCAAGTGCGCGCCTCC 
97 
Antisense CAGCCTTTAGTTCACAACCGAA 
Rb1 NM_017045.1 
Sense TGTATGGCATCTGCAAGGTGA 
100 
Antisense CGTTTAAAGGTCTCCTGGGC 
Id2, Inhibitor of DNA Binding 2; MGF, Mechano growth factor; MYF5, Myogenic factor 5; MYF6, Myogenic factor 6; MyoD, Myogenic differentiation 
factor 1; Mdm2, mouse double minute 2 homolog; Npm1, Nucleophosmin 1; Rb1, Retinablastoma 1. 
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Table 4-2. Soleus and extensor digitorum longus muscle mRNA analyses for markers of 
myogenic activity. 
 Soleus  Extensor Digitorum Longus 
mRNA VEH DOX  VEH DOX 
Id2 1.24 ± 0.33 1.30 ± 0.24  1.03 ± 0.14 0.92 ± 0.16 
Mdm2 1.05 ± 0.42 0.76 ± 0.21  1.08 ± 0.25 0.79 ± 0.24 
MGF 1.25 ± 0.30 1.18 ± 0.13  1.01 ± 0.07 0.80 ± 0.01* 
MYF5 1.07 ± 0.16 1.59 ± 0.13*  1.02 ± 0.11 0.80 ± 0.01 
MYF6 1.08 ± 0.16 0.89 ± 0.09  1.14 ± 0.34 0.54 ± 0.04 
MYOD 1.25 ± 0.35 1.90 ± 0.23  1.18 ± 0.40 0.57 ± 0.08 
Myogenin 1.43 ± 0.54 1.25 ± 0.15  1.16 ± 0.39 0.96 ± 0.17 
Myostatin 1.38 ± 0.38 1.31 ± 0.25  1.18 ± 0.43 0.90 ± 0.24 
Npm1 1.31 ± 0.49 0.94 ± 0.11  1.02 ± 0.12 1.16 ± 0.19 
Rb1 1.23 ± 0.38 0.78 ± 0.11  1.03 ± 0.15 0.93 ± 0.15 
Data are mean ± SE. Values represent relative fold change from vehicle (VEH) as determined 
from the Cq values using the 2–ΔΔCt method (28). *P < 0.05 VEH vs DOX. Inhibitor of DNA 
Binding 2; MGF, Mechano growth factor; MYF5, Myogenic factor 5; MYF6, Myogenic factor 6; 
MyoD, Myogenic differentiation factor 1; Mdm2, mouse double minute 2 homolog; Npm1, 
Nucleophosmin 1; Rb1, Retinablastoma 1. Soleus: VEH, n=8; DOX, n=8; EDL: VEH, n=4; DOX, 
n=6. 
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Figure 4-1. The effect of chronic doxorubicin administration on muscle fiber cross-sectional area 
(CSA). Mean fiber CSA of soleus (A) and extensor digitorum longus (C) presented as mean ± SE. 
Histogram distribution of fiber CSA in soleus (B) and extensor digitorum longus (D). VEH, vehicle 
group; DOX, doxorubicin group. Soleus (VEH, n = 4; DOX, n = 4); extensor digitorum longus (VEH, n 
= 4; DOX, n = 6). *P < 0.05 VEH vs DOX. 
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Figure 4-2. Representative immunohistochemical image of satellite cell detection in the soleus and extensor digitorum 
longus. Merged images (A,F) demonstrating laminin (green), Pax7 (red), and 4′ ,6-diamidino-2-phenylindole (DAPI, blue) 
with satellite cells denoted by white arrowheads. Scale bar represents 50 μm. Merged images (B, G) demonstrating satellite 
cell (red) location within laminin (green), costained with DAPI (blue; C, H) and denoted by white arrowheads. Single-channel 
image (D, I) demonstrating DAPI (blue). Single-channel image (E, J) demonstrating Pax7 (red). 
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Figure 4-3. The effect of chronic doxorubicin administration on satellite cell and myonuclei densities. Mean satellite 
cell density of soleus (A) and extensor digitorum longus (C) presented as mean (bar) with individual animals 
represented by an “X”. Mean myonuclei density of soleus (C) and extensor digitorum longus (D). VEH, vehicle group; 
DOX, doxorubicin group. Soleus (satellite cell: VEH, n = 4; DOX, n = 6; myonuclei: VEH, n = 4; DOX, n = 5); extensor 
digitorum longus (satellite cell: VEH, n = 4; DOX, n = 6; myonuclei: VEH, n = 4; DOX, n = 6). *P < 0.05 VEH vs DOX. 
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Figure 4-4. The effect of chronic doxorubicin administration on capillary density. Merged images (A, E) demonstrating CD31 (white) 
and wheat germ agglutinin (WGA, red). Scale bar represents 50 μm. Single-channel images (B, F) demonstrating CD31 (white). 
Single-channel images demonstrating WGA (red). Mean capillary density of soleus (D) and extensor digitorum longus (H) presented 
as mean (bar) with individual animals represented by an “X”. VEH, vehicle group; DOX, doxorubicin group. Soleus (VEH, n = 4; DOX, 
n = 4); extensor digitorum longus (VEH, n = 4; DOX, n = 6). *P < 0.05 VEH vs DOX. 
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CHAPTER FIVE 
CONCLUSION 
 
 The aim of this dissertation was to advance our ability to develop these strategies 
by addressing challenges to skeletal muscle faced throughout advancing age. Specifically, 
this dissertation is comprised of two distinct studies which aimed to 1) develop noninvasive 
strategies to assess skeletal muscle size, architecture, and composition in young and old 
adults and 2) evaluate the impact of chemotherapeutic treatment on skeletal muscle 
satellite cells and capillaries. The major findings from this dissertation aid in our ability to 
preserve skeletal muscle health and function throughout aging. 
The goal of the first project was to assess the reliability of two predominate 
methodologies for ultrasound-based examination of quadriceps muscle size, architecture, 
and composition in young and old individuals. Ultrasound has been a valuable tool for 
examining the age-related decline in muscle size, pennation angle, and composition, 
which together, largely dictate the functional capacity of a muscle (140, 173). However, 
there lacks consensus on a standardized method to assess skeletal muscle 
characteristics, with the two predominant methodologies being practiced largely differing 
in the posture of the subject during imaging (4, 25). The findings from the first study 
highlight sources of variability associated the use of ultrasound to examine skeletal muscle 
characteristics. Overall, our findings suggest that US measurements of the lateral 
quadriceps are ideal for assessing functional changes in skeletal muscle, particularly given 
their collective relationship with muscle function and resistance to posture in both young 
and old. However, older age was associated with generally lower reliability which may 
impede the ability to accurately detect changes in the skeletal muscle of older adults. The 
findings from this study can be used to improve reproducibility and generalizability across 
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and within scientific investigations. This is particularly relevant given the emerging use of 
ultrasound to assess skeletal muscle characteristics in healthy and clinical populations. 
Future directions for these works include the assessment of the reliability of skeletal 
muscle ultrasound measures in clinical populations in order to more accurately detect 
functionally-relevant changes in skeletal muscle characteristics. 
In addition to aging, disease and associated treatments can accelerate reductions 
in muscle quality. The common chemotherapeutic drug DOX is associated with many 
negative side effects in skeletal muscle including muscle atrophy (27, 32) and dysfunction 
(33, 91, 111, 122), however the cellular mechanisms responsible are still unclear. In this 
regard, satellite cells are a population of resident stem cells that govern the regenerative 
program in skeletal muscle (229). In addition, these cells engage in unique crosstalk with 
neighboring capillaries to facilitate myogenic and angiogenic processes, both of which are 
critical to skeletal muscle health (6, 45). The purpose of the second study was, therefore, 
to determine the impact of the common chemotherapeutic drug, DOX, on the satellite cell 
and capillary content in the soleus and extensor digitorum longus muscles. Specifically, 
these two muscles were studied as they differ substantially in fiber size (231), fiber type 
(88, 132), and capillarization (36), and the function of these muscles appears to be 
differentially impacted by DOX (111, 122). The results from our preclinical animal model 
indicate the chronic DOX administration is associated with reduced fiber size in multiple 
skeletal muscles, however the satellite cell and capillary densities were more impacted in 
the soleus compared to the extensor digitorum longus, indicating that DOX appears to 
impact molecular processes in a muscle-specific manner. These findings indicate that 
varying skeletal muscles may rely on different mechanisms to maintain fiber size and that 
chronic DOX administration may impact fiber size of various skeletal muscles through 
different cellular mechanisms. These findings contribute to a growing body of literature 
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highlighting the myotoxicity associated with DOX and highlight novel therapeutic targets 
for the development of strategies aimed at preserving skeletal muscle throughout DOX 
treatment (33, 58, 90, 122, 186). Future studies are encouraged to examine satellite cells 
and capillaries as therapeutic targets in human cancer patients receiving DOX.  
In summary, advancing age is accompanied by an inevitable physiological decline 
over time. Skeletal muscle mass and function steadily decline with old age, leading to 
reduced independence and diminished quality of life in older adults. Unfortunately, this 
decline is often exacerbated by occurrences including injury, illness, or the direct and 
indirect effect of drug treatments. These occurrences present particularly difficult 
challenges to skeletal muscle by accelerating the normal age-related decline in muscle 
quality, increasing the risk for disability or frailty. Thus, in order to sustain quality of life 
and independence into old age, focus must be placed on the development of therapeutic 
strategies aimed at preserving skeletal muscle health and function through advancing age. 
Collectively, the findings from this dissertation 1) improve the ability to non-invasively 
examine changes in muscle size, composition, and function that can be used to monitor 
changes with age-related impairments or improvements following rehabilitation, and 2) 
identify promising therapeutic targets to protect skeletal muscle from the harmful effects 
of chemotherapy treatment. The works from this dissertation aid in the development of 
strategies aimed at returning muscle back to a normal, healthy state of aging following 
these challenges. 
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Title of research study: A comparison of two ultrasound techniques for measuring muscle 
thickness, muscle fiber angle, and their association with muscle function among young and older 
adults. 
Investigator:  Jared Dickinson, PhD 
 School of Nutrition and Health Promotion 
 Arizona State University 
 
 Siddhartha Angadi, PhD 
 College of Nursing and Health Innovation 
 Arizona State University 
 
 Andrew D’Lugos, MS 
 College of Nursing and Health Innovation 
 Arizona State University 
 
Why am I being invited to take part in a research study? 
We invite you to take part in a research study because: 
• You are either between 18 and 35 years of age or 60 and 85 years of age  
• You are healthy, and do not have any major health problems such as heart trouble, lung, kidney 
or liver problems, active cancer, infections, or existing muscle/ bone injuries 
• You do not participate in regularly scheduled heavy weight lifting exercise. 
 
Why is this research being done? 
Changes in muscle size are often related to changes in muscle function or strength. For instance, 
a bigger muscle is usually a stronger muscle. Ultrasound imaging is a safe and painless way of 
taking pictures of your muscles to deterimine their size. 
 
Two common methods are used by researchers to measure muscle size using ultrasound.  The 
main difference between protocols is the position of the patient while the images are captured, 
either standing or laying down. Nobody has compared the standing protocol versus the laying down 
protocol on the same set of individuals.   
 
The purpose of this study is to determine which ultrasound imaging protocol of the thigh muscles 
is more accurate and reliable.  We will also want to examine which protocol is more closely related 
to the strength of your thigh muscles and which protocol is more closley related to the total amount 
of muscle you have in your legs.  Lastly, we also want to see whether these relationships are similar 
or different in younger and older men and women. 
 
All subjects will perform and participate in the same number of tests and visits to the lab.  These 
tests and visits are described below.   
How long will the research last? 
We expect that individuals participating in the proposed activities will spend about 4 hours at our 
lab, which is located in the Arizona Biomedical Collaborative Building on the Downtown Phoenix 
Campus of Arizona State University.  You will be asked to visit the lab on two (2) separate 
occasions.  The visits should require you to be in our lab for ~ 120 minutes (or 2 hours) for each of 
the visits. We expect that you will be able to complete all these visits over a 1-2 week period 
depending on scheduling. 
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How many people will be studied? 
We expect about 80 people from the Phoenix area will participate in this research study. 
What happens if I say yes, I want to be in this research? 
It is up to you to decide whether or not to participate. 
 
If you decide to participate, then as a study participant you will join a study involving research to 
determine which ultrasound imaging protocol is more reliable in measuring muscle characteristics 
(muscle size, muscle fiber angle) and is more closely related to muscular strength.  All visits will 
take place at the Arizona Biomedical Collaborative building on the Downtown Phoenix campus of 
Arizona State University.  You will only interact with members of the research team.  As part of your 
participation you will be asked to perform the following tests: 
 
Visit #1 (Consent, Familiarization, Trial 1)  
Time Commitment: 120 minutes 
1) You will be asked to arrive to the lab after a three (3) hour fast. We will ask you not to consume 
anything except water for three (3) hours before your scheduled arrival time. We will ask you 
to wear or bring with you a pair of shorts that can be worn during the visit. 
2) You have been invited to Arizona State University for an initial visit, review of the information 
provided on the online questionnaire, distribution of the consent form, and an explanation of 
the study procedures.  
3) If you agree to participate and sign this consent form, you will complete the first of two visits.  
Before the initiation of any measurement, you will have your height, weight, and blood pressure 
measured. 
4) We will ask you to perform a Physical Activity Readiness Questionnaire to determine how safe 
it is for you to exercise. 
5) We will measure the size of your muscles in your upper leg and the angle of muscle fibers 
within these muscles, using ultrasound imaging. You will be asked to either stand on a 
cushioned mat or lie down on a padded examination table and relax for twenty (20) minutes. 
During this time the researcher will measure and mark imaging sites along the upper leg, using 
a tape measure and medical marker. Next, the researcher will place the ultrasound device on 
the skin and proceed to capture pictures of the upper leg muscles.  We will take these measures 
on both your right and left leg.  You will be asked to stand up for some measures and lay down 
for some measures. 
6) We will ask you to perform exercises that will familiarize you (like practice) with exercises we 
will ask you to perform at the second visit. 
a. Muscle Performance:  This exercise will be performed for each leg on a specialized 
piece of exercise equipment.  For this test, you will be seated on the exercise 
equipment and strapped in around your shoulders and hips to keep you in position.  
One of your legs will be attached to the leg attachment with a padded ankle strap.  
For this test, you will be asked to move your knee from a bent position to a 
straighten position and then from a straightened position to a bent position using 
your leg muscles to push and pull the bar as hard as you can in both directions.  
For a separate test, you will be asked to push against a stationary bar as hard as 
you can. 
 
7) We will establish a schedule for Visit #2, ranging from five (5) to fifteen (15) days from Visit 
#1. 
Visit #2 (Trial 2)  
Time Commitment: 120 minutes 
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1) You will be asked to arrive to the lab after a three (3) hour fast. We will ask you not to consume 
anything except water for three (3) hours before your scheduled arrival time. We will ask you 
to wear or bring with you a pair of shorts that can be worn during the visit. 
2) Before the initiation of any measurement, you will have your height, weight, and blood pressure 
measured. 
3) We will repeat the same ultrasound measures as described for Visit #1 
4) We will ask you to perform the same muscular performance test as Visit #1. 
5) You will be asked to receive a DXA scan (similar to a low-dose x-ray). You will be escorted to 
the second floor of the ABC building and positioned on a padded, examination table lying face 
up. The DXA scan will last no more than five (5) minutes and will consist of a scanning head 
that will travel over top of the body. A licensed radiology technician will perform the DXA scan.  
If you are of child-bearing age, before you receive the DXA scan we will ask you to perform a 
pregnancy test that we provide and use this test to determine that you are not pregnant prior 
to performing the DXA scan. 
 
Dietary and Activity Control: Three days prior visits #1 and #2 you will be asked to maintain your 
normal dietary habits.  You will be asked to abstain from consuming any food (except water) 3 
hours prior to visits #1 and #2.  You will also be asked to refrain from alcohol consumption 24 hours 
prior to visits #1 and #2 and any unordinary physical activity beginning three days prior to visits #1 
and #2.   
 
What happens if I say yes, but I change my mind later? 
You can leave the research at any time it will not be held against you. 
If you stop being in the research project, data collected up to the point of your withdrawal from the 
study will remain with the research team to ensure the integrity of the research project.  These data 
will be handled the same as research data.   
If you decide to stop the research project, no explanation is required. 
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Is there any way being in this study could be bad for me? 
If you decide to participate in this study, then you may face a risk.  These risks include: 
1) Muscle Performance Testing.  Muscle soreness or cramps may occur.  These are the most 
likely side effects of exercise, and can be reduced with an adequate warm-up.  Exercise may also 
expose you to a low risk of cardiovascular events, such as a heart attack, especially if you have 
a predisposing condition.  However, a cardiovascular event such as a heart attack is a very rare 
potential risk in individuals without a predisposing condition.  The exercise portion of this study is 
considered minimal, and our screening procedures are specifically designed to minimize your 
risk. 
 
2) Dietary and Activity control. No known risks 
 
3) Ultrasonography.   Ultrasound imaging has been used for over 20 years and has an excellent 
safety record. It does not have the same risks as x-rays or other types of imaging.  Even though 
there are no known risks of ultrasound imaging, it can heat the tissues slightly.  However, we 
do not anticipate that the time it takes for us to image your muscles will produce any noticeable 
heating effects on your body. 
 
4) DXA Scan.  This procedure will expose you to a very small amount of radiation, much less than 
most routine X-ray procedures, and less than the amount of radiation you would be exposed to 
in a 2-hour airplane flight. Exposure to radiation can increase the risk of getting cancer and birth 
defects. The amount of radiation to which you will be exposed during the DXA scan is so small 
that the exact risk is unknown.  The exposure of radiation via X-ray during DXA scans is 
especially risky for women who are pregnant or have a risk of being pregnant.   
 
5) Confidentiality.  There is a general risk of disclosure of personal sensitive data in a clinical 
investigation.   To minimize this risk only the investigators and the laboratory personnel will have 
access to your personal information.  All research data containing your name will be locked in the 
Principal Investigator’s office. To preserve confidentiality, immediately after enrollment you will be 
assigned a code by which each research sample will be identified for further analysis, thus avoiding 
identification by technicians or non-qualified individuals. 
Other unforeseen or unknown risks may occur.  And as with any research, there is some 
possibility that you may be subject to risks that have not yet been identified. You will be closely 
monitored for any unforeseen risks.  
You should not be or become pregnant while in this research study. 
Alternative Treatment.  There are no feasible alternative procedures available for the procedures 
utilized in this study. An alternative would be not to participate in this study. 
Will being in this study help me any way? 
We cannot promise any benefits to you or others from your taking part in this research.  
However, the knowledge gained from this study could have a benefit to society by providing  new 
data regarding whether standing or lying down during ultrasound imaging results in more reliable 
measurements and which protocol relates more to muscular strength.  
What happens to the information collected for the research? 
Efforts will be made to limit the use and disclosure of your personal information to people who have 
a need to review this information. We cannot promise complete secrecy. Organizations that may 
inspect and copy your information include the IRB and other representatives of this organization.   
Federal law provides additional protections of your medical records and related health information. 
These are described in an attached document. 
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What else do I need to know? 
If you agree to take part in this research study, we will pay you for your time and effort.  You will be 
paid $20 for completion of the protocol.  If you drop out or are excluded, you will not receive any 
payment.  You will receive the full $20 only for the completion of all research visits.  Also, please 
note that in the unlikely event that a visit or test needs to be repeated, you will not receive additional 
compensation or payment. 
 
All study-related costs associated with your participation will be paid by funds allocated to the 
research team.  There will be no cost to you, the subject, during your participation in this study 
other than the cost of travel to and from the Arizona Biomedical Collaborative Building.   
 
If you agree to participate in this study, then your consent does not waive your legal rights.  
However, no funds have been set aside to compensate you in the event of injury. However, if any 
injury occurs due to the experimental procedures, first aid will be provided. If there is a situation 
that the research team believes needs attention by a primary care practitioner, you will be referred 
to the Nurse Practitioner Clinic on the Downtown Arizona State University campus (approximately 
two (2) blocks from the lab). If any injury occurs after the Nurse Practitioner Clinic is closed you 
should seek attention at an urgent care facility.  If a medical emergency were to occur during this 
study, we will call “911” to bring emergency medical personnel to the lab.  You will be responsible 
for any costs incurred. 
 
Your participation may be stopped by the research team without consent if  
1) You do not meet the inclusion/exclusion criteria of this study.  
2) You experience adverse events such as extreme muscle soreness or inability to complete 
the measurements during Visits #1 and #2. 
3) You are not compliant with the pre-study instructions. 
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Who can I talk to? 
If you have questions, concerns, or complaints, or think the research has hurt you, please contact 
the research team at ###-###-#### (business hours), jared.dickinson@asu.edu (any time) or ###-
###-#### (business hours), andrew.dlugos@asu.edu (any time). 
This research has been reviewed and approved by the Bioscience IRB (“IRB”). You may talk to 
them at (480) 965-6788 or research.integrity@asu.edu if: 
• Your questions, concerns, or complaints are not being answered by the research team. 
• You cannot reach the research team. 
• You want to talk to someone besides the research team. 
• You have questions about your rights as a research participant. 
• You want to get information or provide input about this research. 
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Written Informed Consent 
• Your participation in this study is completely voluntary and you have been told that you may refuse 
to participate or stop your participation in this project at any time without penalty or loss of benefits 
and without jeopardizing any relationships with Arizona State University.  If you decide to stop your 
participation in this project and revoke your authorization for the use and disclosure of your health 
information, Arizona State University may continue to use and disclose your health information in 
some instances.  This would include any health information that was used or disclosed prior to 
your decision to stop participation and needed in order to maintain the integrity of the research 
study.  If we get any information that might change your mind about participating, we will give you 
the information and allow you to reconsider whether or not to continue.   
 
• The purpose of this research study, procedures to be followed, risks and benefits have been 
explained to you.  You have been allowed to ask questions and your questions have been 
answered to your satisfaction.  You have been told who to contact if you have additional questions.  
You have read this consent form and voluntarily agree to participate as a subject in this study.  
You are free to withdraw your consent, including your authorization for the use and disclosure of 
your health information, at any time.  You may withdraw your consent by notifying Andrew 
D’Lugos, MS at 602-827-6328.  You will be given a copy of the consent form you have signed. 
 
Informed consent is required of all persons in this project.  Whether or not you provide a signed 
informed consent for this research study will have no effect on your current or future relationship with 
Arizona State University. 
 
 
Your signature below documents your permission to take part in this research. 
   
Signature of participant  Date 
 
 
Printed name of participant 
   
Signature of person obtaining consent 
 
 
 Date 
Printed name of person obtaining consent  
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ULTRASOUND IMAGE COLLECTION PROTOCOL 
 
Supplies Needed / Used Item Number 
Terason Ultrasound Terason:  uSmart 3300 
Ultrasound Probe Terason:  Linear Phased Array 15-4 mHz 
Bed Medical Positioning, Inc. Ultra Scan Plus 
Ultrasound Gel Parker Aquasonics 100 
Surgical Skin Markers AliMed: 933294 
General Lab Equipment 
Tape Measure  
 
1. Positioning Subject 
a. Position subject supine on bed or standing on mat with selected leg closest to 
researcher 
b. If supine, place foot of selected leg in foot holder 
c. If supine, place rolled towel under knee to achieve ~10o knee bend 
d. Allow subject to rest for 15 min 
2. Mark Imaging Sites 
a. *Tip: Mark measurement points with “” and imaging sites with “X” 
b. Create lateral plane on quadriceps by measuring from the head of the greater 
trochanter of femur to lateral epicondyle of knee 
c. Record distance (cm) as “leg length”.  
d. Calculate 22%, 39%, 55% of this length. 
e. Mark points on leg corresponding to desired imaging sites  
i. 22%, 39%, 56% up from the knee 
f. With tape measure, create anterior plane from anterior superior iliac spine to proximal 
border of patella (no need to measure length, this is just to create an anterior line on 
quadriceps) 
g. Mark anterior imaging sites by tracing 22%, 39% and 56% points from the lateral plane 
to the anterior plane 
h. Mark lateral imaging sites as the midpoint between lateral and anterior points 
i. *Note distance from anterior point 
3. Imaging 
a. Open U smart software 
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b. Enter Patient ID, Select Exam Type: Musculoskeletal 
c. Press ‘Preset’, and select D’Lugos Protocol- Muscle Thickness 
i. Gain= 50, Dynamic Range= 55, Focal Zones= 4 
d. Coat probe with generous amount of gel 
e. Orient probe so horizontal bevel is proximal, angled toward the midline of the body 
f. Without applying any pressure on the leg, manipulate probe until desirable image is 
visible 
g. Adjust depth so that the superior border of femur is visible 
h. Adjust dynamic range and/or frequency so that aponeuroses of muscles and fascicles 
(for pennation angle) are clearly visible 
i. Once a sufficient image is obtained, select ‘Freeze’  
j. Scroll backward to select best image then select ‘Store’ 
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ULTRASOUND IMAGE ANALYSES PROTOCOL 
Muscle Thickness of the Quadriceps 
 
Supplies Needed / Used Item Number 
iMac Apple 
NIH Image J https://imagej.nih.gov/ij/index.html 
 
1. Open ImageJ with photo. 
a. Drag image file onto ImageJ icon on Dashboard 
2. Process -> Sharpen 
3. Image Navigation 
a. Zoom In = “Command” plus “+” 
b. Zoom Out= “Command” plus “-“ 
c. Draw Straight, 90o line = Hold “Shift” while drawing line 
4. Calibrate Image J 
a. Using the Straight Line Tool, draw line (while holding ‘Shift’) from 0cm to 2cm marks 
along teal ruler on right of screen. 
b. Click ‘Enter’ 
c. Analyze -> Set Scale -> Enter ‘Known distance’ to 2.0 and ‘Unit of Length’ to cm; click 
OK 
d. From this point on, the measurements for the opened image will be presented in 
centimeters (cm). 
5. Define 10%, 50%, 90% of Field of View (FOV) 
a. Using the Straight Line Tool, draw line (while holding Shift) from the left border of the 
image to the right. Zoom in to ensure accurate line placement. 
b. After positioning your horizontal line, hover over the left end-point with cursor and enter 
the “x=” value into “X-Coord. LEFT” cell on line locator spreadsheet. Do the same with 
the right end-point of the line. 
c. Based on the three “x=” values generated from the spreadsheet, begin to place your 
vertical lines (while holding Shift) at each corresponding “x-coordinate”. 
6. Drawing your Vertical Thickness Lines 
a. At each determined “x-coordinate” draw your line from the superficial fascia to the deep 
fascia (while holding Shift). 
b. Place the end points of your lines on the interior borders of the fascia.  Zoom in to 
refine the positioning of each end point of your line. 
c. After drawing your line, click “T”. A new window titled “ROI Manager” will appear. 
  197 
 
i. Repeat for each new line drawn 
ii. Each new line will be assigned a number (i.e. 1-12) 
d. In the “ROI Manager” window, check “Show All” and “Labels”. 
e. Begin drawing your lines from left to right (10% to 90%), beginning with the most 
superficial muscle, then the deep muscle, then both muscle combined, finishing with 
the subcutaneous fat. 
7. Obtaining your Thickness Measurements 
a. After drawing your thickness lines, click “Measure” in the “ROI Manager” window. 
b. All angles should be either 90 or -90. Enter the “Length” number into the US Data 
Spreadsheet. 
8. Saving your Analyzed Image 
a. Click “Save As” -> .jpeg 
b. Add “_ANALZYED” to the end of the image and save as .jpeg 
c. Save Analyzed image in the “Analyzed” folder for the given subject.  
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ULTRASOUND IMAGE ANALYSES PROTOCOL 
Pennation Angle of the Quadriceps 
 
Supplies Needed / Used Item Number 
iMac Apple 
NIH Image J https://imagej.nih.gov/ij/index.html 
Fixed Angle Line Tool https://imagej.nih.gov/ij/macros/tools/FixedAngleLineTool.txt 
 
1. Open ImageJ with photo. 
a. Drag image file onto ImageJ icon on Dashboard 
2. Process -> Sharpen 
a. Up to 2 times, depending on clearness of fascicles 
3. Image Navigation 
a. Zoom In = “Command” plus “+” 
b. Zoom Out= “Command” plus “-“ 
4. Tracing the Deep Aponeurosis 
a. Using the Straight Line tool, draw a line on the superficial border of the deep 
aponeurosis, spanning approximately 2 inches over the left and right side of the field 
of view. 
b. Click ‘Enter’, then ‘M’ 
c. This will save a yellow line on the image 
5. Tracing Pennation Angles 
a. Using the Angle Tool, click on the superficial portion of a visible fascicle, move cursor 
to the yellow line along the deep aponeurosis and click again.  
i. It is crucial to plot the second point exactly on the yellow line of the deep 
aponeurosis (zoom in if needed). 
ii. There are now 2 points plotted along a fascicle to the deep aponeurosis. 
b. Next, move cursor along the yellow line, to the right and click. This completes your 
angle. 
c. Click ‘T’; “ROI Manager” window will appear. 
d. In the “ROI Manager” window, press “M” to measure the angle of drawn lines; 
“Angle” values will appear in “Results” window. 
 
6. Trace Pennation Angles NOT Touching Deep Aponeurosis 
a. Right click on Fixed Angle Line Tool, and enter the same degree of the line drawn on 
the deep aponeurosis. 
i. Any new line drawn should be parallel with deep aponeurosis. 
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b. Draw new line at the base of fascicles that are not touching deep aponeurosis. 
i. Click ‘Enter’, line is now saved on image 
c. Using the Angle Tool, repeat the steps in #5 
7. Close the “ROI Manager” window and select “Save as Overlay”. Then, save the image as 
“image title_ANALYZED.jpg” 
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ULTRASOUND IMAGE ANALYSES PROTOCOL 
Echogenicity of the Quadriceps 
 
Supplies Needed / Used Item Number 
iMac Apple 
NIH Image J https://imagej.nih.gov/ij/index.html 
Optical Density Calibration Tool https://imagej.nih.gov/ij/docs/examples/calibration/index.html 
 
1. Calibrate ImageJ for Optical Density 
a. Calibrate ImageJ Optical Density (OD) by opening the “ImageJ OD Calibration Tablet” 
in ImageJ 
b. Open the brightness/contrast control (Image → Adjust → Brightness/Contrast) 
c. Starting with the left most white panel, draw a vertical panel that fills most of each 
shaded panel. 
i. Press “T” after each rectangle to save ROI for later measurement. 
d. Draw a rectangle in the first 19 panels, starting from left to right. Adjust the 
contrast/brightness to better visualize the panels following the 8th rectangle. 
e. In the “ROI Manager” window, select “Measure” after drawing all 19 rectangle. Results 
window should show 19 measurements. 
f. Open Calibration control ((Analyze → Calibrate). All 19 measurements should 
automatically populate left panel in window. 
i. From the “Function” drop down menu, select “Rodbard” 
ii. Enter “O.D.” in the “Unit” option 
iii. Check the “Global Calibration” box 
iv. Copy and paste the 19 “ImageJ O.D. Calibration Values” from the desktop into 
the right panel in window 
2. Measurement of Echogenicity 
a. Prior to analysis, confirm ultrasound image settings are constant: 
i. Image being directly compared over time (i.e. Pre to Post): 
1. Images of a particular site (i.e. Right L1) across time (i.e. Pre - Post) 
have identical Gain (Gn), Dynamic Range (DR), and  # of Focal Zones 
(pink stars) 
ii. Image being compared to other sites/individuals (i.e. ultrasound study) 
1. Images between individuals must have identical Gain (Gn), Dynamic 
Range (DR), and  # of Focal Zones (pink stars) 
b. Using the “Polygon Selections” tool, draw a shape that fills most of the subcutaneous 
fat, superficial muscle (vastus lateralis or rectus femoris), and deep muscle (vastus 
intermedius). 
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i. Make sure to avoid including skin, aponeurosis, and bone in the drawn 
polygon. Press “T” following the drawing of each polygon. Then in the “ROI 
Manager” window, press “M” once all polygons have been drawn to obtain 
measurements. 
1. Record the “Mean” value in the spreadsheet under the appropriate 
heading 
c. Close the “ROI Manger” window and select “Save as Overlay”. Then save the image 
as “image title_ANALYZED 
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SKELETAL MUSCLE RNA ISOATION 
 
Supplies Needed / Used Item Number 
PRO200 Bio-Gen Motor Assembly Pro Scientific:  PRO-01-01200 
Multi-Gen Adaptor  Pro Scientific:  PRO-07-07200 
7XL Multigen Generator Pro Scientific:  PRO-07-070MGXL-12 
2.0 ml Tubes USA Scientific:  1620-2700 
1.5 ml Tubes USA Scientific:  1615-5500 
500 µl Tubes USA Scientific:  1405-8100 
PIPETMAN G P200G Gilson: F144058MG 
PIPETMAN G P1000G Gilson: F144059MG 
200 µl Pipette Tips USA Scientific:  1120-8810 
1000 µl Pipette Tips USA Scientific:  1182-1830 
TriReagent Molecular Research Center: TR118 
Chloroform Alfa Aeser:  43685 
100% Isopropanol Fisher:  A464-1 
75% Ethanol Fisher:  BP28184 
RNAse Free Water Fisher:  BP5611 
General Lab Equipment 
Vortex Fisher:  02-215-365 
Refrigerated Centrifuge Fisher:  13-100-676 
 
1. Keep tissue cold if not frozen during this process. 
2. Prepare centrifuge tubes by pipetting 1 ml (50-100 mg sample) TriReagent (MRC# TR 118) 
into 2ml tube (USA Scientific Cat # 1620-2700). 
3. Pipet 4ul polyacryl carrier (MRC) if little RNA in sample (not necessary very often). 
4. Weight out muscle (~15-30 mg) and homogenize for 1-2 minutes with hand held homogenizer 
(Pro Scientific) 
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5. Let samples sit at RT for 5 minutes. 
6. Add 0.2 ml Chloroform per 1ml TriReagent. Shake vigorously/Vortex for 15sec.  
7. Allow samples to incubate at RT for 15 minutes then centrifuge at 12,200 rpm for 15 min at 4 
C.  
8. Remove upper phase while being careful not to pipette interphase. Put into fresh tube. Volume 
of upper phase is generally about 60% of initial TriReagent. It is advisable to leave a small later 
of upper phase to reduce risk of pipetting interphase.   Use 200ul pipette. 
o Place into 1.5 ml tube (USA Scientific Cat# 1615-5500) 
9. Pipette 0.5 ml 100% Isopropanol per 1 ml TriReagent into RNA phase. Mix by pipetting up and 
down. Allow the samples to incubate at RT for 10 min. 
10. Precipitate by centrifuging at 12.200 rpm for 8 min at 4 C. Gel-like pellet should form at bottom. 
11. Pour off isopropanol.  Wash pellet with 1 ml 75% Ethanol. Disrupt pellet by vortexing. Centrifuge 
sample at 9,600 rpm for 5 min at 4 C.  
12. Remove ethanol by inverting. Remove excess ethanol with 10 ul pipette. Let air dry for 3-5 min.  
Do not completely dry pellet.  
13. Dissolve the pellet in 1.5 ul of RNAse free water (Fisher BP5611) by pipetting up and down 
and vortexing.  Place RNA into fresh 500 ul tube (USA Scientific Cat# 1405-8100). 
14. Label tube as RNA 
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DETERMINATION OF RNA CONCENTRATION – BIOTEK TAKE 3 PLATE 
 
Supplies Needed / Used Item Number 
BioTek H1 Synergy Plate Reader BioTek:  43685 
BioTek Take3 Microplate Fisher: 11-120-571 
PIPETMAN G P10G Gilson: F144055MG 
10 µl Pipette Tips USA Scientific:  1121-3810 
General Lab Equipment 
Dry Bath Fisher: 11-718-4Q 
Dry Block Fisher:  11-718-23Q 
Dry Block Fisher:  11-718-9Q 
Thermometer Fisher:  13-201-644 
 
1.   Turn on heat block to 70 °C 
2. Thaw RNA samples on ice 
3. Power on Gen5 plate reader software 
4. Selected Read Now and specify sample type as RNA 
5. Specify the number of samples on the microplate setup 
6. Blank microspots by pipetting 2 ul of nuclease free water onto microspots 
 a.  Close lid of microplate and place into plate reader 
 b.  Read plate and approve blank read 
7. Heat RNA samples for 2 minutes, allow samples to cool on tube rack for 1 minute 
8. Pipette 2 ul of RNA sample onto microspots, close microspot lid, place into plate reader 
9. Microsoft Excel will open after read and will display RNA concentration results  
 
 
 209 
APPENDIX H 
 
DNASE TREATMENT OF ISOLATED RNA 
 210 
DNASE TREATMENT OF ISOLATED RNA 
 
Supplies Needed / Used Item Number 
DNA-Free Kit Ambion:  AM1906 
500 µl Tubes USA Scientific:  1405-8100 
PIPETMAN G P2G Gilson: F144054MG 
PIPETMAN G P20G Gilson: F144056MG 
2 µl Pipette Tips USA Scientific:  1121-3810 
20 µl Pipette Tips USA Scientific:  1120-1810 
General Lab Equipment 
Centrifuge Fisher:  13-100-676 
Oven or Incubator  
 
1. NOTE: For use with Applied Biosystems DNA-free kit; AM1906 
2. Use up to 5 ug (when using 1ul rDNase 1) of RNA and put into new 500 ul tube (USA Scientific 
Cat# 1405-8100) 
3. Pipet 0.1 volume of DNase 1 Buffer and 1 ul rDNase 1 into each sample. Mix gently. 
a. Note: This is good for up to 50 ul reaction 
4. Incubate at 37 C for 25 minutes. 
5. Add 2 ul (or 0.1 volume, which ever is greater) of DNase inactivating reagent. Mix well by 
pipetting up and down and flicking.  
6. Incubate at RT for 2 min. Mix occasionally (2-3x) 
7. Centrifuge at 10,000 rpm for 2min. Pipet off RNA to fresh 500 ul tube (USA Scientific Cat# 
1405-8100).  
8. Label tube as DNASE 
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cDNA SYNTHESIS 
 
Supplies Needed / Used Item Number 
Bioline SensiFast cDNA Synthesis Kit Bioline:  BIO-65053 
Nuclease Free H2O Fisher:  BP5611 
Low Profile 8 tube strip BioRad:  TLS0801 
Low Profile 8 tube cap BioRad:  TCS0803 
PIPETMAN G P2G Gilson: F144054MG 
PIPETMAN G P10G Gilson: F144055MG 
PIPETMAN G P20G Gilson: F144056MG 
Pipette Tips USA Scientific:  1121-3810 
Pipette Tips USA Scientific:  1120-1810 
General Lab Equipment 
Thermocycler (CFX Connect) BioRad:  1855201 
 
1. NOTE: For use with Bioline SensiFast cDNA Synthesis Kit 
2. Turn on CFX connect to warm-up 
3. Set up Reaction Protocol on CFX connect. Listed as “iScript cDNA Synthesis Protocol JMD 
a. No plate reads will occur 
4. Determine volume of DNASE treated RNA to add, equivalent to 1 ug total RNA 
5. Determine amount of nuclease-free water to add (ul H2O = 20 ul - x ul RNA - 4 ul TransAmp 
Buffer - 1 ul reverse transcriptase). Add to 500 ul reaction tube 
a. BioRad TLS0801 (8 tube strip) 
b. BioRad TCS0803 (8 tube cap) 
6. Add 4 ul of 5X TransAmp Buffer 
a. For several samples, may want to create master mix with TransAmp Buffer (4 ul per 
sample) + reverse transcriptase (1 ul per sample).  Use appropriate sized RNAse free 
tube 
7. Add RNA template 
8. Add Reverse Transcriptase (1 ul) 
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9. Label tube as cDNA 
10. For human cDNA dilute cDNA 1:8 with nuclease-free water by adding 6 ul of cDNA to 42 ul 
nuclease-free water.  Label tube as cDNA 1:8. Diluted cDNA is used for PCR reactions 
 
 
5 X TransAmp Buffer   4 ul 
Reverse Transcriptase   1 ul 
Nuclease-free Water   x ul 
RNA template    x ul 
    _______________ 
Total volume    20 ul 
 
Temperature Protocol 
25 C  10 min 
42 C  15 min 
85 C  5 min 
4   C  Hold (optional) 
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PRIMER DESIGN AND DILUTION 
 
Supplies Needed / Used Item Number 
1X TE Buffer Invitrogen:  12090015 
PIPETMAN G P200G Gilson: F144058MG 
200 µl Pipette Tips USA Scientific:  1120-8810 
General Lab Equipment 
Mini Centrifuge Fisher:  12-006-901 
Vortex Fisher:  02-215-365 
 
1. Go to Pubmed home 
2. Type in name of the gene/protein and species (Rrbp1 mouse; Naf-1 homo sapien) and select 
Gene on the drop down menu 
3. Click on gene name 
4. Scroll down to “mRNA and Protein(s)” heading 
5. Click on appropriate accession number (NM_xxxxxxx) – can double check against TAQMAN 
probes on life technologies website 
6. Scroll down to CDS (coding sequence) and click it 
7. Click Pick Primers from right hand menu 
8. Set amplicon length to 70-120 
9. Melting Temperature 60 d (57-63) or 55d (52-58) 
10. Highlight and change that primers to span an exon-exon junction 
11. Make sure organism is “homo sapiens” should be 9606 
12. Also can allow primers to amplify mRNA splice variants at the bottom of the page 
13. Get Primers! 
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NOTES: 
• Primer should be 18-22 bp 
• Melt temp <65d, 60 or 55 ideal, depends on selection 
• 40-60% GC Content 
• Product close to 100bp ideal 
• Product with least potential overlaps should be chosen 
  
PRIMER ORDERING 
• Invitrogen (Life Technologies) website (lifetechnologies.com): 
o Go to “Custom DNA Oligos”  
o Researcher Name:  
o Oligo Name: gene name Fwd or Rev 
o Oligo sequence: cut and paste appropriate sequence 
o Synthesis Scale: 25 nmol 
o Purification: desalted 
 
DILUTION 
• Upon arrival, spin down primer tubes for 1 minute 
• Dilute primers with 1X TE buffer 
o 10 x nmol concentration- look on data sheet 
o e.g. 10 x 16.0 nmol = 160 ul 1X TE buffer 
• Vortex and spin down 
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PRIMER TESTING AND OPTIMIZATION 
 
Supplies Needed / Used Item Number 
Thermocycler (CFX Connect) BioRad:  1855201 
PIPETMAN G P10G Gilson:  F144055MG 
PIPETMAN G P20G Gilson:  F144056MG 
PIPETMAN G P100G Gilson:  F144057MG 
PIPETMAN G P1000G Gilson:  F144059MG 
10 µl Pipette Tips USA Scientific:  1121-3810 
20 µl Pipette Tips USA Scientific:  1120-1810 
100 µl Pipette Tips USA Scientific:  1120-1840 
1000 µl Pipette Tips USA Scientific:  1182-1830 
1.5 ml Tubes USA Scientific:  1615-5500 
200 µl Colored Tubes USA Scientific:  1402-8108 
Low Profile 96 Well Plate (unskirted) BioRad:  MLL9601 
96 Well Plate Adhesive Seals BioRad: MSB1001 
Plate Sealer (Scraper) Option, BioRad: MSR0001   
General Lab Equipment 
Vortex Fisher:  02-215-365 
Mini Centrifuge Fisher:  12-006-901 
Centrifuge Beckman Coulter: Allegra 64R 
Centrifuge Rotor Beckman Coulter:  S2096 
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SERIAL DILUTION PCR RUN TO DETERMINE PRIMER EFFICIENCY 
1. Create 6 point 1:2 decreasing dilution series of cDNA 
a. Pipette 15 ul of nuclease free water into 6 500 ul clear tubes 
i. Label tubes 1 – 6 
ii. cDNA concentration of dilution series ranges from 1:2 to 1:64 
b. Pipette 15 ul of cDNA into tube #1 
i. Vortex and spin down 
c. Pipette 15 ul of tube #1 into tube #2 
i. Vortex and spin down 
d. Repeat step “c” for tubes 3, 4, 5, 6 
2. Determine how many samples and gene targets you plan to analyze (6 samples x primers 
being tested) 
3. Record samples/genes on blank 96-well plate template 
4. Label 1 clear 1.5 ml tube with the name of each primer. This is your master mix tube 
5. Label colored 500ul tubes with name of sample and primer  
a. (Hint: multiply the number of samples you have by the number of targets you plan to 
analyze and this equal the number of colored tubes to label) 
6. Follow the ‘SYBR RT PCR Pipetting Spreadsheet’ formula for creating your master mix for 
each target gene. Make sure to vortex and spin-down each tube prior to adding to master mix 
a. Determine the number of reactions (samples x 2 duplicates per sample) 
b. Add x ul of nuclease free water (9.5 ul per reaction) 
c. Add x ul Sybr Green Supermix (12.5 ul per reaction) 
d. Add x ul of forward and reverse primers (0.5 ul per reaction)  
7. Vortex and spin-down master mix tubes 
8. Aliquot 48.2ul of each master mix into the colored 500ul reaction tubes for that target 
9. Vortex and spin-down cDNA tubes 
10. Add 4.28ul of cDNA from each sample into the appropriate reaction tubes. You should now 
have 52.48ul total volume in each colored tube (master mix + cDNA) 
11. Vortex and spin-down completed reaction tubes 
12. Pipette in duplicate, 25ul from reaction tube into assigned wells on plate (use template). 
Duplicates should be horizontal (i.e. A1 and A2) and should be pipetted using the same tip 
13. Seal plate with adhesive seal and white scraper 
14. Spin-down plate in large centrifuge at 1000 rpm for 2 min. Rotor#: 2096 
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15. Place plate in thermocycler with A1 in back left corner. Wipe top of plate with kimwipe 
 
SETTING UP THE THERMOCYCLER SOFTWARE 
1. Open ‘Bio-Rad CFX Manager’ on desktop 
2. Click OK at login window 
3. Click ‘User Defined’ at Startup Window 
4. Select the appropriate protocol in the ‘Express Load’ dropdown window 
a. All SYBR protocols are titled “CFX_2StepAmp+Melt --d SYBR” 
i. The correct run temperature (--d) will be based on primer testing results 
5. Click the Plate tab 
6. Select the appropriate plate in the ‘Express Load’ dropdown window 
a. All SYBR PCR’s will use plate titled “Bio-Rad_96 wells_SYBR-pltd” 
7. Click ‘Edit Selected’. Highlight all well and click ‘Clear Wells’ 
8. Under ‘Editing Tools’, click ‘Setup Wizard’ 
a. Assign ‘Target names’ and ‘Sample names’ to their respective wells and click OK 
9. Highlight all wells and assign ‘Sample Type’ as ‘Standard’ 
a. Next, highlight wells and input ‘Replicate Series’. Replicate size will always be 2 
b. Next, highlight wells and input ‘Dilution Series’. Dilution factor = 2, Decreasing 
10. If you are running a RT-qPCR, highlight all wells and assign ‘Sample Type’ as ‘Unknown’ 
11. Click OK, and YES to save plate 
12. Click the Start Run tab 
13. Under ‘Notes’ input date, target genes, samples 
14. Visually inspect Melt Curve Analysis 
a. Ensure each dilution series results in a single melt peak (variation in melt temperature 
up to 1.0 degrees between 6 points acceptable) 
15. Visually inspect Efficiency, R2, and Ct range of standard curve 
a. Efficiency should be between 95% and 110% 
b. R2 should be above 0.995 
c. Ct range should be greater than 20 while not exceeding 35 
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AGAROSE GEL – PRIMER DESIGN TESTING 
 
Supplies Needed / Used Item Number 
Agarose BioRad; 161-3101 
10X TBE BioRad; 161-0733 
Ethidium Bromide BioRad; 161-0433 
EZ Load 20bp Molecular Ruler BioRad; 170-8351 
PIPETMAN G P2G Gilson: F144054MG 
PIPETMAN G P10G Gilson: F144055MG 
2 µl Pipette Tips USA Scientific:  1121-3810 
10 µl Pipette Tips USA Scientific:  1121-3810 
Power Supply Unit BioRad:  1645050 
Mini Sub Cell GT BioRad:  1704466 
General Lab Equipment 
25 mL Flask  
Microwave  
Petri Dish  
1. Dilute 15ml 10X TBE (BioRad; 161-0733) to 0.5X in 285ml Millipore H2O  
2. Cast Agarose Gel (2.5%) in Mini Sub Cell GT (BioRad; 170-4487): 
a. Suspend 625mg Agarose (BioRad; 161-3101) in 25ml 0.5X TBE 
b. Microwave for 1min, spinning flask every 10-15 sec 
i. After microwaving, place pietri dish over flask to reduce evaporation 
c. Add 1 ul of Ethidium Bromide (10mg/ml; BioRad; 161-0433) after Agarose is cooled 
(1-2 min). Twirl flask to mix 
d. Add appropriate comb into gel 
e. Slowly pour into Mini Sub Cell GT (avoid air bubbles). Pop with pipette tip if present 
3. Allow gel to polymerize for 30 min 
4. Cover gel with 0.5X TBE until wells are covered (1-2 cm) 
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5. Remove comb from gel 
6. Load Molecular Ladder (5 ul; BioRad EZ Load 20bp Molecular Ruler; 170-8351) 
7. Prepare samples: 
a. Mix 4ul DNA product and 1ul 5X Loading Buffer (BioRad; 161-0767) 
b. Load on gel 
8. Fill Mini Sub Cell GT with remaining 0.5X TBE 
9. Power Unit: 75V for 60min (Black → Red electrode direction) 
10. Each lane should have a single band at the targeted bp for the expected product. 
 
IMAGE DNA AGAROSE GEL 
1. Open Image Lab software 
2.  Select New Protocol 
3. Select Single Channel 
4. Under Application, select Ethidium Bromide 
5. Position gel onto UV tray, image gel 
6. Visually inspect gel image to ensure each sample results in a single band at appropriate 
product size 
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PCR ANALYSIS PROTOCOL 
 
Supplies Needed / Used Item Number 
Thermocycler (CFX Connect) BioRad:  1855201 
PIPETMAN G P10G Gilson:  F144055MG 
PIPETMAN G P20G Gilson:  F144056MG 
PIPETMAN G P100G Gilson:  F144057MG 
PIPETMAN G P1000G Gilson:  F144059MG 
10 µl Pipette Tips USA Scientific:  1121-3810 
20 µl Pipette Tips USA Scientific:  1120-1810 
100 µl Pipette Tips USA Scientific:  1120-1840 
1000 µl Pipette Tips USA Scientific:  1182-1830 
1.5 ml Tubes USA Scientific:  1615-5500 
200 µl Colored Tubes USA Scientific:  1402-8108 
Low Profile 96 Well Plate (unskirted) BioRad:  MLL9601 
96 Well Plate Adhesive Seals BioRad: MSB1001 
Plate Sealer (Scraper) Option, BioRad: MSR0001   
iTaq Universal Sybr Green Supermix BioRad: 1725120 
Nuclease Free H2O Fisher:  BP5611 
General Lab Equipment 
Vortex Fisher:  02-215-365 
Mini Centrifuge Fisher:  12-006-901 
Centrifuge Beckman Coulter: Allegra 64R 
Centrifuge Rotor Beckman Coulter:  S2096 
 
1. Determine how many samples and gene targets you plan to analyze  
2. Record samples/genes on blank 96-well plate template 
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3. Label 1 clear 1.5 ml tube with the name of each target gene. This is your master mix tube 
4. Label colored 500ul tubes with name of sample and target gene.  
a. (Hint: multiply the number of samples you have by the number of targets you plan to 
analyze and this equal the number of colored tubes to label) 
5. Follow the ‘SYBR RT PCR Pipetting Spreadsheet’ formula for creating your master mix for 
each target gene. Make sure to vortex and spin-down each tube prior to adding to master mix 
a. Determine the number of reactions (samples x 2 duplicates per sample) 
b. Add x ul of nuclease free water (9.5 ul per reaction) 
c. Add x ul Sybr Green Supermix (12.5 ul per reaction) 
d. Add x ul of forward and reverse primers (0.5 ul per reaction)  
6. Vortex and spin-down master mix tubes 
7. Aliquot 48.2ul of each master mix into the colored 500ul reaction tubes for that target 
8. Vortex and spin-down cDNA tubes 
9. Add 4.28ul of cDNA from each sample into the appropriate reaction tubes. You should now 
have 52.48ul total volume in each colored tube (master mix + cDNA) 
10. Vortex and spin-down completed reaction tubes 
11. Pipette in duplicate, 25ul from reaction tube into assigned wells on plate (use template). 
Duplicates should be horizontal (i.e. A1 and A2) and should be pipetted using the same tip 
12. Seal plate with adhesive seal and white scraper 
13. Spin-down plate in large centrifuge at 1000 rpm for 2 min. Rotor#: 2096 
14. Place plate in thermocycler with A1 in back left corner. Wipe top of plate with kimwipe 
 
SETTING UP THE THERMOCYCLER SOFTWARE 
1. Open ‘Bio-Rad CFX Manager’ on desktop 
2. Click OK at login window 
3. Click ‘User Defined’ at Startup Window 
4. Select the appropriate protocol in the ‘Express Load’ dropdown window 
a. All SYBR protocols are titled “CFX_2StepAmp+Melt --d SYBR” 
i. The correct run temperature (--d) will be based on primer testing results 
5. Click the Plate tab 
6. Select the appropriate plate in the ‘Express Load’ dropdown window 
a. All SYBR PCR’s will use plate titled “Bio-Rad_96 wells_SYBR-pltd” 
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7. Click ‘Edit Selected’. Highlight all well and click ‘Clear Wells’ 
8. Under ‘Editing Tools’, click ‘Setup Wizard’ 
a. Assign ‘Target names’ and ‘Sample names’ to their respective wells and click OK 
9. If you are testing primers, highlight all wells and assign ‘Sample Type’ as ‘Standard’ 
a. Next, highlight wells and input ‘Replicate Series’. Replicate size will always be 2 
b. Next, highlight wells and input ‘Dilution Series’. Dilution factor = 2, Decreasing 
10. If you are running a RT-qPCR, highlight all wells and assign ‘Sample Type’ as ‘Unknown’ 
11. Click OK, and YES to save plate 
12. Click the Start Run tab 
13. Under ‘Notes’ input date, target genes, samples 
14. Start Run 
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SKELETAL MUSCLE IMMUNOHISTOCHEMICAL ANALYSES 
CSA and Fiber Type 
MHC I, MHC IIa, Laminin, DAPI in frozen muscle 
 
Supplies Needed / Used Item Number 
Superfrost Plus Microscope Slides Fisher:  12-550-15 
Cover Glasses Rectangle No.1 Fisher:  12-545F 
Hydrophobic Pen Vector:  H-4000 
Normal Goat Serum (NGS) Fisher:  31872 
1X PBS Recipe 
Vectashield Antifade Mounting Medium Vector #H-1000 
10% Normal Goat Serum Fisher:  31872 
Mouse anti-MHCI IgG2b DSHB: BAD5 Mouse IgG2b, supernatant 
Mouse anti-MHCIIa IgG1 DSHB: SC71 Mouse IgG1, supernatant 
Rabbit anti-Laminin IgG Sigma: L9393 (Rabbit IgG) 
2o antibody: Goat anti mouse IgG2b AF488 
(MHC I) 
Invitrogen: A21141 
2o antibody: Goat anti mouse IgG1 AF 546 
(MHC IIa) 
Invitrogen:  A21123 
2o antibody: Goat anti rabbit IgG AF633 
(Laminin) 
Invitrogen:  A21071 
DAPI Invitrogen:   D3571 
General Lab Equipment 
PIPETMAN G P100G Gilson:  F144057MG 
100 µl Pipette Tips USA Scientific:  1120-1840 
Cryostat Leica: CM1950 
DSHB, Developmental Studies Hybridoma Bank 
 
 
Note: This stain requires approximately 5 hours 
1. Air dry sections for 30 mins at RT 
2. Encircle sections with hydrophobic pen 
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3. Rehydrate sections in 1X PBS for 3 mins 
4. Wash in 1X PBS (2x2min) 
5. Block with 10% NGS for 60mins 
6. Wash in 1X PBS (pipette rinse) 
7. Incubate in 1o antibody for 90min at RT 
a. MHCI: BAD5 Mouse IgG2b (1:10; DSHB, supernatant) 
▪ Note: All antibodies diluted in 1X PBS 
b. MHCIIa: SC71 Mouse IgG1 (1:10; DSHB, supernatant) 
c. Laminin Rabbit IgG (1:50; Sigma, L9393) 
8. Wash in 1X PBS (4x5min) 
9. Apply 2o antibody for 60min at RT 
a. MHCI: Goat anti mouse IgG2b AF488 (1:300; Invitrogen, A21141) 
▪ Note: All antibodies diluted in 1X PBS 
b. MHCIIa: Goat anti mouse IgG1 AF 546 (1:300; Invitrogen, A21123) 
c. Laminin: Goat anti rabbit IgG AF633 (1:300; Invitrogen, A21071) 
10. Wash in 1X PBS (3x5min) 
11. Incubate in DAPI (1:10,000) in 1X PBS for 5min 
12. Wash in 1X PBS (3x5min) 
13. Dry excess liquid on slide 
14. Air dry for 2mins 
15. Mount coverslip with Vectashield 
16. Image slide at 100X magnification 
 
 
 
Phosphate Buffered Saline (10X) – Dilute to 1X 
Chemical Vendor Amount for 10X 
1. NaCl  (Fisher: S271-500) 80g 
2. KCl (Fisher: P217-500) 2g 
3. Na2HPO4 (Sigma: 255793) 14.4g 
4. KH2PO4 (MP Biomedicals: MP021954531) 2.4g 
 
 231 
APPENDIX O 
 
SKELETAL MUSCLE IMMUNOHISTOCHEMICAL ANALYSES – SATELLITE CELLS AND 
MYONUCLEI 
 232 
SKELETAL MUSCLE IMMUNOHISTOCHEMICAL ANALYSES 
Satellite Cells and Myonuclei 
Pax7, Type 1, Laminin IHC Protocol for frozen rat skeletal muscle 
 
Supplies Needed / Used Item Number 
Superfrost Plus Microscope Slides Fisher:  12-550-15 
Cover Glasses Rectangle No.1 Fisher:  12-545F 
Hydrophobic Pen Vector:  H-4000 
Vectashield Antifade Mounting Medium Vector #H-1000 
4% PFA Recipe 
1X PBS Recipe 
30% H2O2 in PBS Fisher:  H325 
TSA Kit (Alexa fluor 555 tyramide) Invitrogen:  T-30955 
PAX-7 (Concentrate) DSHB 
Mouse anti-MHCI IgG2b DSHB: BAD5 Mouse IgG2b, supernatant 
Laminin Sigma: L9393 (Rabbit IgG) 
Biotin-SP-AffiniPure Goat Anti-Mouse IgG, 
Fcγ Subclass 1 Specific 
Jackson Immuno Research Cat #115-065-205 
2o antibody: Goat anti-Rabbit AF488 Invitrogen:  A-11034 
2o antibody: Gt anti-Ms IgG2B AF647 Invitrogen:  A-21242 
DAPI Invitrogen:   D3571 
General Lab Equipment 
PIPETMAN G P100G Gilson:  F144057MG 
100 µl Pipette Tips USA Scientific:  1120-1840 
Water Bath  
Cryostat Leica: CM1950 
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Day 1 
1.  Cut 7µm thin sections & air dry for 1hr at RT. 
2.  Fix sections with 4%PFA for 7min. 
3.  Wash 3x3min in PBS 
4.  Perform AntiRetrival step*(see below) with Na.citrate (10mM, Pᴴ 6.5) at 92ºC water bath for 
20min.  Then cool slides to RT. 
5.   Wash 3x3min in PBS. 
6.   Block endogenous peroxidases with 3% H2O2 in PBS for 7min. 
7.   Wash 3x3min in PBS. 
8.  Block 1hr in 1% blocking reagent (came with Invitrogen TSA kit – item D, or use BSA). 
9.  Incubate in 1ºAb for 1hr at RT then overnight at 4ºC in 1% blocking reagent: Ms IgG1 Pax7 
(1:500) (DSHB); Type 1 BA.D5 Ms IgG2b (1:500) (BA.D5 –C, from DHSB Iowa); Rb laminin 
(1:500) (Sigma cat #L9393) in 2.5% NHS at 4⁰C. 
Day 2 
10. Wash 4x5min in PBS. 
11. Incubate 70min in 2ºAb in 1% blocking reagent: Gt α Ms Biotinylated 2ºAb (1:1000), 2⁰Ab 
Gt anti-Ms IgG2b, AF647 (1:500) (Invitrogen, Cat # A-21242), Gt anti Rb IgG AF488 (1:500) 
(Invitrogen, Cat # A-11034). 
12. Wash 3x3 min in PBS. 
13. Incubate 1hr in SA-HRP (1:500, blue top) in PBS (came with Invitrogen TSA kit – item C). 
14. Wash 3x3min in PBS. 
15. Incubate 15-20 min in Alexa flour 488 (1:500) in amplification diluents (came with Invitrogen 
TSA kit – item E). 
16. Wash 3x3min in PBS. 
17. Incubate 10min in DAPI. (From Invitrogen, Cat# D35471) at RT 
a. (Dilute (100µM) DAPI stock, 1:10,000 in PBS) 
18. Wash 2x3 min in PBS 
19. Mount slides with vector shield fluorescent mounting media. 
20. Image slide at 10-20X magnification 
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*Antigen Retrival: add slides to Na.citrate in glass coplin jar or glass beaker & preheat water bath 
to 65ºC, then place beaker/coplin jar containing slides and NA Citrate in water bath and raise the 
temperature to 92 ºC. Water bath temperature will slowly raise to 92ºC (it will take 7-10 min to reach 
temp from 65ºC to 92ºC, then keep the slides at 92ºC for an additional 10 min) 
 
Phosphate Buffered Saline (10X) – Dilute to 1X 
Chemical Vendor Amount for 10X 
NaCl  (Fisher: S271-500) 80g 
KCl  (Fisher: P217-500) 2g 
Na2HPO4 (Sigma: 255793) 14.4g 
KH2PO4 (MPBiomedicals:  MP021954531) 2.4g 
 
4% Paraformaldehyde (PFA) 
Chemical Vendor Amount for 1L 
PFA  (Sigma: P6148) 40g 
1X PBS Recipe 1000 ml 
a. Slowly dissolve PFA in 1X PBS over low heat until solution clear. Pass through 
filter, then use immediately or aliquote and store at -20C  
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SKELETAL MUSCLE IMMUNOHISTOCHEMICAL ANALYSES 
Capillary Density 
IHC-Fr: Capillary CD31, and WGA on frozen rat muscle 
 
 
Supplies Needed / Used Item Number 
Superfrost Plus Microscope Slides Fisher:  12-550-15 
Cover Glasses Rectangle No.1 Fisher:  12-545F 
Hydrophobic Pen Vector:  H-4000 
Mouse anti- CD31/PECAM IgG1 BD Biosciences: 550300 
Goat anti-mouse IgG1 AF555 Invitrogen:  A-21127 
Goat anti-mouse AF488 conjugated WGA Invitrogen:  W11261 
DAPI Invitrogen:  D3571 
Normal Horse Serum (NHS) Vector:   S-2012 
1X PBS Recipe 
Acetone Fisher:  A18P-4 
Vectashield Antifade Mounting Medium Vector:  #H-1000 
General Lab Equipment 
PIPETMAN G P100G Gilson:  F144057MG 
100 µl Pipette Tips USA Scientific:  1120-1840 
Cryostat Leica:  CM1950 
 
Day 1 
1. Cut 7µm thin sections & air dry them. 
2. Fix sections 10min in acetone at -20°C. 
3. Wash 3x3 min in 1X PBS. 
4. Block 1hr in 2.5% NHS blocking solution at RT (Vector #S-2012) 
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5. Incubate overnight in 1⁰Ab, Ms IgG1 CD31/PECAM (1:50) (BD Biosciences cat #550300) 
in 2.5% NHS at 4⁰C. 
 
Day 2 
6. Wash 3x3 min in 1X PBS. 
7. Incubate 1hr in 2⁰Ab Gt anti Ms IgG1 AF555 (1:500) (Invitrogen, Cat #A-21127); AF488 
conjugated WGA (Invitrogen, Cat #W11261) in 1X PBS at RT 
8.  Wash 3x3 min in 1X PBS. 
9. Incubate 10min in DAPI (Invitrogen, cat#D3571); dilute (100µm) stock (1:10,000 in PBS) 
at RT. 
10. Wash 2x3min in 1X PBS. 
11. Mount slides with vector shield mounting media. Drain excess mounting media before 
storing slides at 4°C.  
12. Image slide at 10X magnification 
 
Phosphate Buffered Saline (10X) – Dilute to 1X 
Chemical Vendor Amount for 10X 
5. NaCl  (Fisher: S271-500) 80g 
6. KCl (Fisher: P217-500) 2g 
7. Na2HPO4 (Sigma: 255793) 14.4g 
8. KH2PO4 (MP Biomedicals: MP021954531) 2.4g 
